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INTRODUCTION
1. Aspiration thrombectomy with primary PCI for STEMI
Primary percutaneous coronary intervention (PCI) has greatly improved outcomes in patients 
with ST-elevation myocardial infarction (STEMI) and has become the preferred reperfusion 
strategy in patients with STEMI.
The presence of detectable coronary thrombus at the time of primary PCI creates special 
challenges for the interventional cardiologist. Large thrombus burden is associated with an 
increased incidence of distal embolization and no-refl ow, and may limit reperfusion at the 
microvascular level as measured by myocardial blush and ST-segment resolution (STR). Large 
thrombus burden is associated with a greater frequency of major adverse cardiac events 
(MACE) and is a strong independent predictor of late mortality1.
There are many ways to deal with coronary thrombus at the time of primary PCI: pharmaco-
logic strategies (typically glycoprotein IIb/IIIa platelet inhibitors), embolic protection devices 
(fi lters and distal balloon occlusion with aspiration), mechanical thrombectomy (AngioJet, 
Medrad Interventional/Possis, Minneapolis, Minnesota, and X-sizer, EV3, Plymouth, Minne-
sota), and manual or aspiration thrombectomy devices.
1.1. Major randomized trials
The TAPAS (Thrombus Aspiration during Percutaneous coronary intervention in Acute 
myocardial infarction) Trial was a landmark study that brought manual thrombectomy 
into the mainstream as adjuctive therapy with primary PCI for STEMI2. This trial random-
ized 1,071 patients with STEMI of less than 12 hours duration to primary PCI with manual 
thrombectomy with the Export catheter versus primary PCI alone. Aspiration was able to be 
performed in 90% of patients and retrieved visible thrombus or atheromatous material in 
72% of patients. Aspiration resulted in signifi cant improvement in the primary endpoint of 
frequency of myocardial blush grade 3 (MBG 3) (46% versus 32%, p<0.001) and signifi cant 
improvement in the secondary endpoint of frequency of complete ST-segment resolution 
within 90 minutes(STR>70%) (57% versus 44%, p<0.001). More importantly, this trial showed 
a signifi cant mortality reduction with aspiration thrombectomy at one year3. These results 
were impressive but not conclusive, since (a) this was a single center study,(b) the study 
was not powered to detect diff erences in clinical endpoints, and (c) mortality was not a pre-
specifi ed endpoint. 
The EXPIRA (Thrombectomy with EXPort catheter in Infarct-Related Artery during primary 
percutaneous coronary intervention) Trial randomized 175 patients with STEMI to primary 
PCI alone versus primary PCI with manual thrombectomy and showed a signifi cant improve-
ment in the primary endpoints of myocardial blush grade 3 and complete ST-resolution4. 
This study was unique in that it evaluated infarct size by MRI and found that the extent of 
microvascular obstruction was less in the acute phase with aspiration (31.5% versus 72.9%, 
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p= 0.0005; 1.7 g versus 3.7 g, p = 0.0003) and improvement in infarct size at 3 months was 
observed with aspiration but not in the control group.
1.2. Meta-analyses
In addition to the two trials described above, there have been numerous small randomized 
trials evaluating manual thrombectomy, mechanical thrombectomy, and distal protec-
tion devices in patients undergoing primary PCI for STEMI. None of these trials has been 
adequately powered to evaluate clinical events. For this reason, several meta-analyses have 
been performed to help evaluate the role of manual thrombectomy (and other devices) as 
adjunctive therapy with primary PCI for STEMI.
Bavry and Bhatt analyzed 13 trials with manual thrombectomy, 5 trials with mechanical 
thrombectomy (AngioJet, Medrad Interventional/Possis, Minneapolis, Minnesota, and 
X-sizer, EV3, Plymouth, Minnesota), and 12 trials with distal protection devices (Percusurge-
GuardWire, Medtronic; FilterWire, Boston Scientifi c, SpideRx, ev3; Angioguard, Cordis)5. This 
meta-analysis showed that manual thrombectomy resulted in better myocardial blush scores 
and better STR; distal protection resulted in better myocardial blush but no improvement in 
ST-resolution; and mechanical thrombectomy resulted in no improvement in either myocar-
dial blush or STR. Mortality was improved with aspiration, was neutral with distal protection, 
and was worse with mechanical thrombectomy. The results of mechanical thrombectomy 
were driven primarily by the results of the AiMI (AngioJet in Myocardial Infarction) Trial6.
New data from the JetSTENT Trial suggest better myocardial reperfusion (better ST-segment 
resolution) and lower MACE at 6 months and 1 year with rotational thrombectomy in patients 
with moderate and large thrombus burden (grades 3–5)7 .
De Luca and colleagues analyzed nine randomized trials with 2,417 patients and compared 
PCI using manual thrombectomy with PCI alone8. This meta-analysis found that manual 
thrombectomy was associated with more frequent TIMI 3 fl ow post-PCI (87% versus 81%, 
p<0.0001), more frequent grade 3 myocardial blush (MBG 3) (52% versus 32%, p<0.0001), less 
distal emboli (7.9% versus 19.5%, p<0.0001) and lower 30-day mortality (1.7% versus 3.1%, 
p=0.04) compared to PCI alone.
Burzotta and colleagues performed a meta-analysis of 11 randomized trials with mechanical 
or manual thrombectomy upon primary PCI using a patient level analysis which allowed 
evaluation of outcomes in subgroups9. Overall mortality and MACE were reduced with 
thrombectomy, but subgroup analyses found that these benefi ts were observed only in 
patients treated with manual thrombectomy and only in patients treated with glycoprotein 
IIb/IIIa inhibitors. Time to reperfusion, infarct-related artery, and initial TIMI fl ow did not have 
any signifi cant impact on the benefi t of thrombectomy.
Mongeon and colleagues performed a Bayesian meta-analysis of 21 randomized trials, 16 tri-
als evaluating aspiration thrombectomy and 5 trials evaluating mechanical thrombectomy10. 
The authors presented the results of all 21 trials combined and also presented the results of 
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the 16 trials with aspiration, and the results were similar. In patients treated with aspiration, 
there were fewer distal emboli, less no-refl ow, more frequent TIMI 3 fl ow post-PCI, more ST 
resolution >50%, and more MBG3 compared to no aspiration. There were no signifi cant dif-
ferences in 30-day mortality between both groups of patients.
1.3. Limitations of current evidence
The evidence supporting the benefi t of aspiration thrombectomy on surrogate outcomes 
(TIMI fl ow, myocardial blush grade, and ST-resolution) and angiographic outcomes (distal 
emboli and no-refl ow) is strong and convincing. However,the evidence supporting the ben-
efi t in mortality reduction is less strong and has limitations.
The TAPAS Trial, which showed a signifi cant mortality reduction at 1 year with aspiration 
thrombectomy, was a single center study and was not powered to evaluate mortality2. The 
46% reduction in mortality was certainly not expected and may have occurred by chance3. 
Some of the benefi t of aspiration may be from direct stenting, which was performed in 59% 
of patients who underwent thrombus aspiration, although direct stenting would not dimin-
ish the benefi t of thrombus aspiration.
1.4. Current guidelines
Based on the TAPAS Trial and the meta-analyses mentioned above, the ACC/AHA Guidelines 
have given aspiration thrombectomy a Class IIa (Level of Evidence B) indication with primary 
PCI for STEMI, and the ESC Guidelines recently upgraded aspiration thrombectomy to Level of 
Evidence A11, 12. This opinion states that “aspiration thrombectomy is reasonable for patients 
with STEMI undergoing primary PCI.” The committee did not feel that the evidence for benefi t 
on clinical outcomes was strong enough to warrant a Class I indication.
1.5. Selective strategy of thrombus aspiration
All randomized trials with aspiration thrombectomy have been performed in “all comers” 
with STEMI, and it is not clear which subgroups may benefi t most and which subgroups may 
not benefi t at all. There are little data to help answering this question. 
Sianos and colleagues have shown that both angiographic outcomes and clinical outcomes 
are worse in STEMI patients with large thrombus burden1. Napodano and colleagues found 
that patients with RCA infarcts, long lesions and high thrombus score had the highest 
frequency of distal embolization13. We might expect these subgroups to benefi t most from 
thrombectomy, but data from the TAPAS trial do not support this2. Improvement in myocar-
dial blush grade with aspiration was no better in patients with RCA infarcts versus non-RCA 
infarcts, and was no better in patients with visible thrombus compared with patients without 
visible thrombus2. There was a trend for more benefi t in patients with reperfusion time of 
less than 3 hours, but there were no diff erential benefi ts in patients stratifi ed by pre-PCI TIMI 
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fl ow2. Overall, there is scarce data to support selective use of aspiration thrombectomy in any 
subgroup of STEMI patients treated with primary PCI.
Aspiration thrombectomy has limited ability to remove large thrombi and is occasionally as-
sociated with incomplete thrombus removal, no-refl ow, and/or distal emboli. There is recent 
evidence that mechanical thrombectomy may eff ectively improve outcome in patients with 
large thrombus burden7. Whether mechanical thrombectomy is preferable to aspiration 
thrombectomy in patients with large thrombus burden or in patients presenting late with 
organized thrombus remains an unanswered question.
2.  Angiographic thrombus burden classifi cation in patients with STEMI treated 
with primary PCI
Thrombus formation is a sensitive, dynamic process which demands accurate classifi cation 
and compulsive management. Optimal angiographic visualization of thrombus is the fi rst 
step. Thrombus is assessed according to the criteria summarized by Mabin et al14. These crite-
ria include; (i) the presence of an intraluminal central fi lling defect or lucency surrounded by 
contrast material that is seen in multiple projections, and (ii) persistence of contrast material 
within the lumen. Intracoronary thrombus was angiographically identifi ed and scored in fi ve 
grades as previously described by the TIMI study group15. According to this classifi cation, 
in thrombus Grade 0 (G0), no cineangiographic characteristics of thrombus are present.
In thrombus Grade 1 (G1) thrombus may be present, with angiographic characteristics as 
reduced contrast density, haziness, irregular lesion contour, or a smooth convex “meniscus” 
at the site of total occlusion suggestive but not diagnostic of thrombus. In thrombus Grade 
2 (G2), there is defi nite thrombus, with greatest dimensions ≤ 1/2 the vessel diameter. In 
thrombus Grade 3 (G3), there is defi nite thrombus, but with greatest linear dimension > 1/2 
but < 2 vessel diameters. In thrombus Grade 4 (G4), there is defi nite thrombus, with the larg-
est dimension ≥ 2 vessel diameters, and in thrombus Grade 5 (G5), there is total occlusion.
3. Adjunctive abciximab in STEMI 
GpIIb-IIIa inhibitors are the most powerful class of antiplatelet therapies, and their adjunctive 
benefi cial eff ects to improve perfusion and mortality in STEMI patients have been shown 
in several randomized trials16-18. A previous meta-analysis of randomized trials has shown 
signifi cant benefi ts of GpIIb-IIIa inhibitors in mortality and re-infarction of STEMI patients19. 
However, these benefi ts have disappeared in recent large randomized trials (BRAVE-3 and 
HORIZONS trials)20, 21 conducted with abciximab on top of clopidogrel administration. In the 
BRAVE-3 trial20, 800 patients were randomized to abciximab or placebo before angioplasty, on 
top of 600 mg clopidogrel loading dose. This study did not show benefi ts of abciximab either 
in the primary endpoint (infarct size as estimated by scintigraphic techniques) or mortality 
(2.5 vs. 3.2%). It should be emphasized that even though the aim of the study was to evalu-
ate the impact of abciximab on infarct size, the median ischemic time was 4.5 h. It may be 
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arguable whether any adjunctive therapy in the late phase of ‘golden hours’ would provide 
adjunctive benefi ts in terms of infarct size22. Furthermore, the risk profi le was relatively low to 
evaluate the benefi ts in terms of clinical outcome. A relatively low-risk population has been 
enrolled in BRAVE-3 trial20 that rather suff er from bleeding complications than from throm-
botic complications. In the large HORIZONS trial21 3602 STEMI patients were randomized to 
heparin + GpIIb-IIIa inhibitors, or tobivalirudin. Patients received 300 or 600 mg clopidogrel 
loading dose (the decision was left to the physician’s discretion). Surprisingly, bivalirudin was 
associated with a mortality reduction, despite the signifi cantly higher rate of acute in-stent 
thrombosis. The relatively low mortality may have hampered the conclusion of these recent 
trials. Recently, a meta-regression analysis of randomized trials has also emphasized a mortal-
ity benefi t of abciximab administration especially in patients with a higher risk profi le23. 
3.1. Early abciximab administration
Despite the negative results of the FINESSE trial24, early administration of abciximab may 
certainly be encouraged due to the benefi ts with early administration observed in the Abcix-
imab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and 
Long-Term Follow-up (ADMIRAL) trial17, and in several recent reports25-28.
Since high-dose clopidogrel administration takes 3–4 h to reach the top of inhibition of plate-
let aggregation29, GpIIb-IIIa inhibitors are considered to rapidly inhibit platelet aggregation, 
with subsequent benefi ts in mortality according to the risk profi le. The use of risk scores, such 
as the TIMI Risk Score30, should be strongly encouraged to identify a high risk population with 
thrombotic complications that largely outweigh the risk of bleeding complications. Those 
patients may subsequently benefi t in terms of mortality from aggressive antithrombotic 
therapy. It was also concluded in our study (Chapter 3) that absence of pre-infarction angina 
(PIA) could predict higher thrombus burden compared to patients with PIA and should be 
taken in consideration, among other risk scores, if a selective strategy of pre-hospital abcix-
imab administration is to be adopted.
4. Drug eluting stents, future perspectives
Drug eluting stents (DES) have changed the landscape of interventional cardiology with their 
high effi  cacy in preventing restenosis. Several DES are available for clinical use with diff erent 
drugs, polymers and platforms. Despite all the benefi ts of DES, concerns have been raised 
with regard to their long-term safety, with particular reference to stent thrombosis. Especially 
the permanent polymers, that carry the drug to be eluted, are infl icted in this regard. In an 
eff ort to address these concerns, newer stents have been developed including; DES with bio-
degradable polymers, DES that are polymer free, stents with novel coatings, and completely 
biodegradable stents. Many of these stents are currently undergoing pre-clinical and clinical 
trials; however, early results seem promising31.
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4.1. Biolimus A9
Biolimus A9 is a highly lipophilic sirolimus analogue that has been combined with an ablu-
minal poly-lactic acid (PLA) biodegradable polymer on a number of diff erent stent platforms. 
The polymer biodegrades within 6 to 9 months, and its abluminal location ensures more 
targeted tissue release and reduced systemic exposure (Figure 1). Biomatrix® and Nobori® 
stents are the two main biolimus A9-eluting stents. 
Figure 1: The elution pattern of Biolimus A9 (BA9) and the corresponding biodegradation pattern of the 
poly-lactic acid (PLA) polymer. Adapted from Garg and Serruys et al31
4.1.1. BIOMATRIX STENT®
The Biomatrix stent (Biosensors, Morges, Switzerland), carrying a biodegradable PLA polymer, 
was shown to be noninferior for MACE, a composite of cardiac death, MI, and ischemia-driven 
target vessel revascularization (TVR) at 12-month follow-up when compared with the Cypher 
sirolimus eluting stent (SES) among the 1,707 patients enrolled in the randomized, all-comers 
LEADERS (Limus Eluted from A Durable versus ERodable Stent coating) trial (Biomatrix 10.6% 
vs. Cypher 12.0%, p = 0.37)32. More recently, the preservation of this noninferiority has been 
confi rmed at 2-year follow-up33. Further promising data in support of a biodegradable poly-
mer were obtained in an optical coherence tomography (OCT) substudy, that demonstrated a 
higher rate of near complete (>95%) strut coverage with the Biomatrix stent when compared 
with the Cypher SES at 9-monthsfollow-up (89.3% vs. 63.3%, p = 0.03)34.
4.1.2. NOBORI STENT®
The Nobori stent (Terumo, Leuven, Belgium) utilizes the same PLA polymer and the same 
antiproliferative agent as the aforementioned BioMatrix stent. Physically, both stent plat-
forms are identical, the only diff erences being the delivery system, delivery balloon, and the 
stent coating process. The BioMatrix stent is coated by an automated autopipette proprietary 
technology, whereas the Nobori stent is not coated using an automated process. The Nobori 
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stent has so far been compared with the Cypher SES and TAXUS paclitaxel eluting stent (PES) 
with promising results35-37. In the NOBORI CORE study, the reported late loss at 9-month 
follow-up between the 99 patients randomized to treatment with either the Nobori stent or 
the Cypher SES was 0.10 mm, and 0.12 mm, respectively (p =0.66)37. Moreover, treatment with 
the Nobori stent also appeared to result in a signifi cantly better recovery of endothelial func-
tion compared to Cypher SES38. This fi nding has subsequently been reconfi rmed by Hamilos 
et al39 who demonstrated normal vasodilation after implantation of the Nobori stent, in line 
with other second generation DES and BMS, compared with the paradoxical vasoconstric-
tion observed following implantation of fi rst generation DES. Following on from this, the 
Nobori I study randomized 243 patients to treatment with either the Nobori stent (n =153) 
or the TAXUS PES stent (n = 90). Results at 9 months among the 86% of patients returning for 
follow-up demonstrated non-inferiority, and subsequent superiority, of the Nobori stent with 
respect to late loss when compared with the TAXUS PES stent (0.11 mm vs. 0.32 mm, p non-
inferiority =0.001, p-superiority = 0.001). Similarly, the rate of Academic Research Consortium 
(ARC)-defi ned stent thrombosis at 9-month follow-up was also lower with the Nobori stent 
(0.0% vs. 2.2%)36. Overall, the evaluation of the Nobori stent has so far been performed in over 
3,000 patients, and encouragingly, no episodes of very late in-stent thrombosis have been 
reported. Further assessment of the stent is underway, including randomized comparisons in 
“real-life” populations with the Xience V EES in the COMPARE 2 (n=2,700) and BASKET PROVE 
2 (n = 2,400) studies and with the Cypher Select SES in SORT-OUT IV study (n=2,400)40.
5. In-stent restenosis and thrombosis. Defi nitions and classifi cations
Restenosis, or reduction in lumen diameter after PCI, is the result of arterial damage with 
subsequent neointimal tissue proliferation. Binary angiographic restenosis is defi ned as 
≥ 50% luminal narrowing at follow-up angiography. Mehran and colleagues proposed an 
angiographic classifi cation of restenosis41 (Figure 2). The most widely accepted defi nition of 
clinical restenosis, assessed as a requirement for ischemia-driven repeat revascularization, 
was proposed by the Academic Research Consortium42. This defi nition requires both an as-
sessment of luminal narrowing and the patient’s clinical context (Table 1). Stent thrombosis 
frequently presents as myocardial infarction (MI), whereas in-stent restenosis presents as MI 
in a small minority of cases43. The Academic Research Consortium proposed a defi nition of 
stent thrombosis that found general acceptance (Table 1). In addition to the level of certainty, 
stent thrombosis is stratifi ed relative to the timing of the event as: acute stent thrombosis 
(0-24 hours after stent implantation), subacute stent thrombosis (>24 hours to 30 days after 
stent implantation), late stent thrombosis (>30 days to 1 year after stent implantation), and 
very late stent thrombosis (> 1 year after stent implantation). Acute or subacutestent throm-
bosis can also be replaced by the term early stent thrombosis (0-30 days).




Type IA: articulation or gap Type IB: margin
Type IC: focal body
Type II: intrastent Type III: proliferative
Type IV: total occlusion
Type ID: multifocal
Figure 2: Schematic representation of 4 patterns of in-stent restenosis (ISR). Pattern I contains 4 types (A-
D). Patterns II through IV are defi ned according to geographic position of ISR in relation to previously im-
planted stent. Adapted from Mehran et al40
6. Stent malapposition
Stent malapposition (SM) is defi ned as a lack of contact between stent struts and the underly-
ing vessel wall not overlying a side branch. SM can be quantifi ed by:
• measuring the number of malapposed struts
• the arc subtended by the malapposed struts
• the distance between the malapposed struts and the vessel wall
•  the area, the length and the volume of the gap between the stent and the vessel wall.47
SM can be acute, occurring at the time of stent implantation, or late, detected at follow-up. 
Focusing on late stent malapposition, several mechanisms have been proposed:
•  positive arterial remodeling with an increase of external elastic membrane (EEM) out of 
proportion to the increase in persistent plaque and media
•  a decrease in plaque and media due to dissolution of jailed thrombus or plaque debris, i.e. 
patients undergoing stent implantation during STEMI
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•  SM not recognized at implantation and detected at follow-up (persistent SM); this may be 
mediated in part by severely calcifi ed lesions not allowing for homogenous stent expansion 
and resulting in stent under-expansion
• chronic stent recoil without any change in arterial dimensions.48
Table 1: Defi nition and Classifi cation of restenosis and thrombosis according to ARC41
Angiographic restenosis and classifi cation (Figure 2)
Diameter stenosis ≥ 50%
Type 1 focal: ≤ 10 mm in length




Typ2 diff use: >10 mm intrastent
Type 3 proliferative: >10mm extending beyond the stent margin
Type 4 total occlusion: restenotic lesion with TIMI fl ow grade of 0
Clinical Restenosis: Assessed Objectively as Requirement for Ischemia-Driven Repeat Revascularization
Diameter stenosis ≥ 50% and one of the following:
Positive history of recurrent angina pectoris, presumably related to target vessel
Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to 
target vessel
Abnormal results of any invasive functional diagnostic test (e.g., coronary fl ow velocity reserve, FFR <0.80); IVUS 
minimum cross-sectional area <4 mm2 (and <6.0 mm2 for left main stem) has been found to correlate with 
abnormal FFR and need for subsequent TLR44-46.
TLR with diameter stenosis ≥ 70% even in absence of the above ischemic signs or symptoms
Stent Thrombosis
Defi nite stent thrombosis
•  Angiographic confi rmation of stent thrombosis
Presence of thrombus that originates in stent or in the segment 5 mm proximal or distal to stent and at least 1 
of the following within a 48-h time window:
Acute onset of ischemic symptoms at rest
New ischemic ECG changes that suggest acute ischemia
Typical rise and fall in cardiac biomarkers
•  Pathologic confi rmation of stent thrombosis
Evidence of recent thrombus within stent determined at autopsy or via examination of tissue retrieved 
following thrombectomy
Probable stent thrombosis
• Any unexplained death within fi rst 30 days after stent implantation
•  Irrespective of time after the index procedure, any myocardial infarction that is related to documented acute 
ischemia in the territory of the implanted stent without angiographic confi rmation of stent thrombosis and in 
the absence of any other obvious cause.
Possible stent thrombosis
• Any unexplained death from 30 days after intracoronary stenting
ARC, academic research consortium; ECG, electrocardiography; FFR,fractional fl ow reserve; IVUS, intravas-
cular ultrasound; MI, myocardial infarction; TIMI,Thrombolysis In Myocardial Infarction; TLR,target lesion 
revascularization.
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6.1. Innovative therapies to handle stent malapposition
Self-expandable stents were the fi rst stents to be implanted in coronary arteries49, being 
quickly followed by balloon-expandable stents, such that both technologies were used with-
similar frequency in the early days of coronary stenting. Self-expandable stents are made from 
nitinol, an alloy of nickel and titanium that allow it to withstand large amounts of recoverable 
strain. In addition to comparable outcomes, self-expandable stents off er distinct advantages 
over balloon-expandable stents, such as a lower incidence of edge dissections50, 51, reduced 
rates of side-branch occlusion and no-refl ow51, and positive remodeling51. Unfortunately, the 
introduction of DES led to a loss of interest among stent companies in pursuing the develop-
ment of self-expandable stents, and they were largely abandoned for coronary use. However, 
there is renewed interest in this technology for niche coronary settings following new stent 
designs that have incorporated thinner struts, a drug coating, and improved delivery systems.
In addition to its initial promising results in treatment of bifurcation lesions52,  recent results 
from the completed APPOSITION II trial (Randomized Comparison Between the STENTYS 
Self-expanding Coronary Stent and a Balloon-expandable Stent in Acute Myocardial Infarc-
tion) (NCT01008085) using the STENTYSTM (STENTYS, Princeton, New Jersey and Paris) self-
expanding stent in treatment of patients with acute myocardial infarction, showed that, on 
optical coherence tomography, 0.51% of the struts were malapposed in the STENTYS group 
versus 5.33% in the balloon expandable stents at 3 days representing a 10-fold reduction. 
Taking >5% malapposed struts as a defi nition of malapposed stent, no STENTYS stents were 
malapposed compared to 28% of the balloon expandable stents (p<0.001). No events of 
stent thrombosis were recorded in both arms at 30 days follow-up53.
Another option is the fully biodegradable stent, which off er several potential advantages 
over conventional bare or drug-coated metallic stents. Since drug elution and vessel scaff old-
ing are only provided by the biodegradable stent until the vessel has healed, no malapposed 
stent struts are present at long term54.
7. Objective and outline of this thesis
In light of the issues described in this introduction chapter, the aim of this thesis was: 1) 
to evaluate the adjunctive role of aspiration thrombectomy among ST-segment elevation 
myocardial infarction (STEMI) patients receiving early (in-ambulance) abciximab prior to 
primary percutaneous coronary intervention (PPCI), 2) to assess the predictors of thrombus 
burden in STEMI patients undergoing PPCI and whether there is a diff erence in infarct size 
among patients with high and low thrombus grades, 3a) to evaluate and review the clini-
cal performance of various biodegradable-polymer drug eluting stents (DES) , comparing 
the incidence of defi nite stent thrombosis and target lesion revascularization between 
biodegradable-polymer biolimus-, sirolimus- and paclitaxel-eluting stents, 3b) to compare 
the incidence of defi nite stent thrombosis and target lesion revascularization between 
biodegradable-polymer DES and permanent-polymer DES, 4) to review the recently emerg-
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ing drugs for coronary artery disease with special emphasis on antiplatelets, antithrombotics 
and antidyslipidemics, 5) to provide an overview of the recent innovations for optimizing 
the outcomes of coronary stenting, as well as up-to-date information about prevention and 
treatment of in-stent restenosis, and 6) to present a review of late stent malapposition in the 
bare metal stent (BMS) and DES era.
In Chapter 2 we present a retrospective analysis in the MISSION! prospective interventional 
study, comparing PPCI with thrombus aspiration (thrombectomy-facilitated PCI) to PPCI 
without thrombus aspiration (conventional PCI) in patients with STEMI receiving early 
(in-ambulance) abciximab. We illustrate the primary end-point of the study (complete ST 
segment resolution at 90 min. post-PCI), as well as secondary end-points represented by 
enzymatic infarct size (measured by peak levels of creatine kinase and troponin-T), and 
left ventricular ejection fraction (LVEF) at 3 months (evaluated by myocardial scintigraphy). 
Finally we describe the incidence of major adverse cardiac events (all-cause death, cardiac 
death, recurrent myocardial infarction and revascularization) at 1 year follow-up.
Chapter 3 is a sub-study of the former. We tried to assess the predictors of thrombus grade 
among diff erent clinical, angiographic and laboratory data. We categorized patients accord-
ing to baseline TIMI thrombus grade into those with high thrombus grade (HTG) and low 
thrombus grade (LTG). We also assessed infarct size and scintigraphic LVEF at 3 months in 
both patient groups.
In Chapter 4 we present a meta-analysis and systematic review comparing the risk of defi nite 
stent thrombosis (DST) and target lesion revascularization (TLR) among biodegradable-
polymer biolimus, sirolimus and paclitaxel DES. We also compare the risk of DST and TLR 
between biodegradable-polymer DES and permanent-polymer DES.
Chapter 5 is a review article in which we provide an almost complete overview of the recent 
and emerging drug therapies of CAD. This includes drugs for the treatment of atherogenic 
dyslipidemia, drugs that stabilize atherosclerotic plaques and halt their progression guided 
by novel anti-infl ammatory concepts in atherosclerosis treatment, anti-anginal treatments, 
renin-angiotensin-aldosterone system inhibitors, antiplatelet drugs and anticoagulant drugs.
In Chapter 6 we provide an overview of in-stent restenosis as one of the challenges that we 
encounter in interventional cardiology. We discuss the up-to-date developments in preven-
tion and treatment of in-stent restenosis and optimization of the outcomes of PCI.
Chapter 7 presents a review on late stent malapposition. We discuss its much debated role in 
stent thrombosis and future perspectives in handling it.
Finally, in Chapters 8 and 9 a general summary, conclusion and future perspectives are 
described in English and Dutch respectively.
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ABSTRACT
Background The benefi ts of early abciximab administration and thrombus aspiration in 
ST elevation myocardial infarction (STEMI) patients undergoing primary percutaneous 
coronary intervention (PPCI) have been previously elaborated. However, whether there 
is adjunctive eff ect of thrombus aspiration among STEMI patients, with angiographic 
evidence of thrombus, receiving early pre-hospital abciximab remains unclear. 
Methods In the context of a fi xed protocol for PPCI, 158 consecutive patients with STEMI 
were enrolled, in whom abciximab was started early before hospital arrival (in-ambulance); 
79 patients who had PPCI with thrombus aspiration (thrombectomy-facilitated PCI group), 
were compared to 79 who had PPCI without thrombus aspiration (conventional PCI group) 
in a prospective non-randomized study. The primary end-point was complete ST-segment 
resolution within 90 min. Secondary end-points included distal embolization, enzymatic 
infarct size as well as left ventricular ejection fraction (LVEF) assessed by Gated-Single 
Photon Emission Computed Tomography (SPECT). Major adverse cardiac events (MACE) 
were evaluated up to 12 months. 
Results Both groups were comparable for baseline characteristics. ST-segment resolution 
was signifi cantly higher in the thrombectomy-facilitated group (p=0.002), and multivariate 
analysis identifi ed thrombectomy as an independent predictor of ST-segment resolution 
(OR= 9.4, 95% CI = 2.6-33.5, p=0.001). Distal embolization was higher in the conventional 
PCI group among patients with higher thrombus grades. No diff erence was observed 
between both groups in infarct size assessed by peak CK (p=0.689), and peak Tn-T levels 
(p=0.435). Also the LVEF at 3-months was similar (p=0.957). At 12 month clinical follow-up, 
thrombus aspiration was however associated with reduced all-cause mortality (log-rank 
p= 0.032). 
Conclusion Among STEMI patients treated with PPCI and in-ambulance abciximab, it ap-
pears that a selective strategy of thrombus aspiration still has additive benefi t.
Key words ST segment elevation myocardial infarction, primary percutaneous coronary 
intervention, abciximab, thrombus aspiration.
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INTRODUCTION
It has been widely observed that primary percutaneous coronary intervention (PPCI) off ers 
greater reperfusion benefi ts in the setting of acute myocardial infarction (MI) compared 
to intravenous thrombolytic therapy1. However, despite a good epicardial fl ow after PPCI, 
a considerable percentage of patients have impaired myocardial perfusion mainly due to 
embolization of the microcirculation2. Poor myocardial reperfusion is associated with adverse 
outcome including reduced left ventricular function and mortality3-5
Recent studies demonstrated that Glycoprotein (GP) IIb,IIIa platelet receptor antagonists have 
positive eff ects on reperfusion in the setting of primary percutaneous coronary interven-
tions, with improved clinical outcome6. Many studies showed that these benefi ts are more 
apparent when GP IIb,IIIa platelet receptor antagonists are introduced as early as achievable 
in the setting of acute myocardial infarction7-12.
Additionally, numerous adjunctive coronary devices have been developed in an attempt 
to decrease or prevent distal embolization during revascularization and thereby trying to 
improve clinical outcome as well.
Recent randomized trials demonstrated that patients treated with a thrombectomy catheter 
showed better angiographic and electrocardiographic signs of myocardial reperfusion, as 
well as improved 1 year clinical outcome13-16. These data have been confi rmed by recent meta-
analyses demonstrating that adjunctive manual thrombectomy in the setting of primary PCI 
is associated with improved epicardial and myocardial perfusion, less distal embolization17, 
as well as improved clinical outcome18 
However, it is still unknown whether there is a possible benefi t of using thrombus aspiration 
devices in the setting of PPCI among STEMI patients receiving early GP IIb,IIIa platelet recep-
tor antagonists. Therefore, in this study the results of adjunctive manual thrombus aspiration 
using aspiration thrombectomy catheter were compared to no thrombus aspiration in a 




This is a single center non-randomized prospective study. All patients were treated according 
to the institutional STEMI protocol (MISSION!) implemented at Leiden University Medical 
Centre (LUMC) since February 2004, which includes a standardized prehospital, in-hospital 
and outpatient clinical framework for decision making and treatment19, 20. The tertiary center 
provides a round-the-clock service of PPCI with highly experienced PCI physicians and dedi-
cated nurses. 
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Study population
Inclusion and exclusion criteria
The inclusion criterion was a diagnosis of acute MI defi ned by chest pain suggestive of 
myocardial ischemia for at least 30 minutes, with a time from onset of symptoms of <9 hours 
before hospital admission, and an electrocardiogram (ECG) with ST-segment elevation of >0.1 
mV in ≥2 leads. Exclusion criteria were recent surgery, recent stroke, hemorrhagic diatheses, 
and known contraindications for therapy with abciximab, aspirin, clopidogrel or heparin.
Study groups
A total of 158 consecutive patients; who fulfi lled the inclusion and exclusion criteria for 
this study, and who received early in-ambulance abciximab, were enrolled: 79 consecutive 
patients, in whom a thrombectomy catheter was used at the start of the procedure (the 
thrombectomy-facilitated PCI group); were compared to 79 consecutive patients within the 
same period, in whom thrombectomy catheter was not used (the conventional PCI group). 
The study complies with the Declaration of Helsinki. The MISSION! protocol has been ap-
proved by the local ethics committee.
Medication
All patients received abciximab (Centocor B.V., Leiden, The Netherlands) as a bolus injection 
of 0.25 mg/ kg body weight, followed by 0.125 mcg/kg/min with a maximum of 10 mcg/
min as a continuous infusion for 12 hr. Abciximab administration started early in the am-
bulance according to the adapted MISSION! protocol19, 20. Furthermore all patients received 
an equivalent of 300 mg of acetylsalicylic acid, 600 mg clopidogrel as a loading dose in the 
ambulance and heparin given as a bolus of 5000 IU at the start of the PCI procedure. After the 
procedure, all patients received aspirin (75 mg/day) indefi nitely and clopidogrel (75 mg/day) 
for one year. Other medications, including b-blockers, ACE-inhibitors, nitrates, and statins, 
were prescribed according to MISSION! protocol.
Invasive Procedure and Angiographic Evaluation
All PPCI was performed through a 6F femoral sheath. Patients underwent PPCI and stenting 
of the infarct-related artery (IRA) according to standard techniques. The choice of stent (bare-
metal stent or drug-eluting stent) was left to the operator’s discretion. Direct stenting, which 
is stent placement without balloon pre-dilatation, was performed only in cases presenting 
clear views of the arterial lesion with adequate fl ow. We also considered stent placement 
which was only preceded by thrombectomy as direct stenting. Otherwise, the patient was 
subjected to balloon angioplasty and stenting was done subsequently. The choice of the bal-
loon size was left to the operator’s decision. Stent implantation was successfully completed 
in all patients, apart from only one patient in the thrombectomy-facilitated PCI group where 
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the procedure was complicated by a spiral dissection occurring after thrombectomy and 
had to undergo emergency coronary artery bypass graft (CABG), and this patient survived 
and completed the follow-up period. The choice of performing thrombectomy was left to 
the operator’s discretion. Thrombectomy was often, but not exclusively, performed when 
high thrombus burden was observed at the initial angiographic image of the target vessel. 
There was no change in the frequency of use of thrombectomy over the time period of the 
study. Thrombus was assessed according to the criteria summarized by Mabin et al.21. These 
criteria include the presence of an intraluminal central fi lling defect or lucency surrounded 
by contrast material that is seen in multiple projections; the absence of calcium within the 
defect; and persistence of contrast material within the lumen. Thrombus score was graded as 
previously described by the thrombolysis in myocardial infarction (TIMI) Study Group22, 23. We 
further categorized the thrombus score into 2 overall grades; a high thrombus grade (grades 
4 and 5), and a low thrombus grade (grades 1-3). We decided to use this cut-off  value in line 
with 2 recent studies24, 25 suggesting prognostic implications of this cut-off . Coronary fl ow 
was graded according to TIMI criteria26. TIMI fl ow grade was evaluated at baseline and after 
the PCI procedure. Distal embolization after PCI was defi ned as a fi lling defect with abrupt 
cutoff  in the vessel located distally of the culprit lesion. Procedural success was defi ned as 
residual stenosis <20% and TIMI fl ow grade 3. The coronary angiograms were reviewed off -
line by two independent interventional cardiologists who were blinded to the clinical data.
Thrombectomy catheter
The Export Aspiration Catheter (Medtronic Corporation, Minneapolis, Minnesota (MN), USA) 
is a 6F thrombus aspiration catheter13. Thrombosuction was started proximal to the occluded 
site, gently pushing the catheter through the occlusion and then pulling it in a proximal 
direction, keeping negative pressure once the occlusion was crossed or if there was no longer 
backfl ow in the syringe. This could be repeated several times. Withdrawal of the catheter 
from the artery and from the guiding catheter was performed with permanent negative pres-
sure. After each pass the catheter was fl ushed and the syringe emptied over a fi lter, to show 
the retrieved debris.
End-points and clinical follow-up
According to the MISSION! Protocol all patients were seen at the dedicated out-patient clinic 
after 1, 3, 6, and 12 months. The primary endpoint was ST-segment resolution within 90 min. 
after PPCI; secondary endpoints were distal embolization, enzymatic infarct size and LVEF as 
assessed by Gated-SPECT. Also major adverse cardiac events (MACE) occurring within one year 
of follow-up were recorded. These include all-cause death, cardiac death, reinfarction, target 
vessel and target lesion revascularization; death was regarded as cardiac unless an unequivocal 
non-cardiac cause of death was established. Reinfarction was defi ned as recurrent symptoms 
with new ST-segment elevation and elevation of cardiac markers to at least twice the upper 
Tarek Ahmed bw.indd   31 15-11-11   18:04
32 Chapter 2
limit of normal. Target vessel (TVR) and target lesion (TLR) revascularization were defi ned as 
any revascularization procedure of the target vessel or target lesion (from 5 mm distally to the 
stent up to 5 mm proximally to the stent), respectively. All major adverse cardiac events were 
assessed and classifi ed by an interventional cardiologist unaware of the treatment allocation. 
Electrocardiographic data
The 12-lead ECG was recorded at presentation and within 90 min after PPCI. The magnitude 
of ST-segment elevation is measured 60 milliseconds from J point. ST-segment score is calcu-
lated as the sum of ST-segment elevation > 0.1 mV for leads V1 through V6 and I, II, and aVL 
in anterior infarction and I, II, aVF, V5, and V6 in non-anterior infarction27. All ECGs were col-
lected and analyzed by an investigator blinded to the assigned treatment. Total ST-segment 
elevation at inclusion was compared with that taken within 90 min after PPCI. A complete 
ST-segment resolution was calculated, defi ned as resolution of the initial ST-segment eleva-
tion of ≥70%28.
Enzymatic Infarct Size
Creatine kinase (CK) activity and cardiac troponin-T (Tn-T) concentration in plasma were 
determined at admission and every 6 hr in the fi rst 48 hr after PPCI. Subsequently these 
levels were determined every day up to discharge, unless clinical events suggested repeat 
measurements. Peak levels of CK and Tn-T in plasma were calculated as a measure of infarct 
size in each patient by an investigator blinded to the assigned treatment.
Myocardial Perfusion Imaging
According to the MISSION! Protocol all included patients were enrolled for a myocardial per-
fusion study at 90 days post-PPCI. An ECG-gated single photon emission computed tomog-
raphy (SPECT) acquisition at rest using intravenous Technetium 99 m Tetrofosmin (MYOVIEW, 
Amersham, Buckinghamshire, UK) was used to measure the left ventricular ejection fraction 
(LVEF) 90 days after PPCI. LVEF was calculated using an automated and validated method (QGS 
software, version 2.0; Cedars-Sinai Medical Center, Los Angeles, CA, USA). Detailed methods 
are described elsewhere29. Patients in whom the gated SPECT could not be performed due 
to technical diffi  culties, LVEF estimated by echocardiographic biplane method was used 
instead. LVEF assessment was done by an investigator blinded to the assigned treatment.
Statistical analysis
Categorical variables were compared using the X 2 test or Fisher’s exact test. Continuous 
normally distributed data were tested by student t-test or in the case of a non-Gaussian 
distribution by a nonparametric test for independent samples (Mann Whitney U test). One 
year clinical outcomes were analyzed using Kaplan Meier methodology and were compared 
with log-rank test pooled over strata. Multivariate linear regression and logistic regression 
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analyses were used to create models for both PCI groups (as the variable of interest) adjusted 
for all potentially relevant variables including; age, sex, hypertension, smoking, diabetes, dys-
lipidemia, symptom onset to balloon time, prior medications (aspirin, clopidogrel, statins), as 
well as angiographic and procedural variables ( Infarct related artery, proximal location of the 
culprit lesion, balloon predilatation and thrombus grade), to identify whether thrombectomy 
is an independent predictor for the end points of ST-segment resolution, distal embolization, 
infarct size assessed by cardiac enzymes or LVEF. All tests were two-sided, and a p-value of < 
0.05 was considered signifi cant. All analyses were performed with PASW version 17.0 statisti-
cal software (SPSS Inc. - An IBM Company, Chicago, IL, USA).
RESULTS
Study population
One-hundred and fi fty-eight patients were included in the study according to the eligibility 
criteria (Figure 1 Flow diagram). The baseline clinical characteristics were comparable be-





79 patients undergo PCI
without export catheter
“Conventional PCI”










LVEF estimation ±90 days
by echocardiographic 2-D
biplane method for those





Figure 1: Flow diagram of the study patients. LVEF, left ventricular ejection fraction; PPCI, primary percuta-
neous coronary intervention; SPECT, single photon emission computed tomography; STEMI, ST elevation 
myocardial infarction; IH, in hospital.
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Angiographic and peri-procedural fi ndings
Angiographic and procedural data are summarized in Table 2. There was a signifi cantly higher 
rate of high grade thrombus in the thrombectomy-facilitated group (p<0.001), also there was a 
signifi cantly higher rate of balloon predilatation in the conventional PCI group (p= 0.002). The 
rate of distal embolization was higher in the conventional PCI group, though not signifi cant 
(p=0.516). However, when the analysis was restricted only to patients with high thrombus grade 
(grades 4 and 5), the rate of distal embolization turned out to be signifi cantly higher in the con-
ventional PCI group (p=0.012). Multivariate regression analysis including all potentially relevant 
clinical, angiographic and procedural risk factors, identifi ed only high thrombus grade as an 
independent predictor for distal embolization (odds ratio= 11.2, 95% CI= 1.6-76.6, p=0.013).






Age in years 59±10 56±12 0.080a
Male, n (%) 59(75) 62(78) 0.573b
Medical History, n (%)
 Hypertension 28(35) 24(30) 0.498b
 Hyperlipidemia 17(21) 24(30) 0.204b
 Smoking 53(67) 49(62) 0.796b
 Family history 31(39) 36(45) 0.421b
 Diabetes mellitus 7(9) 6(8) 0.772b
 Previous MI 8(10) 8(10) 1.0b
 Previous PCI 5(6) 7(9) 0.548b
 Previous CABG 1(1) 4(5) 0.173b
Killip Class. , n (%) 0.943b
 Class II 5(6) 5(6)
 Class III/IV 5(6) 4(5)
Heart rate (beats/min.) 73±16 73±17 0.924a
Systolic BP(mmHg) 133±26 127±22 0.145a
Symptoms to balloon (min) 135(90-195) 140(93-225) 0.707c
Start of abciximab to balloon (min) 40 (25-52) 35 (27-47) 0.554c
Previous aspirin 16(20) 10(13) 0.198b
Previous clopidogrel 0(0) 1(1) 1.0b
Previous statins 12(15) 13(16) 0.827b
Data are presented as mean ± standard deviation, number (%) of patients or median (Interquartile range).
MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; 
BP, blood pressure.
a Compared using unpaired t test.
b Compared using Chi-square or Fisher exact test.
c Compared using Mann-Whitney U test.
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Infarct related artery, n (%) 0.191b
 Left main artery 1(1) 2(2)
 Left anterior descending artery 31(39) 28(35)
 Circumfl ex artery 15(19) 7(9)
 Right coronary artery 32(40) 42(53)
Diseased vessels, n (%) 0.211b
 1-vessel 44(56) 48(61)
 2-vessel 26(33) 28(35)
 3-vessel 9(11) 3(4)
Proximal culprit lesion, n (%) 35(44) 40(50) 0.426b
Abciximab 78(98.7) 79(100) 0.924b
Initial TIMI fl ow grade, n (%) 0.779b
 0 41(52) 39(49)
 1 14(18) 15(19)
 2 13(16) 17(21)
 3 11(14) 8(10)
Final TIMI fl ow grade, n (%) 0.319b
 1 0(0) 2(2)
 2 11(14) 13(16)
 3 68(86) 64(81)
Drug eluting stents, n (%) 45(57) 52(70) 0.096b
Stent number 1.5±0.7 1.5±1.0 0.789a
Multiple stents, n (%) 31(39) 24(32) 0.402b
Predilatation, n (%) 66(83) 49(62) 0.002b
Thrombus detected, n (%) 75(95) 78(99) 0.367b
Thrombus grade, n (%) <0.001b
 High thrombus grade
 (Grades 4, 5)
29(39) 65(83)
 Low thrombus grade
 (Grades 1, 2, 3)
46(61) 13(17)
Distal embolization 10(13) 8(10) 0.516b
Distal embolization in high thrombus grade 9 (32%) 7(11%) 0.012b
Data are presented as mean ± standard deviation, number (%) of patients.
TIMI, Thrombolysis In Myocardial Infarction.
a Compared using unpaired t test.
b Compared using Chi-square or Fisher exact test.
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Electrocardiographic evaluation
The rate of post-PCI complete ST-segment resolution of ≥ 70% was observed more frequently 
in the thrombectomy-facilitated PCI group (87% vs. 65%, p=0.002) (Table 3).
Multivariate logistic regression analysis for ST-segment resolution among both PCI groups 
adjusted for all relevant clinical, angiographic and procedural variables identifi ed aspiration 
thrombectomy (odds ratio= 9.4, 95% CI = 2.6-33.5, p=0.001), shorter symptom to balloon time 
and absence of balloon predilatation as independent predictors of complete ST-segment 
resolution within 90 min. Post-PPCI.






Complete ST-segment resolution within 
90 min. (%)
45/69(65) 66/76(87) 0.002b
Peak CK (U/I) 2117±1927 2286±2168 0.689a
Time to peak CK (hours) 13(9-18) 14(10-17) 0.687a
Peak Tn-T(μg/l) 6.2±8.5 5.8±6.1 0.435a
Time to peak Tn-T (hours) 13(10-19) 14(11-17) 0.535a
Data are presented as mean ± standard deviation, number (%) of patients 
CK, creatine kinase; Tn-T, Troponin T.
a Compared using Mann-Whitney U test.
b Compared using Chi-square or Fisher exact test.
Enzymatic infarct size assessment
Peak levels of CK and Troponin-T were comparable in both PCI groups (p = 0.689 and p=0.435, 
respectively), and so were the time to peak levels of CK and Troponin-T (p=0.687 and p=0.535, 
respectively) (Table 3.). Multivariate linear regression analysis for Peak levels of CK and Tn-T 
including the aforementioned factors did not identify PCI groups as an independent predic-
tor of higher peak CK (B = 171.6, 95% CI= -620.4 – 963.6, p=0.669) and Troponin T (B = 0.77, 
95% CI= -2.19 – 3.73, p=0.610). 
Three-month LV function evaluation
One-hundred and thirty-eight patients underwent LV function assessment by myocardial 
perfusion scintigraphy (MYOVIEW) (Figure 1). Patients who did not undergo scintigraphy had 
their LV function assessed using biplane 2-D echocardiographic evaluation at 3 months, and 
one patient had unavailable data regarding the LV function assessment post-PCI due to in-
hospital death. LVEF was not signifi cantly diff erent between both groups (p=0.957) (Table 4). 
Multivariate linear regression analysis adjusted for all potentially relevant covariates did not 
identify aspiration thrombectomy as an independent predictor of improved LVEF (B = -1.0, 
95% CI= -5.96 – 3.95, p=0.689). 
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Clinical outcomes
All patients were followed for a median of 367 days , 5 patients died in the conventional PCI 
group (including one in-hospital death) vs. 0 patients in the thrombectomy-facilitated PCI 
group (p= 0.023), three (4%) of those deaths were cardiac (p=0.080). The 2 non-cardiac deaths 
were due to hepatic failure and terminal renal failure. Three (4%) patients underwent a target 
vessel revascularization in the conventional PCI group vs. 5(6%) patients in the thrombecto-
my-facilitated group (p= 0.719). Target lesion revascularization occurred in 4(5%) patients 
in the conventional PCI group vs. 2(2%) patients in the thrombectomy-facilitated group (p= 
0.405). Recurrent myocardial infarction occurred in 2 patients in the conventional PCI group 
vs. 0 patients in the thrombectomy-facilitated group (p= 0.155). Overall MACE occurred in 
10(13%) patients in the conventional PCI group vs. 7(9%) in the thrombectomy-facilitated 
group (p= 0.441) (Table 4).The Kaplan-Meier curves showed that allocation to thrombectomy 
was associated with a signifi cant reduction in 1-year all-cause mortality (log-rank p= 0.032) 
;( Figure 2), and a trend towards a reduction of the combined endpoint of cardiac death or 
reinfarction (log-rank p= 0.056); (Figure 3).






LVEF by Gated-SPECT 53.35±13.8 53.46±11.8 0.957a
Clinical follow up period 368(362-397) 367(188-391) 0.138c
Clinical end-points, n (%):
 Cardiac death 3(4) 0(0) 0.080b
 All-cause death 5(6) 0(0) 0.023b
 Re-infarction 2(3) 0(0) 0.155b
 Cardiac death/re-infarction 4(5) 0(0) 0.043b
 TVR 3(4) 5(6) 0.719b
 TLR 4(5) 2(2) 0.405b
 MACE 10(13) 7(9) 0.441b
Data are presented as mean ± standard deviation, number (%) of patients or median (Interquartile range).
LVEF, left ventricular ejection fraction; SPECT, Single Photon Emission Computed Tomography;
TVR, target vessel revascularization; TLR, target lesion revascularization; MACE, major adverse cardiac 
events.
a Compared using unpaired t test.
b Compared using Chi-square or Fisher exact test.
c Compared using Mann-Whitney U test.
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DISCUSSION
The main fi ndings of this study are: 1) A strategy of thrombus aspiration before stenting dur-
ing primary PCI among patients treated with early abciximab was associated with a higher 
rate of complete ST-segment resolution (≥ 70%) within 90 min post-PCI, 2) Among patients 
with high thrombus grades, thrombus aspiration was associated with less distal emboliza-
tion, 3) Thrombus aspiration was associated with a lower incidence of all-cause mortality, 
and a trend towards a lower incidence of combined end-point of cardiac death or reinfarction 
through a 1-year median clinical follow up. TVR, TLR and overall MACE were similar in both 
groups.
Unlike the TAPAS trial16, where abciximab was administered during the procedure of PPCI, 
our study provides a unique experience of the adjunctive infl uence of thrombus aspiration to 
early abciximab administration before PPCI. In the ATTEMPT study18, Burzotta and colleagues 
have interestingly shown that the benefi t of thrombectomy was more evident in patients who 
received GPIIb,IIIa-inhibitors thus suggesting a possible additive benefi t of thrombectomy in 
patients treated with GPIIb,IIIa-inhibitors. It might be speculated that pharmacological and 
mechanical thrombus remodeling are synergic to obtain the best myocardial reperfusion 
and, consequently, the best clinical outcome. Indeed, in the ATTEMPT study, patients treated 
by both thrombectomy and GPIIb,IIIa-inhibitors had the lowest mortality rate, those who 
had none of these treatments had the highest mortality rate, while patients receiving only 
one of these therapies exhibiting intermediate outcome. On the other hand, in the VAMPIRE 
trial30, where GP IIb,IIIa receptor antagonists were not used at all, patients presenting late 
after STEMI (>6 hours after symptoms) appeared to benefi t the most from thrombectomy, 
Patients at risk 
C-PCI                           79           76           73           71           62 
TF-PCI                         79           73           67           55            46 
Total                           158         149         140         126          108 
p= 0.032 
Figure 2: Kaplan-Meier 12 month cumulative 
event free survival from the endpoint of all-cause 
death; TF-PCI: Thrombectomy-facilitated PCI group, 
C-PCI: conventional PCI group.
Patients at risk 
C-PCI                           79           76           73           71           62 
TF-PCI                         79           73           67           55            46 
Total                           158         149         140         126          108 
Figure 3: Kaplan-Meier 12 month cumulative event 
free survival from the combined endpoint of car-
diac death or reinfarction. TF-PCI: Thrombectomy-
facilitated PCI group, C-PCI: conventional PCI group.
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suggesting that the use of GP IIb,IIIa receptor antagonists would have infl uenced the results. 
In our study, patients received abciximab prior to PCI, where abciximab was started before 
the arrival to the hospital. The benefi ts of this has been investigated in previous randomized 
clinical trials (RCTs)7, 8, 10-12, and in the study conducted by Hassan et al9 in the context of the 
MISSION! protocol, where it has been found that very early administration of abciximab (in-
ambulance) signifi cantly improves early reperfusion in STEMI patients treated with PPCI, this 
was also refl ected clinically with smaller infarct size, improved LV function and a lower risk 
of heart failure on follow up. This may explain why some of our study outcomes including 
enzymatic infarct size, LVEF, and some of the clinical end-points did not diff er between the 
2 groups, as it is likely that the early abciximab administration supersedes the infl uence of 
thrombectomy catheter.
Procedural and angiographic characteristics
In the current study there was a signifi cantly higher rate of direct stenting among the throm-
bectomy-facilitated group, a fi nding which is consistent with other randomized controlled 
trials13, 14, 16, 31-35.This can be explained by the fact that thrombus aspiration establishes a better 
antegrade coronary fl ow which allows selection and placement of a stent of appropriate 
length and diameter without the need for further balloon predilatation. The overall rate of 
distal embolization was not signifi cantly diff erent between both groups. However, limiting 
the analysis to patients with high thrombus grade (grades 4 and 5), showed a signifi cantly 
higher rate of distal embolization in the conventional PCI group. This was comparable to the 
results of the REMEDIA trial, where the overall distal embolization was not signifi cantly diff er-
ent between the studied groups. However, a subgroup analysis showed greater angiographic 
and electrocardiographic reperfusion benefi t with thrombus aspiration among patients with 
higher thrombus scores36. Diff erent studies showed variable results regarding post-PCI distal 
embolization. Despite its favorable procedural and clinical outcomes, the TAPAS trial showed 
no diff erence in the rates of distal embolization between conventional PCI and thrombus 
aspiration groups16. On the other hand, two large meta-analyses showed lower rates of distal 
embolization in the thrombus aspiration group37, 38.
ST-segment resolution
The eff ect of manual thrombus aspiration on the surrogate markers of myocardial reperfu-
sion has been widely discussed in many studies. ST-segment resolution post-PCI is one of the 
most widely used and assessed markers. In our study there was a signifi cantly higher rate of 
complete ST-segment resolution within 90 min in the thrombectomy-facilitated PCI group. 
This outcome is in accordance with some previous randomized controlled trials (RCTs)14, 16, 
32, 35, 36, 39, 40, and two recent large meta-analyses38, 41. On the other hand, some other RCTs re-
vealed no signifi cant diff erence in the rate of ST-segment resolution among both randomized 
groups13, 30, 31, 34, 42.
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Enzymatic infarct size
In our study there was no signifi cant diff erence between both study groups regarding the 
enzymatic infarct size as estimated by peak levels of CK and Tn-T. Several trials assessing 
thrombus aspiration devices measured infarct size using biochemical markers with variable 
results. The largest study published to date, using the Export catheter system, the TAPAS trial, 
also showed no diff erence in peak CK and CKMB levels between groups with and without 
thrombus aspiration16. The same was also noted in the EXPIRIA trial14. On the contrary, it has 
been noted by Kaltoft and colleagues in their randomized trial that peak Tn-T was signifi -
cantly higher in the thrombus aspiration group42, a result that has also been reported in the 
randomized trial by Anderson and colleagues43.
Left ventricular ejection fraction (LVEF)
There is a variety of confl icting data about the eff ect of thrombus aspiration on the infarct 
size which is the best surrogate end point for the assessment of new therapeutic tools in 
the setting of acute myocardial infarction44, 45, and which is refl ected by improved LV systolic 
function. In our study there was no benefi t in terms of LVEF after thrombus aspiration, which 
is consistent with some previous trials14, 30-32, 34, 42, 43, 46. Other trials showed diff erent results 
from our study39, 47. 
Clinical follow-up
In our study clinical data of the patients were available for a relatively long follow-up period 
(around 1 year), revealing that allocation to export aspiration thrombectomy was associated 
with lower incidence of all-cause mortality, in accordance with the fi ndings of the 2 large 
RCTs using the export catheter; TAPAS16 and EXPIRIA14, the meta-analysis conducted by Bavry 
and colleagues41, and the large patient-data pooled analysis ;ATTEMPT study18. In our study 
also there was a trend towards lower incidence of the combined end-points of cardiac death 
or re-infarction, in agreement with TAPAS trial16 and ATTEMPT study18. On the other hand, the 
incidence of cardiac death in our study was not diff erent between both groups, unlike the 
fi ndings in the TAPAS16 and EXPIRIA14 trials; however the large meta-analysis presented by 
Bavry et al41, as well as the ATTEMPT study18 only showed benefi ts in terms of all-cause mor-
tality and not in cardiac mortality, moreover in the TAPAS trial16 analysis of cardiac death after 
30 days showed no signifi cant diff erence between export aspiration group and conventional 
PCI group. Our study, in consistence with the TAPAS trial16, showed no diff erence between 
both groups regarding TVR/TLR, suggesting that thrombus aspiration has no infl uence on 
neointima hyperplasia. 
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LIMITATIONS
Our study is a single-center, non-randomized, prospective study. However, we tried to 
overcome this limitation by taking two groups of consecutive patients within the same time 
period, who were comparable regarding the baseline clinical and procedural characteristics. 
All patients were submitted to the fi xed MISSION! protocol throughout the study period. 
This is a rigorously standardized protocol concerning pre-, peri-, and post-PPCI treatment up 
to 1 year19, 20, so it is unlikely that procedural changes over time would have infl uenced the 
outcome.
In our study, there was a higher tendency to use the thrombus aspiration catheter in patients 
with higher thrombus grades, which represents a drawback due to the bias introduced. How-
ever, adjusting for thrombus grade among other covariates/confounders during the analysis 
of ST-segment resolution, cardiac enzymes and LVEF through multivariate regression models 
showed no signifi cant change in these outcomes among the study groups. Moreover, in our 
study there was comparable baseline TIMI fl ow rate between both groups (TIMI fl ow 0-1 was 
70% in the conventional PCI group vs. 68% in the thrombectomy- facilitated PCI group).
Better techniques are required to analyze the thrombus burden, especially with the fact 
that most of the patients are presented with totally occluded infarct-related artery on the 
initial angiography which limits the analysis of the thrombus burden; most of those patients 
subtend large thrombus burden but still some do not. 
CONCLUSION
Among STEMI patients treated with PPCI and receiving early (in-ambulance) abciximab, 
it appears that the adjunctive use of manual thrombectomy signifi cantly improves post-
procedural ST-segment resolution, decreases distal embolization and may be associated 
with a lower clinical event rate. Therefore, although no benefi t was observed regarding the 
enzymatic infarct size or LV function as assessed by Gated-SPECT, it appears that a selec-
tive strategy of thrombus aspiration still has an additive benefi t, even with early abciximab 
administration. This needs further confi rmation in appropriately powered randomized trials.
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ABSTRACT
Background High thrombotic burden, subsequent distal embolization and myocardial 
no-refl ow remain a big obstacle which may negate the benefi ts of urgent coronary re-
vascularization in patients with ST-elevation myocardial infarction (STEMI). We aimed at 
assessing the predictors of (1) thrombus grade in patients undergoing primary percuta-
neous coronary intervention (PPCI), and (2) infarct size, in order to optimize therapy to 
reduce thrombus burden. 
Methods One-hundred and fi fty-three consecutive patients presenting with STEMI and 
undergoing PPCI were included. Thrombus was evaluated on angiography and scored 
according to the TIMI study group score. Next, patients were categorized into two groups 
having either high thrombus grade (HTG; score 4-5) or low thrombus grade (LTG; score 
1-3). We evaluated predictors of angiographic thrombus grade among a number of clini-
cal, angiographic and laboratory data. We also assessed infarct size and scintigraphic left 
ventricular ejection fraction (LVEF) at 3 months in both patient groups. 
Results Ninety-four patients (58±11 y, 75% males) presented with HTG, whereas 59 
patients (58±12 y, 78% males) presented with LTG. Pre-infarction angina (PIA) was more 
frequently encountered in the LTG group than in the HTG group (25% vs. 10%, p=0.009). 
Pre-procedural TIMI fl ow was signifi cantly lower in the HTG group (p<0.001), and throm-
bosuction was more frequently applied in the HTG group (p<0.001). Absence of PIA 
(OR=0.29, 95% CI=0.11-0.75, p=0.01) and proximal culprit lesion (OR=2.10, 95% CI=1.02-
4.36, p=0.04) were the only independent predictors of HTG. HTG proved an independent 
predictor of higher peak levels of CK (p<0.001) and troponin-T (p<0.001), as well as lower 
LVEF (p=0.05) along with male gender and absence of prior statin therapy. 
Conclusion Absence of PIA and proximal culprit lesions are associated with higher throm-
bus grade. Higher thrombus grade is associated with larger infarct size and slightly worse 
LV function. This may have clinical implications in planning strategies, particularly regard-
ing pharmacotherapy, that aim to decrease thrombus burden prior to stent implantation.
Keywords: ST-elevation myocardial infarction, Primary percutaneous coronary interven-
tion, Pre-infarction angina, Thrombus grade, TIMI fl ow, Infarct size
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INTRODUCTION
Primary percutaneous coronary intervention (PPCI) for patients with ST-segment elevation 
myocardial infarction (STEMI) aims at early restoration of patency and adequate blood fl ow 
both in the epicardial and in the microvascular coronary circulation. However, despite ad-
equate epicardial patency many patients fail to recover sustained myocardial perfusion due 
to microvascular obstruction1, 2, which carries a prognostic indication of a poor outcome3, 4.
A high thrombotic grade has been shown to predict distal embolization, and subsequent 
microvascular obstruction, thus prompting the development of strategies aimed at decreas-
ing thrombus grade before stent deployment such as thrombus aspiration5 and use of 
glycoprotein (GP) IIb/IIIa receptor antagonists6, 7.
Pre-infarction angina (PIA) occurring shortly before the onset of acute myocardial infarction 
(AMI) has a cardioprotective eff ect by the mechanism of ischemic preconditioning8-10, i.e. the 
phenomenon by which brief episodes of ischemia increase the tolerance of the heart to a 
subsequent major ischemic insult. Moreover, PIA has been shown to preserve microvascular 
function after reperfusion11.
It has been shown that patients with AMI who have intermittent infarct-related pain or 
unstable angina in the seven days preceding the infarction have faster coronary artery reper-
fusion and smaller infarcts after thrombolytic therapy than patients without pre-infarction 
angina, suggesting two diff erent types of thrombus growth and thus diff erent responses to 
thrombolytic therapy12. During PPCI variable grades of thrombus formation are observed 
that can only be detected on the initial angiography. Ideally it will be possible to predict the 
thrombus grade clinically or through rapid laboratory investigations prior to PCI procedure. 
This may help to plan for an earlier and enhanced pre-hospital management using adjunctive 
pharmacotherapy, particularly with the newly emerging rapid-acting reversible antiplatelet 
agents which are currently under intense research and are expected to have higher effi  cacy 
and safety profi les than the existing treatments. 
In this study we aimed at assessing factors predicting angiographic thrombotic grade in a 
consecutive series of patients presenting with STEMI treated by PPCI. In addition, the subse-




We studied 158 consecutive patients with a diagnosis of STEMI, having clear evidence of 
thrombus on the initial angiography who underwent PPCI and received abciximab prior to 
PPCI. Patients were selected from an ongoing registry (operational since 2004) in Leiden 
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University Medical Center, which evaluates the eff ects of an all-phase integrated AMI care 
program (MISSION!) on short- and long-term outcomes13,14. Diagnosis of STEMI was made 
on the basis of typical electrocardiographic changes with clinical symptoms associated with 
elevation of cardiac biomarkers. All patients were treated according to the institutional AMI 
protocol (MISSION!). The MISSION! Protocol is a rather stringent, rigorously standardized 
protocol. It comprises a well-organized pre-hospital, in-hospital and outpatient clinical 
framework for decision making and treatment, so it is unlikely that procedural changes over 
time would have infl uenced the outcomes. Clinical data were prospectively entered in the 
departmental Cardiology Information System (EPD-Vision®, Leiden University Medical Cen-
ter) and retrospectively analyzed13. The tertiary center provides a round-the-clock service of 
PPCI with highly experienced PCI physicians and dedicated nurses. 
Medication
All patients received abciximab (Centocor B.V., Leiden, The Netherlands) as a bolus injection of 
0.25 mg/ kg body weight, followed by 0.125 mcg/kg/min with a maximum of 10 mcg/min as a 
continuous infusion for 12 hr. Abciximab administration started before PCI according to MIS-
SION! Protocol13. Furthermore all patients received an equivalent of 300 mg of acetylsalicylic 
acid, 600 mg clopidogrel as a loading dose before PCI and heparin given as a bolus of 5000 
IU at the start of the PCI procedure. After the procedure, all patients received aspirin (75 mg/
day) indefi nitely and clopidogrel (75 mg/day) for one year. Other medications, including b-
blockers, ACE-inhibitors, nitrates, and statins, were prescribed according to MISSION! protocol.
Invasive procedure and angiographic evaluation
All PPCI were performed through a 6F femoral sheath. Patients underwent PPCI and stenting 
of the infarct-related artery according to standard techniques.
The choice of stent (bare-metal stent or drug-eluting stent) was left to the operator’s discre-
tion. Direct stenting was performed only in cases presenting clear views of the arterial lesion 
with adequate fl ow. Otherwise, the patient was subjected to balloon angioplasty and stenting 
was done subsequently. Thrombectomy was frequently, but not exclusively, performed when 
high thrombus burden was observed at the initial angiographic image of the target vessel. 
Thrombus score was graded as previously described by the TIMI Study Group6, 15. Briefl y, in 
TIMI thrombus grade 0, no cineangiographic characteristics of thrombus are present; in TIMI 
thrombus grade 1, possible thrombus is present with such angiographic characteristics as 
reduced contrast density, haziness, irregular lesion contour, or a smooth convex “meniscus” 
at the site of total occlusion, suggestive but not diagnostic of thrombus; in TIMI thrombus 
grade 2, there is defi nite thrombus, with the greatest dimensions ≤ ½ the vessel diameter; 
in TIMI thrombus grade 3, there is defi nite thrombus but with greatest linear dimension > 
½ but < 2 vessel diameter; in TIMI thrombus grade 4, there is defi nite thrombus, with the 
largest dimension ≥ 2 vessel diameters; and in TIMI thrombus grade 5, there is total occlusion. 
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We further categorized the thrombus score into two overall grades: a high thrombus grade 
(grades 4 and 5), and a low thrombus grade (grades 1-3) (Figure 1). We decided to use this 
cut-off  value in line with previous studies16-18 that showed prognostic value of this cut off . 
The inter-observer agreement was calculated with weighted Kappa statistics and showed 
good agreement (κ= 0.92, p<0.001). Coronary fl ow was graded according to Thrombolysis 
In Myocardial Infarction (TIMI) criteria19. TIMI fl ow grade was evaluated at baseline and after 
the PCI procedure. Procedural success was defi ned as residual stenosis <20% and TIMI fl ow 
grade 3. The coronary angiograms were reviewed off -line by two independent interventional 
cardiologists who were blinded to the clinical data.
Laboratory investigations
Cardiac troponin-T concentration in plasma was measured on a third generation Elecsys 2010 
analyzer (Roche Diagnostics, Almere, the Netherlands). Creatine kinase (CK) activity in plasma 
was measured on a Roche Hitachi Modular P800 analyzer (Roche Diagnostics). According to 
MISSION! Protocol13 blood samples were collected at admission and every 6 h in the fi rst 48 
h after PPCI. Subsequently these levels were determined every day up to discharge, unless 
clinical events prompted repeat measurements. Peak levels of CK and troponin-T in plasma 




Figure 1: Thrombus (white arrows) graded according to TIMI working group classifi cation: A: Thrombus 
grade 1; B: Thrombus grade 2; C: Thrombus grade 3; D: Thrombus grade 4; and E: Thrombus grade 5. We 
further scored the thrombus into two overall grades: a high thrombus grade (grades 4 and 5), and a low 
thrombus grade (grades 1-3).
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LVEF assessment by gated-SPECT
According to the MISSION! Protocol13 all included patients were enrolled for a myocardial per-
fusion study at 90 days post-PPCI. An ECG gated-single photon emission computed tomog-
raphy (SPECT) acquisition at rest using intravenous 99mTechnetium-Tetrofosmin (MYOVIEW, 
Amersham, Buckinghamshire, UK) was used to measure the left ventricular ejection fraction 
(LVEF) 90 days after PPCI. LVEF was calculated using an automated and validated method (QGS 
software, version 2.0; Cedars-Sinai Medical Center, Los Angeles, CA, USA). Detailed methods 
are described elsewhere20. In patients in whom gated-SPECT could not be performed due to 
technical diffi  culties, LVEF was estimated by echocardiographic biplane method. LVEF assess-
ment was done by an investigator blinded to the assigned treatment.
Defi nition of pre-infarction angina
Pre-infarction angina (PIA) was defi ned as at least one episode of typical chest or left arm or 
jaw pain, either at rest or during exercise, less than 7 days before STEMI. The presence of PIA 
was diagnosed by a physician, blinded to the results of the PCI, from detailed clinical history 
taken before PCI.
Tested variables
We evaluated predictors of thrombus grade among diff erent clinical, angiographic and labo-
ratory data. Clinical data included age, gender, traditional risk factors, PIA, and symptom to 
balloon time. Prior pharmacotherapy at admission was also recorded including aspirin, clopi-
dogrel, statins, β-blockers (BB), angiotensin converting enzymes inhibitors or angiotensin 
receptor blockers (ACEI/ARBs). Among laboratory data plasma troponin-T levels at admission 
were recorded. Angiographic data included the culprit artery, location of culprit lesion, and 
number of diseased vessels.
Statistical analysis
Categorical variables were compared using the X2 test or Fisher’s exact test. Continuous 
normally distributed data were tested by Student’s t-test or in the case of a non-Gaussian 
distribution by a nonparametric test for independent samples (Mann Whitney U-test).The 
inter-observer agreements were calculated using weighted Kappa statistics. Variables that at 
univariate analysis had a p value ≤ 0.15 were included in a multiple logistic regression model 
with the 2-categories thrombus grade as the outcome. Infarct size as assessed by peak CK and 
peak troponin-T (after logarithmic transformation), as well as 3-months LVEF were analyzed in 
a multivariate linear regression model among diff erent potentially relevant variables. Correla-
tion between the outcomes was tested using Spearman’s correlation. Data were expressed 
as mean ± SD or as median + inter-quartile range for continuous variables according to the 
data distribution; categorical variables were expressed as percentages. All analyses were 
performed using SPSS version 17.0 statistical software (SPSS Inc., Chicago, IL, USA).
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RESULTS
Baseline characteristics
Hundred and fi fty-eight consecutive patients were selected for this evaluation. From this 
group, 5 patients were excluded due to incomplete data sets, the study population thus com-
prised 153 patients; 94 had high thrombus grade (HTG), and 59 had low thrombus grade (LTG). 
Baseline clinical and angiographic characteristics of the studied population are presented in 
Tables 1 and 2, respectively. The rate of PIA was signifi cantly higher in the LTG group (25% 
vs. 10%, p=0.009) than in the HTG group (Figure 2). Among the angiographic characteristics, 
there was less initial TIMI fl ow grade in the HTG group (p<0.001), and higher rate of using a 
thrombectomy catheter in the HTG group (p<0.001) than in the LTG group. HTG tended to be 
more frequently encountered in proximal culprit lesions (54% vs. 39%, p=0.06).






Age in years 58.4±11.5 57.6±12.0 0.68a
Male, n (%) 70(74.5) 46(78) 0.62b
Medical History, n (%)
 Hypertension 28(29.8) 23(39) 0.24b
 Hyperlipidemia 21(22.3) 19(32.2) 0.17b
 Smoking 55(58.5) 28(47.5) 0.18b
 Family history 43(45.7) 24(40.7) 0.53b
 Diabetes mellitus 6(6.4) 8(13.6) 0.16b
 Previous MI 10(10.6) 5(8.5) 0.66b
 Previous PCI 6(6.4) 5(8.5) 0.62b
 Previous CABG 4(4.3) 1(1.7) 0.38b
Symptoms to balloon (min) 143(95-226) 135(88-225) 0.47c
Abciximab to ballon (min) 37(29-48) 36(24-60) 0.95c
Pre-infarction angina 9(9.6) 15(25.4) 0.009b
Previous aspirin 16(17) 9(15.3) 0.77b
Previous clopidogrel 1(1.1) 0(0) 0.42b
Previous statins 15(16) 9(15.3) 0.91b
Data are presented as mean ± standard deviation, number (%) of patients or median (Interquartile range).
MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting.
a Compared using unpaired t test.
b Compared using Chi-square or Fisher exact test.
c Compared using Mann-Whitney U test.
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Predictors of high thrombus grade (HTG)
Univariate and multivariate logistic regression analyses with thrombus grade as outcome 
revealed that only absence of PIA (OR=0.29, 95% CI=0.11-0.75, p=0.01) and presence of a 
proximal culprit lesion (OR=2.10, 95% CI=1.02-4.36, p=0.04) were independent predictors of 
HTG (Table 3).






Infarct related artery, n (%) 0.1b
 Left main artery 3(3.2) 0(0)
 Left anterior descending artery 33(35.1) 24(40.7)
 Circumfl ex artery 9(9.6) 12(20.3)
 Right coronary artery 49(52.1) 23(39)
Diseased vessels, n (%) 0.18b
 1-vessel 57(60.6) 31(52.5)
 2-vessel 33(35.1) 21(35.6)
 3-vessel 4(4.3) 7(11.9)
Proximal culprit lesion, n (%) 51(54.3) 23(39) 0.06b
Abciximab 94(100) 58(98.3) 0.9b
Initial TIMI fl ow grade, n (%) <0.001b
 0 61(64.9) 16(27.1)
 1 16(17) 12(20.3)
 2 14(14.9) 16(27.1)
 3 3(3.2) 15(25.4)
Final TIMI fl ow grade, n (%) 0.16b
 1 2(2.1) 0(0)
 2 18(19.1) 6(10.2)
 3 74(78.7) 53(89.8)
Aspiration thrombectomy 65(69.1) 13(22) <0.001b
Drug eluting stents, n (%) 45(57) 52(70) 0.1b
Stent number, n (%) 0.25b
 0 4(4.2) 0(0)
 1 59(62.8) 37(62.7)
 >1 31(33) 22(37.3)
Predilatation, n (%) 66(70.2) 46(78) 0.29b
Data are presented as mean ± standard deviation, number (%) of patients.
TIMI, Thrombolysis In Myocardial Infarction.
a Compared using unpaired t test.
b Compared using Chi-square or Fisher exact test.
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Infarct size 
Peak levels of CK and troponin-T in plasma were signifi cantly higher in the HTG group than in 
the LTG group (p<0.001 for both) (Table 4). Among the potentially relevant variables including 
age, sex, symptom to balloon time, hypertension, current smoking, hypercholesterolemia, 
diabetes mellitus, PIA, prior drug therapy, number of vessels diseased, culprit artery, proximal 
culprit lesion, thrombus grade and use of thrombosuction, HTG predicted high peak levels of 
CK (B= -1.0, 95% CI= -1.4 – -0.6, p<0.001) and troponin-T (B= -1.1, 95% CI= -1.6 – -0.6, p<0.001).
Scintigraphic LVEF at 3 months
LVEF was not signifi cantly diff erent between both groups of thrombus grade (Table 4). 
However, when corrected for the aforementioned factors in a multivariate linear regression 
model, it was found that HTG predicted a slightly worse LVEF (B=4.9, 95% CI= -0.06 – 10, 
p=0.05), along with male gender and absence of prior statin therapy. The outcomes were 
moderately correlated (r= -0.45, p<0.0001 for LVEF and peak CK, and r= -0.5, p<0.0001 for 
LVEF and peak TnT)
DISCUSSION
Key fi ndings of the present study were: 1) the absence of PIA and a proximal location of 
the culprit lesion independently predicted higher angiographic thrombus grade, 2) Higher 













































Figure 2: Rate of pre-infarction angina among the two categories of thrombus grade. HTG, high thrombus 
grade; LTG, low thrombus grade.
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Table 3. Univariate and multivariate logistic regression analyses with thrombus grade as end-point
Predictors Univariate analysis Multivariate analysis
OR 95% CI P OR 95% CI P
Male gender 0.82 0.38- 1.78 0.62
Age 1.01 0.97-1.03 0.68
Symptom to balloon time 1.00 0.99- 1.00 0.72
Hypertension 1.51 0.76- 2.99 0.24
Hypercholesterolemia 1.65 0.79- 3.43 0.17
Current smoking 0.64 0.33- 1.23 0.18
Family history 0.81 0.42- 1.57 0.54
Diabetes Mellitus 2.30 0.76- 7.00 0.14 2.61 0.81-8.39 0.11
Pre-infarction angina 0.31 0.13- 0.77 0.01 0.29 0.11-0.75 0.01
Prior aspirin therapy 0.87 0.36- 2.14 0.77
Prior statin therapy 0.95 0.39- 2.33 0.91
Prior β-blocker therapy 1.29 0.33- 5.02 0.71
Prior ACEI/ARB therapy 1.54 0.70- 3.39 0.28
Infarct related artery † : 0.12 0.17
LAD (including LM) 0.70 0.34-1.44 0.34 0.62 0.29-1.34 0.22
CX 0.35 0.13-0.95 0.04 0.39 0.14-1.11 0.08
Number of diseased vessels *: 0.21
2-vessel disease 0.85 0.42-1.72 0.66
3-vessel disease 0.31 0.08-1.14 0.08
Proximal culprit lesion 1.86 0.96- 3.60 0.06 2.10 1.02- 4.36 0.04
Admission troponin-T 1.15 0.59- 2.24 0.67
ACEI/ARB, angiotensin converting enzyme inhibitors/angiotensin receptor blockers; LAD, left anterior de-
scending; CX, circumfl ex.
† Right coronary artery (RCA) as reference.
* 1-vessel disease as reference






Peak CK (U/L) 2435±218 1527±234 <0.001a
Peak troponin-T (μg/L) 6.5±0.7 3.8±0.7 <0.001a
LVEF at 3 months* 52±13 54±12 P=0.4b
Data are presented as mean ± standard deviation. 
CK, creatine kinase; LVEF, left ventricular ejection fraction; 
HTG, high thrombus grade; LTG, low thrombus grade.
a Compared using Mann-Whitney U test.
b Compared using unpaired t-test.
* Computed By Myoview, except in 11% of the patients,where 2-D echocardiographic biplane method was 
utilized.
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and troponin-T levels in plasma, as well as lower LVEF at 3 months along with male gender 
and absence of prior statin therapy.
The issue of identifying predictors of thrombus grade has gained wide interest from the time 
PPCI was established as the gold standard reperfusion strategy for STEMI. The presence of 
large thrombus burden has been found to be an independent predictor of major adverse 
cardiac events (MACE) and infarct-related artery stent thrombosis in patients treated with 
drug-eluting stents for STEMI21, 22.
Cardioprotective eff ect of PIA
PIA is associated with improved prognosis after AMI9, 12, 23, 24. Several mechanisms may ex-
plain this protective eff ect of PIA on myocardial reperfusion, such as myocardial ischemic 
preconditioning9, 24, 25, enhanced collateral circulation towards the ischemic myocardium26, 
and increased sensitivity to thrombolysis12.
Recently, a new cardioprotective mechanism of PIA was proposed, which is the inhibition 
of microvascular obstruction phenomenon27-29. This was supported by a study conducted 
by Jesel et al.30, who showed that absence of PIA was the only independent predictor of 
MRI-detected microvascular obstruction. This provides a new hypothetical mechanism for 
the clinical benefi t of PIA, suggesting that PIA attenuates the development of the no-refl ow 
phenomenon, not only through microvascular ischemic preconditioning31, but also through 
limiting the extent of microvascular obstruction induced by distal embolization from large 
thrombus burden. This has to be further elucidated in larger studies reinforced by IVUS or 
OCT on one hand, and MRI or myocardial contrast echocardiography on the other for relating 
the culprit plaque morphology and microvascular obstruction extent respectively with PIA.
Angiographic thrombus burden
In 2010, Sianos et al18 published a score for stratifying thrombus burden in STEMI patients. It 
was actually a modifi cation from the established TIMI study group score6, where they reclas-
sifi ed patients with Thrombus grade 5 into the other categories. They did that either after 
crossing with a wire or predilating with a balloon. In our study we adopted the original TIMI 
classifi cation based on the fact that wire crossing and balloon infl ation may alter thrombus 
grade, by inducing distal embolization. TIMI study group was precise in defi ning thrombus 
grade 5 not only on basis of total occlusion, but also based on the shape of this total occlu-
sion, which ended abruptly, with a squared-off  or an upstream convex termination, creating 
a stump or arterial cul-de-sac from which dye washout was delayed.
PIA and thrombus burden
Our study is the fi rst to address the relation between PIA and thrombus grade in patients with 
STEMI. Previous studies have shown the benefi ts of PIA on surrogate markers of reperfusion29, 
as well as on clinical outcomes32.
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Using IVUS, Higashikuni et al.33 found that the culprit plaques of patients without PIA 
contained larger amount of necrotic core component than patients with PIA, whereas the 
plaques of patients with PIA consisted of larger amounts of the fi brofatty component than 
the plaques of patients without PIA. Moreover, they found more plaque rupture among 
patients without PIA than in those with PIA. This diff erence may explain the diff erence in 
thrombus burden and consequently the diff erence in clinical outcomes between both 
groups of patients. The necrotic core component was shown to be the most thrombogenic 
component in human atherosclerotic plaques34, 35. Exposure of the necrotic core component 
(plaque rupture) leads to exposure of Tissue Factor, thereby increasing thrombogenicity and 
abrupt thrombus formation. Thus, necrotic core-rich plaques may produce large thrombus 
burden, which may often result in sudden onset of AMI without PIA. Previously, Kojima et al.36 
demonstrated that patients with PIA were more likely to have plaque erosion as a substrate 
rather than plaque rupture, with subsequent exposure of the proteoglycan-rich matrix with-
out a large lipid core; this has less potent thrombogenicity than plaques with lipid-rich core 
and consequently leads to less thrombus burden. In a study by Capone et al.37, the incidence 
of thrombus by angiographic analysis was higher in patients with recent onset of rest angina 
than in those with slowly progressive PIA.
Proximal location of culprit lesion and thrombus burden
The present study revealed proximal location of the culprit artery as an independent pre-
dictor of HTG. To our knowledge, there was one previous study which has addressed this 
issue16, revealing no predictive role for the location of the culprit lesion on the thrombus 
grade. However, in their study they analyzed the thrombus in the majority of the cases after 
the insertion of a 6F perfusion catheter, in contrast to our study in which the thrombus was 
analyzed and graded on the initial angiogram. 
The PAMI study38 showed that patients with proximal culprits had worse angiographic fea-
tures with higher rates of initial TIMI 0-1 fl ow, and consequently worse in-hospital clinical 
outcomes despite rapid and successful reperfusion in the vast majority, thus arguing for the 
inclusion of proximal culprit lesion in the angiographic prognostication of AMI patients.
Coronary thromboses leading to AMI are distributed in a nonuniform manner. They tend to 
cluster within the proximal one-third of the coronary arteries and the likelihood of clinically 
signifi cant plaque rupture decreases by 13–30% for each 10 mm distally from the coronary 
artery ostia39, 40. 
Thrombus burden and infarct size
Our study showed that HTG was a predictor of larger infarct size and when corrected for other 
relevant risk factors, HTG was associated with a lower LVEF. 
Although no previous study has related thrombus grade to infarct size or LVEF, previous 
studies have shown that distal embolization and the subsequent no-refl ow, which is partly 
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related to higher thrombus burden, were associated with larger infarct size, LV remodeling, 
and depressed LV function41, 42.
PIA:  a predictor of infarct size?
Although the myocardial protective benefi ts of PIA have been established in previous stud-
ies10, 11, 43, we could not reproduce this fi nding. A possible explanation is that a study with a 
relatively small sample size (only 24 patients had PIA) lacks statistical power. In a previous 
study44, it has been concluded that the protective eff ect of PIA in AMI is overwhelmed by the 
protective eff ects of complete revascularization provided by PPCI.
Future clinical implications
The present study argues for the consideration of PIA as a clinical predictor of thrombus 
burden in STEMI patients, thus setting the basis for implementing strategies aiming to 
decrease thrombus grade before stent implantation such as thrombus aspiration and the 
use of platelet glycoprotein IIb/IIIa antagonists in selected patients. Earlier administration 
of Gp IIb/IIIa antagonists results in higher pre-interventional TIMI fl ow with subsequently 
improved perfusion post-PCI45-47, which in turn refl ects less thrombus burden. Earlier Gp IIb/
IIIa antagonists administration requires treatment in the pre-hospital setting, which for many 
dedicated primary PCI centers may pose substantial logistical obstacles. Therefore, the early 
administration of Gp IIb/IIIa antagonists could be limited to patients in whom high thrombus 
burden is predicted.
This may set a strategy for pre-hospital triage of STEMI patients receiving early pre-hospital 
antithrombotic treatment. Since high-dose clopidogrel administration takes 3–4 h to reach 
the top of inhibition of platelet aggregation48, Gp IIb-IIIa inhibitors are considered to rapidly 
inhibit platelet aggregation, with subsequent benefi ts in mortality according to the risk pro-
fi le. The use of risk scores, such as the TIMI Risk Score49, should be strongly encouraged to 
identify a high risk population with thrombotic complications that largely outweigh the risk 
of bleeding complications, and in whom a selective strategy of pre-hospital/pre-PCI aggres-
sive anti-thrombotic therapy is to be adopted.
Recently, a great deal of research has focused on development of new antiplatelet agents 
that could be administered orally or intravenously and, unlike the currently applied thieno-
pyridines, could provide direct-acting reversible inhibition of the platelet P2Y12 receptor. 
New agents as “Cangrelor”50-53 and “Elinogrel”54, 55 are characterized by a rapid onset of action, 
more eff ective platelet inhibition, and favorable safety profi le with rapid reversal of its anti-
platelet eff ect post-infusion, thus allowing for surgery without a signifi cant delay. Further-
more, “Vorapaxar” (SCH 530348)56, 57 and “Atopaxar” (E5555)58, 59 are orally administered agents 
that reversibly inhibit platelet protease activated receptor (PAR)-1, through which thrombin 
induces its eff ect on platelet aggregation, and thus, thrombus formation. This concept of 
rapidly acting and rapid reversibility of platelet inhibition could fuel further research about 
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the triage of pre-hospital treatment among STEMI patients with suspected high thrombotic 
burden. 
We believe that the next step towards further optimization of care among STEMI patients is 
to improve pre-hospital triage, not only by diagnosing STEMI patients in the ambulance, but 
also starting early pre-hospital pharmacotherapy which necessitates the implementation of 
a risk/benefi t scoring system. This scoring system should take in consideration clinical (as 
PIA) as well as rapid bed-side laboratory data (cardiac biomarkers), among others, to identify 
patients who would benefi t most from early pre-hospital treatment.
LIMITATIONS
The study may have been limited by its observational design, and the relatively small sample 
size which may hinder the prognostic power. However, implementation of a stringent proto-
col for the study population (MISSION! protocol)13 reinforces our results. No long-term clinical 
follow-up was performed.  Therefore, a correlation between thrombus burden and clinical 
outcomes is lacking.
Owing to the small number of included population, and the retrospective nature of the study, 
we could not perform reliable testing of each single thrombus subgroup. However, Sianos et 
al18 validated this categorization in a large cohort of 900 STEMI patients, and found that large 
thrombus (≥ twice the vessel diameter) independently predicted mortality and MACE.
Many factors can infl uence the angiographic assessment of thrombus burden (such as the 
TIMI fl ow, vessel size, culprit complex lesions with ulcers or intra-plaque dissections) that can 
confuse the analyst. More reliable methods to assess thrombus burden should be considered 
such as; the amount of aspirated thrombus, or thrombus assessed by optical coherence 
tomography.
CONCLUSION
PIA is associated with a decreased angiographic thrombus grade, whereas proximal culprit 
lesions are associated with higher thrombus grade. Higher thrombus grade was in turn as-
sociated with larger infarct size as well as slightly worse LV function. This may have clinical 
implications in planning strategies, particularly regarding pharmacotherapy, that aim to 
decrease thrombus burden prior to stent implantation, particularly in high risk patients 
without PIA.
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ABSTRACT
Aim Diff erent biodegradable-polymer drug eluting stents have not yet been systemati-
cally analysed. We  sought to; 1) evaluate the risk of target lesion revascularisation (TLR) 
and defi nite stent thrombosis (DST) among diff erent groups of biodegradable-polymer 
(BioPol) DES, and 2) to compare them with permanent  polymer (PermPol) DES.
Methods and results We searched PubMed and relevant sources from January 2005 
until October 2010. Inclusion criteria were (a) Implantation of a drug eluting stent with 
biodegradable polymer; (b) available follow-up data for at least one of the clinical end-
points (TLR/DST) at short term (30 days) and/or mid-term (one year). A total of 22 studies, 
including randomised and observational studies, with 8264 patients met the selection 
criteria; 9 studies (2042 patients) in whom biodegradable-polymer sirolimus eluting stents 
(BioPol-SES) were implanted, 8 studies (1731 patients) in whom biodegradable-polymer 
paclitaxel eluting stents (BioPol-PES) were implanted, and 7 studies (4491 patients) in 
whom biodegradable-polymer biolimus-A9 eluting stents (BioPol-BES) were implanted. 
At 30 days, there was a higher risk of DST (p=0.04) and subsequently TLR (p=0.006) in 
the BioPol-BES compared to BioPol-SES, with no signifi cant diff erence in the other stent 
comparisons. At 1 year, there was higher risk of TLR in the BioPol-PES (p= 0.01), and the 
BioPol-SES (p=0.04) compared to BioPol-BES. One-year stent thrombosis was not statisti-
cally diff erent between the studied groups (overall p= 0.2). In another analysis compris-
ing 7 randomised trials comparing BioPol-DES (3778 patients) and PermPol-DES (3291 
patients), the risks of TLR and stent thrombosis at 1 year were not signifi cantly diff erent 
(p= 0.5 for both).
Conclusion Performance of diff erent BioPol-DES seems to vary from each other. The short 
and mid-term success rates may not be superimposable. Furthermore, they may not be 
necessarily better than PermPol-DES.
Keywords Meta-analysis, biodegradable-polymer drug eluting stents, permanent-polymer 
drug eluting stents, target lesion revascularization, defi nite stent thrombosis.
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INTRODUCTION
Drug eluting stents (DES) represent a major breakthrough in the fi eld of percutaneous 
coronary interventions (PCI), since they have dramatically reduced the need for repeated 
revascularization procedures1, 2. 
Along with the increasing number of patients receiving DES and the availability of long-term 
follow-up data, concern has arisen regarding the safety of these devices with the potential 
for increased infl ammatory response and stent thrombosis which could have life-threatening 
consequences3-5.
Polymers used for the delivery of antirestenotic agents have been accused for the develop-
ment of late stent thrombosis. This is thought to be secondary to polymer-induced infl amma-
tory reaction, with delayed healing and re-endothelialization of the DES6. Given these issues 
more focus has been placed upon developing bio-degradable polymers, which degrade over 
time, and therefore possibly eliminate the problems of polymer-induced infl ammation.
In some cases, fi ndings from pre-clinical studies can be misinterpreted, especially in cases 
where the drug may be toxic. The polymer may be blamed for the infl ammation or excessive 
fi brin deposition and lack of endothelialization. Yet the diff erence in pharmacokinetics and 
anti-restenotic effi  cacy of the diff erent drugs could also be held responsible for variation in 
clinical outcomes. Thus, a “polymer only” control is essential in distinguishing the culpability 
between polymer versus drug7. However, this is a control diffi  cult to implement in clinical 
studies.
Various studies were conducted to test the clinical performance of a variety of biodegradable 
polymer-based stents eluting sirolimus (BioPol-SES), biolimus A9 (BioPol-BES) or paclitaxel 
(BioPol-PES). 
The aims of the present meta-analysis were: 1) to compare the short term (1 month) and 
mid-term (1 year) performance of sirolimus, biolimus A9 and paclitaxel biodegradable-
polymer DES and 2) to compare, where information was available, the 1-year performance of 
biodegradable-polymer DES (BioPol-DES) with permanent-polymer DES (PermPol-DES).
METHODS
Eligibility and search strategies
To be included in this meta-analysis, studies had to meet the following criteria: (a) Implanta-
tion of a drug eluting stent with biodegradable polymer; (b) available follow-up data for at 
least one of the clinical end-points at short term (30 days) and/or mid-term (up to one year). 
Studies dedicated to specifi c lesion subsets including; left main stenting, bifurcation lesions, 
chronic total occlusions, long lesions, in-stent restenosis and venous grafts were excluded.  
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We searched PubMed, Web of Science, and Embase (OVID) from January 2005 and onwards 
for studies on biodegradable DES. The PubMed  search strategy was formulated as the AND-
combination of 1) DES terms and 2) terms denoting biodegradable or permanent polymer 
as follows: 1) “Drug-Eluting Stents”[Mesh] OR DES[tiab] OR ”drug eluting stent”[tiab] OR 
”drug eluting stents”[tiab] OR ”drug eluted stent”[tiab] OR ”drug eluted stents”[tiab] OR “drug 
coated stent”[tiab] OR “drug coated stents”[tiab]; 2) “biodegradable polymer”[tiab] OR “per-
manent polymer”[tiab] OR “nonbiodegradable polymer”[tiab] OR biodegradable[tiab] OR 
bioabsorbable[tiab] OR “durable polymer” OR (“Polymers”[Mesh] AND (biodegradable[tiab] 
OR bioabsorbable[tiab] OR permanent[tiab] OR nonbiodegradable[tiab])). This search 
strategy was translated to the corresponding vocabulary of Embase and Web of Science. 
Relevant websites (http://www.tctmd.com, www.europcr.com) were searched for pertinent 
abstracts and expert slide presentations. The search was kept updated until October 2010. 
No language restriction was applied.
Data abstraction
Two investigators (T.A.N.A. and S.C.B.) independently extracted all data, and disagreements 
were solved in consultation with a third investigator (J.W.M.P.). A number of 144 papers were 
identifi ed from PubMed, 52 papers from Web of Science and 125 papers from EMBASE, and 4 
additional clinical trials from relevant websites (total of 325 citations) (Figure 1). After reading 
the titles and abstracts, a total of 25 potentially relevant studies were initially identifi ed from 
which 22 were eligible for inclusion. 
Defi nitions and end-points
The clinical end-points of the study were the rates of target lesion revascularization (TLR) and 
defi nite stent thrombosis (DST) at 30 days and one year follow-up. Even in the few studies 
with follow-up more than one year only the data at one year were used. 
TLR was defi ned as percutaneous or surgical revascularization of the target lesion. Defi nite 
stent thrombosis was defi ned, whenever available, according to the defi nition of the Aca-
demic Research Consortium8.
Statistical analysis
For the comparison of the 3 biodegradable-polymer stent types (BioPol-SES, BioPol-PES 
and BioPol-BES), 20 studies provided one patient series and 2 studies provided two patient 
series. Since there were only two studies with two series, we analyzed the 24 patient series 
as independent studies. For each patient series we extracted from the publications the 
number of events (TLR or DST within 30 days or one year) and the corresponding number of 
patients. For each stent type, type of event and follow-up period the exact 95% confi dence 
interval for a binomial proportion was calculated and depicted in a forest plot. If the ob-
served proportion was zero, the one-sided 97.5% confi dence interval was given. To compare 
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the incidences of the diff erent types of events between the diff erent stent types, we used 
random eff ects meta-analysis. More specifi cally, we used random intercept logistic regression 
with two dummy variables representing the three stent types, as described in Stijnen et al9. 
This analysis assumes that the between studies variance was equal for the diff erent stent 
types. In the analysis, the random eff ects take into account the possibility that there may 
be many diff erences between the patient populations of the diff erent studies, infl uencing 
the risks of the considered endpoints. To adjust for multiple comparisons, we fi rst tested at 
α=0.05 the overall null hypothesis that all three stent types had equal incidence. If this test 
was signifi cant, the three pair-wise tests were done at α=0.05. For the incidence of TLR within 
30 days, the estimate of the between studies variance was zero. In that case the analysis 
reduces to ordinary logistic regression and we used exact tests and confi dence intervals for 
the odds ratios. 
Seven studies comprised trials comparing BioPol-DES with PermPol-DES. To make forest plots, 
we calculated exact 95% confi dence intervals for the odds ratio except for studies in which 
less than 2 events in total were observed. We used random eff ects meta-analysis to estimate 
and test the overall odds ratio across studies. Due to the scarcity of data at 30 days among 
the included studies, we decided to assess the events at 1 year only. Because of the small 
numbers of events in some of the studies, the hypergeometric-normal model as described in 
Stijnen et al was used9. 
All statistical analyses were performed using SAS statistical package version 9.1.3. The proce-
dure NLMIXED was used for the random-eff ect meta-analysis.
325 citations retrieved
from database searches
22 studies included in
the meta-analysis
comparing the different




















Figure 1: Flow diagram of the review process: Process of identifi cation and selection of the studies for inclu-
sion in the meta-analysis. BP; biodegradable polymer, PP; permanent polymer, SES; sirolimus eluting stents, 
PES; paclitaxel eluting stents; BES; biolimus eluting stents, DES; drug eluting stents.
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Study Quality assessment
This meta-analysis was especially designed to extract data from various types of available 
studies: observational studies presenting data about BioPol-DES; randomized clinical trials 
(RCTs) in which diff erent BioPol-DES are compared among each other, and RCTs in which 
BioPol-DES is compared with PermPol-DES. Only for the latter category, it was of interest to 
perform an RCT study quality assessment. We have used the Delphi list for the quality assess-
ment of RCTs as described by Verhagen et al10. In short, the Delphi list allocates ‘yes’, ‘no’, or 
‘do not know’ to a total number of nine questions. Quality of RCTs is defi ned as the likelihood 
of the trial design to generate unbiased results. When fi ve or more questions are answered 
‘yes’, the RCT is considered to have a low risk of bias. In a respective manner, RCTs may have 
unclear or high risk to cause bias.
RESULTS
Trials and study characteristics
A total of 22 studies11-33 with a total of 8264 patients were included in this meta-analysis 
(table 1); 9 trials11, 13, 14, 17, 21, 23-25, 30, 32 (2042 patients) with biodegradable polymer sirolimus elut-
ing stents (BioPol-SES), 8 trials12, 20, 22, 23, 27, 28, 31, 32 (1731 patients) with biodegradable polymer 
paclitaxel eluting stents (BioPol-PES) of which two were randomized trials against BioPol-
SES23, 32; and 7 trials15, 16, 18, 19, 26, 29, 33 (4491 patients) with biodegradable polymer biolimus A9 
eluting stents (BioPol-BES). Many of the retrieved trials were observational non-randomized 
trials. The mean age of the participants in individual trials ranged from 53 to 67 years, with 
males representing the majority. The percentage of diabetics was 28% among the BioPol-SES, 
26% among the BioPol-PES and 28% among the BioPol-BES. The recommended duration of 
thienopyridine therapy after stent implantation was variable between the studies; 3 months 
in 2 studies19, 30, 6 months in 12 studies12-16, 21, 22, 25-28, 31, 32, 12 months in 5 studies11, 20, 23, 24, 33, in-
defi nitely in one study17 and unidentifi ed in 2 studies18, 29. The follow–up (FU) duration ranged 
from 6 months to 30 months, with only two studies with FU of 6 months11, 24. 
Among the included studies there were 10 randomized clinical trials (RCT)13-16, 19, 22, 23, 25, 29, 32, 33 
, two studies were randomizing BioPol-SES versus BioPol-PES23, 32, two studies; one random-
izing BioPol-SES versus permanent polymer sirolimus eluting stent (PermPol-SES)13, 25, and 
another randomizing BP-SES versus permanent polymer sirolimus (PermPol-SES) plus evero-
limus eluting stents (PermPol-EES)14, one study randomizing BioPol-PES versus permanent 
polymer paclitaxel eluting stent (PermPol-PES)22, two studies randomizing BioPol-BES versus 
PermPol-SES29, 33, two studies randomizing BioPol-BES versus PermPol-PES15, 16, and fi nally one 
study randomizing BioPol-BES versus bare metal stent19.
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Clinical end-points at 30 days follow-up (Table 2)
TLR
Among the studied population the incidence of TLR at 30 days was 0.4% in the BioPol-SES, 
0.7% in the BioPol-PES and 1.4% in the BioPol-BES. These incidences were statistically sig-
nifi cantly diff erent (overall p-value=0.01); the three pair-wise comparisons were; OR= 3.4, 
95%CI= 1.3-9.6, p=0.006 for BioPol-BES vs. BioPol-SES, OR= 1.7, 95%CI= 0.6-5.1, p= 0.3 for 
BioPol-PES vs. BioPol-SES and OR= 2.0, 95%CI= 0.9-4.7, p= 0.08 for BioPol-BES vs. BioPol-PES.
DST
The incidence of DST at 30 days was 0.2% in the BioPol-SES, 0.3% in the BioPol-PES and 0.9 
% in the BioPol-BES. The overall test on equality of these incidences showed a trend towards 
statistical signifi cance (p-value=0.06); the three pair-wise comparisons were; OR= 3.9, 95%CI= 
1.1-14.0, p=0.04 for BioPol-SES and BioPol-BES, OR=1.4, 95%CI= 0.3-6,0, p= 0.6 for BioPol-SES 
vs. BioPol-PES and OR= 0.4, 95%CI= 0.1-1.2, p= 0.09 for BioPol-BES vs. BioPol-PES.
Clinical end-points at one year follow-up (Table 2)
TLR
Over a follow-up period up to 12 months, the incidence of TLR among the studied popula-
tion was 4.9% in the BioPol-SES, 6.1% in the BioPol-PES and 2.3% in the BioPol-BES. These 
incidences varied signifi cantly among the diff erent stents (overall p-value=0.03). There was 
almost 3 times higher risk of TLR in the BioPol-PES compared to the BioPol-BES (OR=2.8, 
95%CI= 1.3-6.0, p= 0.01), and twice higher risk of TLR in the BioPol-SES compared to BioPol-
BES (OR=2.2, 95%CI= 0.2-1.0, p=0.04), and no signifi cant diff erence in the risk ratio of BioPol-
SES vs. BioPol-PES (OR= 1.3, 95%CI= 0.6-2.6, p= 0.5).
DST
The incidence of DST at one year follow-up was 0.3% in BioPol-SES, 1% in the BioPol-PES and 
0.8% in the BioPol-BES. The pooled odds-ratio was not signifi cant among the diff erent stent 
comparisons (overall p-value=0.2).
Clinical end-points at one year in randomized clinical trials of BioPol-DES vs. 
PermPol-DES (Table 3)
In another analysis, in which clinical end-points were assessed in studies comparing BioPol-
DES with PermPol-DES in a randomized manner (seven randomized controlled studies)13-16, 
22, 25, 29, 33, it was observed that risk of developing TLR at 1 year follow-up was not signifi cantly 
diff erent in PermPol-DES compared to BioPol-DES (OR=0.8, 95% CI=0.5-1.4, p= 0.5) (fi gure 2). 
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Similarly, the one year risk of DST was not signifi cantly diff erent in PermPol-DES compared to 
BioPol-DES (OR=0.7, 95% CI= -0.2-2.4, p=0.5) (fi gure 3).
Randomized clinical trials quality assessment
Each of the RCTs comparing BioPol-DES with PermPol-DES had fi ve or more questions 
answered with ‘yes’ when assessed with the Delphi list. Therefore, all seven RCTs were con-
sidered to have a low risk of introducing bias in the assessment of TLR or DST in BioPol-DES 
vs. PermPol-DES.
DISCUSSION
Three types of biodegradable polymer based DES were analyzed in our study; sirolimus, 
paclitaxel and biolimus A9.
Rapamycin (sirolimus), is a macrolide with cytostatic properties that blocks progression from 
G1 to S in the cell cycle and inhibits thus the vascular smooth muscle cell migration and 
proliferation34.
Biolimus A9 is an analogue of rapamycin that binds to FK binding protein 12 and subsequently 
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Figure 2: One year TLR in BP-DES vs. PP-DES. TLR; target lesion revascularization, BP; biodegradable poly-
mer, PP; permanent polymer, DES; drug eluting stents.
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Figure 3: One year DST in BP-DES vs. PP-DES. DST; defi nite stent thrombosis, BP; biodegradable polymer, 
PP; permanent polymer, DES; drug eluting stents.
Table 3: Clinical events at 1 year in RCTs of BioPol-DES vs. PermPol-DES:
References Trial Acronym Stent Number of 
patients
TLR (N) DST (N)
Mehilli et al 25
Byrne et al 13
























































BioPol: biodegradable polymer; PermPol: permanent polymer; SES: sirolimus eluting stent; 
PES: paclitaxel eluting stent; BES: biolimus eluting stent; EES: everolimus eluting stent; 
TLR: target lesion revascularization; DST: defi nite stent thrombosis; NA: not available.
* Stent thrombosis as defi ned by ARC
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proliferation by blocking the cell cycle progression between the G1 and S phase. The main 
diff erence between biolimus A9 and rapamycin is replacement of hydrogen by alkoxy-alkyl 
group at 40-O position, increasing its lipophilicity which is expected to optimize the drug 
distribution16. Two similar types of biolimus A9 eluting stents were tested in previous studies, 
The BioMatrix® (Biosensors International- Singapore) and The NOBORI® (TERUMO Europe NV, 
Leuven, Belgium).
Paclitaxel inhibits vascular smooth muscle cell migration and proliferation mainly as a result 
of binding to and stabilizing cellular microtubules34, 35.
All stents are coated with a biodegradable poly-lactic acid (PLA) or poly–lactic-co-glycolic 
acid (PLGA) polymer7. In principle, after drug delivery and subsequent complete polymer 
degradation, only the biologically inert bare-metal platform remains.
To our knowledge this is the fi rst meta-analysis that compares the performance of diff erent 
DES with biodegradable polymers in a large cohort of patients with similar inclusion criteria, 
aiming to judge the individual drug performance without the infl uence of permanent poly-
mer. The key fi ndings were that: a) the risk of TLR and DST were highest in the BioPol-BES 
group within short term follow-up (30 days); b) The risk of TLR at one year follow-up was 
three times higher in the BioPol-PES and twice higher in the BioPol-SES when compared to 
the BioPol-BES; c) There was no signifi cant diff erence in the one year risk of DST between the 
studied groups, however we could still observe a higher incidence of stent thrombosis in 
BioPol-PES compared to BioPol-SES (1% vs. 0.3%).
This meta-analysis is based on comparisons between studies. A consequence is that the results 
are more amenable to risk of bias than most meta-analyses, which are based on comparisons 
of meta-analyzed data randomized within studies. Thus our analysis yields valid results only 
under the assumption that, on the average, throughout these diff erent studies the patient 
populations are not systematically diff erent, though they are treated with diff erent types of 
biodegradable-polymer DES. In our view this assumption is likely to be fulfi lled since the 
inclusion and exclusion criteria were very comparable and were not diff erent between the 
groups of studies with diff erent types of stent. 
In an additional analysis performed in randomized trials only, we found that the 1-year risks 
of TLR and DST were not signifi cantly diff erent between BioPol-DES and PermPol-DES.
Long term follow up results (> 2years) are not yet fully available for the majority of biodegrad-
able polymer DES and therefore we did not perform a long-term analysis.
Early stent thrombosis and target lesion revascularization (TLR)
One of the interesting fi ndings in this study was the signifi cantly higher incidence of early 
stent thrombosis (EST), within 30 days, in the BioPol-BES group, and the subsequent higher 
incidence of 30 days-TLR compared to BioPol-SES and BioPol-PES. 
These results should be interpreted cautiously, especially in the considerations that polymer-
or drug-related stent thrombosis tends to present more likely as a mid- or late-term event, 
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and that most of the early thrombotic events which have occurred in the BioPol-BES group 
were encountered in the LEADERS trial33, which involved a diversity of complex lesions. 
However, although ISAR TEST-IV trial14 which tested BioPol-SES, had similar inclusion criteria 
and diverse complex lesions, yet resulted in less early thrombotic events. Moreover, when 
comparing the LEADERS33 and NOBORI-218 clinical trials, the 2 leading “all comers” biolimus 
A9 trials, we could observe that the incidence of EST was obviously diff erent between both 
trials (1.6% vs. 0.1% respectively, Table 2).  
It is still too early to adopt the hypothesis that a more intense antiplatelet regimen should be 
adopted in patients receiving BioPol-BES. Probably a more dedicated pharmacokinetic study, 
that addresses the issue of biolimus A9 tissue distribution and polymer degradation rates in 
diff erent settings as acute coronary syndromes and complex coronary lesions, would shed 
further light on this issue.
Target lesion revascularization (TLR) at mid-term follow-up (1 year)
From this study it was concluded that the incidence of TLR was signifi cantly lower in the 
BioPol-BES compared to both BioPol-SES and BioPol-PES. This goes along with the results 
of the NOBORI series of clinical trials15, 16, 26, 29. A sub-analysis of the LEADERS trial compared 
outcomes at 1 and 2 years36 in BioPol-BES vs. PermPol-SES patients, stratifi ed according to 
Syntax score37 tertiles. Authors showed that BES off ered signifi cant clinical benefi t over SES 
among patients with high Syntax scores, among which was signifi cantly less TLR at 1 year, 
with a strong trend at 2 years follow-up. Recently, the 3 years follow-up of the LEADERS trial 
has been announced, showing the sustained benefi t of BES over SES in patients with high 
Syntax score and among patients with STEMI38. In view of these long-term results, it would be 
advisable to use BioPol-BES among patients with high-risk lesions. 
Biolimus A9 possesses enhanced anti-infl ammatory and antiproliferative activity with an 
improved pharmacokinetic profi le. Unlike currently approved drug eluting stents utilizing 
drugs originally developed for other indications, biolimus A9 has specifi cally been developed 
for local delivery to coronary arteries39. Biolimus A9 is a novel rapamycin derivative that, like 
sirolimus, inhibits smooth muscle cell proliferation via binding to the FK-binding protein and 
subsequent inhibition of the mammalian target of rapamycin (mTOR)40-42. 
The newly developed biolimus A9 eluting stents; Nobori® and BioMatrix® share several unique 
features. The most important are biodegradable polymer carrier (poly lactic acid), and coat-
ing only on the abluminal stent surface. The later feature allows direct release of biolimus A9 
into the vessel wall and, enhanced by its high lipophilicity (~10-fold higher than sirolimus), 
fast uptake by the surrounding tissue15, 16, 33, 43. 
It has been previously reported that sirolimus and paclitaxel drug eluting stents were associ-
ated with paradoxical coronary vasoconstriction up to 12 months after implantation44-47. This 
observation may be attributable to delayed endothelialization caused by the drug and/or 
endothelial dysfunction caused by polymer-induced infl ammation or hypersensitivity reac-
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tion. On the contrary, in a recent study, it has been shown that biolimus A9 eluting stents are 
associated with better preserved endothelial function in coronary arteries compared to the 
fi rst generation DES, which could be partly explained by the better drug release kinetics48. 
Animal studies showed that after BES implantation, the tissue concentration of the drug in 
segments 5 mm proximal and distal to the stent edges is almost non-measurable43 . In addi-
tion, SES and BES have diff erent drug release kinetics: total drug content is released from the 
SES within 60 days with more than 60% released shortly after stent implantation49, versus a 
small initial burst and sustained simultaneous drug release and polymer degradation taking 
place over 6-9 months in the BES43, exposing the surrounding tissue at any given time to a 
lower amount of drug.
Defi nite stent thrombosis (DST) at mid-term follow-up (1 year)
Because durable polymers have been held responsible for some of the thrombotic events 
that are assumed to occur as a result of polymer-mediated infl ammatory reaction and 
delayed endothelialization, it was expected that degradation of the polymer will improve 
arterial healing and thus negate this adverse outcome. This leaves us with the assumption 
that a higher incidence of thrombotic events, if any, would be a “drug only” eff ect. 
In this meta-analysis, the risk of DST was not signifi cantly diff erent between the diff erent 
BioPol-DES at one year follow-up; however we could still observe that the incidence of stent 
thrombosis was numerically 3 times lower in SES vs. PES (0.3% vs.1% respectively). Previ-
ous data, comparing fi rst generation DES, have shown that there is higher risk of ST in PES 
compared to SES3, 50, 51. 
Biodegradable-polymer Biolimus A9 stents (BioMatrix® vs. NOBORI®)
Despite using the same biodegradable polymer (poly-lactic acid) coated on the abluminal 
stent surface, recent pharmacokinetic studies of the two main biolimus A9 stents; Biomatrix®52 
and NOBORI®43, have shown that there is an obvious diff erence between the pharmacokinetics 
of the the two main biolimus A9 stents, which may be an explanation for the more favourable 
clinical outcomes encountered with the latter (Table 4). 
The NOBORI® stent design and coating process diff er from that of the BioMatrix® stent. The 
maximum Biolimus A9 concentrations in blood with a median of 18 pg/mL (range<LLOQ to 
32 pg/mL) and the AUC0– (median 2.9 ng/mL·h, range <LLOQ to 33.1 ng/mL·h) were lower 
than those after BioMatrix® implantation, suggesting that stent design and coating process 
have an impact on Biolimus A9 release kinetics.
In addition to drug distribution and elimination, biolimus A9 pharmacokinetics are signifi -
cantly aff ected by the polymer degradation rate which in turn is infl uenced by the state of the 
vessel. In a vessel with infl ammation, the pH is expected to be low which will accelerate the 
degradation of the polymer material and the subsequent drug release into the vessel wall7 
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Clinical outcomes in randomized clinical trials of BioPol-DES vs. PermPol-DES
In the sub-analysis confi ned to randomised clinical trials comparing BioPol-DES and PermPol-
DES, it was found that the risks of TLR or late DST at 1 year were not signifi cantly diff erent 
between both groups.
Unexpectedly, it was found that the presence of biodegradable polymeric coating did not 
infl uence the risk of stent thrombosis in DES at 1 year follow-up. A lot of awareness has been 
raised lately about the biocompatibility of permanent polymer implants and their potential 
role in contributing to stent thrombosis. Many animal studies have shown that a hypersensi-
Table 4: Comparison of pharmacokinetics and clinical end-points of the two main Biolimus A9 DES:
BioMatrix II NOBORI
Design & Pharmacokinetics:




Drug-Polymer coating Abluminal * Abluminal
Total length (mm) 25.5±10.3 21.4±7.2 
Drug concentration(μg/mm) 14.2-17.5 15.6
Total Biolimus A9 dose (μg) 381.7±155.8 336.55±112.99












% of patients having measurable concentration of 
Biolimus A9(>LLOQ) at 28 days
48% 30%



















TLR 30 days 1.7% 0.3%
TLR 1 year 5.0% 2.1%
DST 30 days 1.6% 0.2% (0.1%) †
DST 1 year 1.8% 0.2% (0.5%) †
t max , time to maximum concentration; t last , time to last quantifi able biolimus A9 concentration (<10 pg/
ml); LLOQ, lower limit of quantitation (<10 pg/ml); C max , maximum concentration; Clast , last quantifi able 
concentration; AUC 0-τ , area-under-the-time-concentration curve over the observation period; TLR, target 
lesion revascularization; DST, defi nite stent thrombosis. Values are expressed as mean ± SD and median 
(minimum -maximum) or as percentages (%).
* Using automatic micropipette coating (AMPC) process.
† Percentages between parentheses show the incidence of DST after including NOBORI-2 results; taking in 
consideration that they include defi nite & probable stent thrombosis. 
Tarek Ahmed bw.indd   81 15-11-11   18:04
82 Chapter 4
tivity reaction may occur as a result of polymer induced infl ammation7, 53. Given these issues 
more focus has been placed upon developing biodegradable polymers which degrade over 
time. 
In a previous study, van der Giessen et al has demonstrated that biodegradable polymers 
may induce marked infl ammatory reactions in the porcine coronary arteries, and that this 
may be attributable to the combination of the parent polymer compound, and biodegrada-
tion products54. Moreover, there are several factors which infl uence the velocity of degra-
dation, either by accelerating or slowing it. Accordingly, It is has be stated that a balance 
between drug release kinetics, the rate of degradation of the polymer and the degradation 
products are essential for the success of bio-erodible stent systems in coronary vasculature7. 
New families of biodegradable polymers have been tested recently in animal studies imple-
mented by Lockwood and colleagues55 which yield fewer acidic by-products than standard 
biodegradable polymers (PLGA, PLA) used in the currently available BioPol-DES, thus making 
it well-tolerated in vivo by providing a better degradation rate and biocompatibility profi le.
In an attempt to overcome the problems encountered with polymers or their degradation 
products, “polymer-free” drug eluting stents have evolved and have been proven to be safe 
in some clinical studies13, 56, and they were even associated with less late lumen loss com-
pared to biodegradable-polymer and permanent-polymer stents in one study13. In a recent 
animal study, polymer-free biolimus A9 coated stents demonstrated more sustained intimal 
inhibition, improved healing and reduced infl ammation compared with the polymer coated 
sirolimus eluting Cypher® stent57. One would expect that a DES without polymer will release 
the drug in a relatively short amount of time, resulting in relatively high systemic and tissue 
peak concentrations, however the superior pharmacokinetics and long half life of Biolimus 
A9 in the target tissues (Biolimus A9 was present in the coronary tissue until 180 days after 
stent implantation), made it a suitable drug for coating on non-polymer stents.
LIMITATIONS
To maximize the utilization of all available data, we included abstract presentations that have 
not been subjected to as much peer review and scrutiny as with full papers, and may not 
be as of high quality; however, we felt that this was necessary for two reasons. Including 
abstracts served as an additional tool to avoid any potential publication bias. The second 
reason is that the magnitude of treatment eff ect can be overestimated by analyzing only the 
published data58.
In our study only DST was used in the analysis, which may underestimate the true incidence 
of stent thrombosis among the studied stents. We preferred to use this end-point rather 
than overall stent thrombosis since not all the included studies reported stent thrombosis 
as defi nite, probable or possible according to the ARC defi nition8. In studies not using ARC 
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defi nition, they stated in their defi nition of stent thrombosis that it was angiographically 
documented which matches defi nite stent thrombosis as defi ned by the ARC.
CONCLUSIONS
This meta-analysis, comparing diff erent biodegradable-polymer DES, showed that the risk of 
early DST and subsequently TLR were highest in the BioPol-BES at 30 days follow-up, whereas 
at 1 year there was signifi cantly less TLR in the BioPol-BES. We could observe a three times 
higher incidence of ST in BioPol-PES compared to BioPol-SES at 1 year. On comparing BioPol-
DES and PermPol-DES in randomized clinical trials, there was no signifi cant diff erence in the 
risk of either TLR or stent thrombosis at 1 year.
These results point to the fact that BioPol-DES do not necessarily perform better than 
PermPol-DES and that short-mid and long term results are to be carefully judged separately 
for newly emerging BioPol-DES before they can become a new standard.
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ABSTRACT
Introduction Coronary artery disease (CAD) is one of the major causes of morbidity and 
mortality worldwide, exerting a huge economic burden. Although drug treatment in 
the past decades has made large advances, signifi cant residual risk remains. However, in 
the coming years there is still a lot ahead with great advances and major breakthroughs 
expected. 
Areas covered New treatments are expected to provide higher effi  cacy, with favorable 
safety profi le. In this review article we are providing an almost full coverage of the recent 
and emerging drug therapies of CAD. This includes: drugs for treatment of atherogenic 
dyslipidemia, drugs that stabilizes atherosclerotic plaque and halts its progression guided 
by novel anti-infl ammatory concepts in atherosclerosis treatment, anti-anginal treatments, 
renin-angiotensin-aldosterone system (RAAS) inhibitors, antiplatelet and anticoagulant 
drugs. 
Expert opinion Eff orts have been made to improve the clinical eff ectiveness and safety 
of established treatment strategies, or to target new frontiers through developing novel 
treatment strategies that tackle diff erent mechanisms of action. Better understanding 
of the diff erent molecular and cellular mechanisms underlying CAD resulted in more 
innovations and achievements in CAD drug therapy, and still a lot is anticipated in the 
forecoming years.  
Keywords CAD, emerging drugs, lipid.
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1. BACKGROUND
Coronary artery disease (CAD) is one of the most important causes of morbidity and mor-
tality world-wide, and it is estimated that mortality from cardiovascular diseases will have 
increased worldwide by 90% by the year 2020 when compared with the situation in 19901. 
Over the past decade drug development in the fi eld of primary and secondary prevention of 
CAD has shown broad advances, particularly after getting to know more about the molecular 
and cellular biology of atherosclerosis, thrombosis and lipid disorders which are the main 
entities contributing to the occurrence of CAD.
Results from 2 large randomized trials for the management of coronary artery disease; COUR-
AGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation)2 and 
BARI-2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes)3 have drawn 
much attention towards optimizing drug therapy of coronary artery disease before invasive/
operative vascular procedures. There are two main treatment goals in patients with coronary 
artery disease: relief of symptoms and ischemia; and prevention of progression of coronary 
artery disease leading to myocardial infarction, left ventricular dysfunction, congestive heart 
failure, and premature cardiovascular death. Currently, coronary artery disease cannot be 
fully eradicated but with the newly emerging drug treatments and other risk factor modifi ca-
tions, the natural history of the disease can be signifi cantly altered in the right direction.
2. MEDICAL NEED
2.1 Lipid therapy
Elevated low-density lipoprotein cholesterol (LDL-C) and reduced high-density lipoprotein 
cholesterol (HDL-C) are among the major risk factors for the development of cardiovascular 
disease (CVD). Despite the widespread use of 3-hydroxy-3-methylglutaryl coenzyme A re-
ductase inhibitors (statins) therapy, the incidence of cardiovascular morbidity and mortality 
remains elevated in many patients with dyslipidaemia, and particularly in those exhibiting 
metabolic disease and insulin resistance4. In large landmark trials, reduction in low-density 
lipoprotein cholesterol (LDL-C) levels with statins has been shown to decrease the incidence 
of major cardiovascular events by 25–45%5-7. Nonetheless, considerable residual cardiovascu-
lar risk, which includes a high frequency of recurrent events, remains even with an aggressive 
statin treatment regimen8-12. New therapeutic options, targeting additional lipid risk factors, 
are clearly needed to further improve the treatment of atherogenic dyslipidaemia by reduc-
ing residual cardiovascular risk.
The Framingham Heart Study in the 1980s demonstrated that the risk of coronary heart 
disease (CHD) was signifi cantly lower among persons with higher levels of high-density 
lipoprotein cholesterol (HDL-C) (normal range 40 to 60 mg/dl)13. Signifi cantly, a recent post 
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hoc analysis of the ‘Treating to New Targets’ trial demonstrated that low HDL-C is predictive of 
major cardiovascular events in patients receiving aggressive statin therapy14.
Clinical studies have shown that therapeutic raising of HDL-C levels was associated with at-
tenuated progression of intima-media thickening in the carotid artery, slowed progression of 
coronary artery atherosclerosis, and reduced cardiovascular risk6, 15-18. The clinical benefi ts of 
raising low HDL-C levels observed in lipid intervention trials and the limitations of available 
therapies have stimulated the search to identify new, more effi  cacious HDL-raising agents. 
2.2 Atherosclerosis anti-Infl ammatory therapy
For a long time atherosclerosis was considered as a lipid-driven disease, but now it is evident 
that it also involves the simultaneous and combined eff ect of infl ammation and immunologi-
cal pathways19-21. The development of new treatments specifi cally targeted against infl amma-
tory mediators can be seen as a new phase in cardiovascular drug development. 
2.3 Anti-anginal medications
2.3.1 Heart rate reduction
In patients with coronary artery disease, epidemiological studies have demonstrated that a 
low resting heart rate is associated with low total mortality and low cardiovascular mortal-
ity22-25. A recent study confi rmed the impact of resting heart rate on cardiovascular events in 
a prospective setting26. Not all patients could tolerate the classical treatments to achieve HR 
reduction (B-Blockers and non-dihydropyridine Ca antagonists); which although eff ective, 
could present negative eff ects on regional myocardial blood fl ow and negative inotropic 
eff ects. 
2.3.2 Coronary vasodilators
Nitrates are known to be eff ective coronary vasodilators, although their eff ect is limited 
by the side eff ects of nitrate-induced fl ushing, hypotension and syncope, as well as the 
reported nitrate tolerance. Moreover, intact epicardial coronary arteries dilate promptly after 
the administration of nitrates or other kinds of vasodilators27, while in contrast, it remains 
controversial28-30as to whether the coronary atherosclerotic site responds to vasodilator 
agents; this continues to be an important topic in terms of the treatment of stable angina 
pectoris. Therefore, other vasodilators than nitrates should be used to more accurately assess 
the vasodilator potential at atherosclerotic lesions.
2.4 RAS Inhibition
Epidemiologic and experimental data suggest that activation of renin-angiotensin system 
(RAS) has an important role in pathogenesis of atherosclerosis. Although angiotensin con-
verting enzyme (ACE) inhibitors and angiotensin-2 (AT2) receptor blockers have been used 
for more than a decade, their benefi t in terms of absolute risk reduction is modest. Many 
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patients with established atherosclerosis continue to suff er from recurrent events related to 
ongoing disease. There is direct experimental animal evidence to support direct renin inhibi-
tor therapy as means to reduce atherosclerotic plaque progression in thoracic aorta31.
2.5 Antiplatelet therapy
The use of antiplatelet agents, both oral and parenteral, in the treatment of CHD was intro-
duced based on the solid evidence for the major role of platelets both in the early stages of 
atherosclerosis as well as in thrombus formation during rupture of the vulnerable plaque. 
Despite the progress achieved, it is generally accepted that our strategies are far from be-
ing considered optimal. The need for new oral antiplatelet agents is mainly driven by two 
reasons: the increased bleeding risk, particularly in those patients in need for double or triple 
antiplatelet therapy, and the variable response or “resistance” of patients to treatment clini-
cally expressed as thrombotic complications or “treatment failure”. The increased bleeding 
risk is strongly associated with the irreversible nature of current agents’ platelet inhibition 
and represents a major issue in the setting of urgent cardiac or non-cardiac surgery. This 
has led to a lot of discussion regarding the appropriate selection of cases suitable for gly-
coprotein (GP) IIb/IIIa inhibitors administration, timing of their administration (in respect 
to patients’ catheterization) and duration of treatment.  On the other hand, “resistance” to 
antiplatelet treatment is both diffi  cult to be assessed and multi-factorial in its nature involv-
ing (commonly neglected) parameters such as poor compliance and inadequate absorption 
but also drug interactions and pharmacogenetic factors. Moreover, it has been shown that 
lower response to aspirin and clopidogrel is frequent among acute coronary syndrome (ACS) 
patients as well as in those with hypertension, diabetes type 2, smoking, obesity (particularly 
in females), heart failure and hypercholesterolemia with the involved pathophysiological 
mechanisms to a signifi cant extent unclear32.
2.2 Antithrombotic therapy
Given the central role of thrombosis in the pathophysiology of ST elevation myocardial 
infarction and ACS, heparin and other antithrombotic agents have always been considered 
fundamental elements of our treatment strategies. Despite the availability of wide range of 
parenteral and oral anticoagulants with diff erent mechanisms of action, yet it still remains 
with many limitations regarding increased bleeding risk, dosing regimens, therapeutic 
response, and thrombocytopenia33. All this have urged the development of newer classes 
that are supposed to have better safety and tolerability profi les, especially among oral anti-
coagulants, with the increasing need of triple antithrombotic therapy (dual antiplatelet plus 
oral anticoagulant therapy) in treating co-morbidities directly or indirectly related to CAD 
e.g. vein thromboembolism, prosthetic valves, atrial fi brillation, severe left ventricular (LV) 
dysfunction, LV aneurysms and thrombi. 
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3. EXISTING TREATMENT
Given the fact that atherosclerosis is a multifactorial disease, current medical treatment of 
CHD is diverse and includes a broad spectrum of agents with a variety of pharmacological 
and physiological eff ects. To date the conventional drug treatment for coronary artery dis-
ease has been:
Nitrates: Mainly relieve symptoms by increasing myocardial oxygen supply (coronary artery
vasodilatation and redistribution of blood fl ow to ischemic areas) and decreasing myocardial 
oxygen demand (decreased preload and afterload)34.
ß-Blockers: Reduce death and nonfatal MI in patients who have had a previous MI35, 36. Symp-
tomatic improvement of angina37by decreasing myocardial oxygen demand (decreased inot-
ropy, chronotropy, and hypertension) and increasing myocardial oxygen supply (increased 
duration of diastole).
Ca antagonists: Not only relieve symptoms but diminish clinical events as well38. It exerts 
its anti-ischemic eff ect by reducing myocardial oxygen demand (decreased afterload ± 
decreased inotropy and chronotropy) and increasing myocardial oxygen supply (coronary 
artery vasodilatation ± increased duration of diastole). It is the drug of choice for coronary 
vasospasm39.
Renin-angiotensin-aldosterone system (RAAS) blockers: ACE inhibitors decrease car-
diovascular death, all-cause death, nonfatal MI, stroke, revascularization procedures, and 
chronic heart failure (CHF)40, 41. The eff ects of ACE inhibitors extend beyond blood pressure 
reduction to endothelial protective eff ect and possibly directly infl uencing the atherosclero-
sis process42. A recent meta-analysis of 3 large clinical trials left no doubt that CAD patient 
should receive ACE inhibitors unless contraindicated43. However, the same cannot be said 
of ARBs, The major ARB trials in high risk patients demonstrated almost complete lack of 
reduction in MI and mortality despite signifi cant reduction in blood pressure. In fact, the 
rates of MI in some trials have actually increased with ARBs44, 45, raising the issue of “ARB-MI 
paradox”46which has triggered a lot of discussion and debate. So far, there is no consensus 
on whether ARBs have a tendency to increase MI, but there is also no substantive evidence to 
indicate that ARBs are able to reduce MI.
A recent meta-analysis has raised further debate suggesting that ARBs, particularly Tilmes-
artan, may be associated with a modestly increased risk of new cancer diagnosis47. This has 
been refuted by a later meta-analysis and trial sequential analysis of 324,168 participants 
from randomized trials, nevertheless showing that an increased risk of cancer with the com-
bination of ACE inhibitors and ARBs couldn’t be ruled out48.  
Lipid therapy
The reduction of LDL-C with statins has a strong positive eff ect on the occurrence of cardio-
vascular events49. A decrease in LDL-C levels from statin therapy is associated with a decrease 
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in the progression of atherosclerosis50. Increases in HDL-C between 5% and 15% have been 
reported with statin-mediated therapy, with an average increase of ~ 9%16. 
Fibrates are peroxisome proliferator-activated receptor (PPAR) - α agonists that lower LDL-C 
by 10% to 20%, lower triglycerides by 25% to 45%, and increase HDL-C modestly by 10% to 
15%, and have shown, at least in subgroups, to reduce cardiovascular events51.
Ezetimibe selectively blocks absorption of dietary and biliary cholesterol from the gut by 
blocking uptake of cholesterol into jejunal enterocytes52. Ezetimibe has an additional LDL 
cholesterol-lowering eff ect of around 15–20%, either alone or in the presence of a statin53. 
In a recent meta-analysis of randomized trials, ezetimibe monotherapy was found to induce 
signifi cant potentially favorable changes in lipid and lipoprotein levels relative to baseline54. 
Nevertheless, ezetimibe monotherapy has never been shown to reduce event rates in a 
mortality-morbidity trial. In the recently published ARBITER 6-HALTS trial (Arterial Biology for 
the Investigation of the Treatment Eff ects of Reducing Cholesterol 6-HDL and LDL Treatment 
Strategies in Atherosclerosis)55, comparing the eff ect of ezetimibe versus extended-release 
niacin (ER niacin) on atherosclerosis, showed that the regression of carotid intima-media 
thickness (CIMT) induced by ER niacin is superior to ezetimibe in patients taking statins. This 
trial was terminated early on the basis of the pre-specifi ed interim analysis showing superior-
ity of niacin over ezetimibe on change in CIMT.  
Bile-acid sequestrating agents or resins that are currently available are colestyramine, 
colestipol and colesevelam. Their mode of action is usually considered to be similar. They 
are anion exchange resins which bind bile acids in the intestinal lumen. Therapy with bile-
acid sequestrants has been shown to lower circulating LDL cholesterol by increasing hepatic 
catabolism via the LDL receptor-mediated pathway56. Colesevelam is a newer bile-acid se-
questrant which causes fewer side-eff ects and, in combination with a statin, has been shown 
to decrease C-reactive protein levels more markedly than with statin alone57, which might 
confer greater protection against CHD.
Antiplatelet therapy
The Antithrombotic trialists’ meta-analysis published in 2002 can be considered as the cor-
nerstone for the implementation of guidelines of current oral antiplatelet therapy58. Overall, 
antiplatelet therapy reduces the combined outcome of any serious vascular event by 25%, 
non-fatal myocardial infarction by 30%, non-fatal stroke by 25% and vascular mortality by 
16% with no apparent adverse eff ect on other cause mortality. Furthermore, for this group 
of patients studied, clopidogrel and its analogue ticlopidine further reduced serious vascular 
events by 10% when compared with aspirin. 
Aspirin has always been considered the “reference” to which any other compound is 
compared. It irreversibly inhibits platelet cyclo-oxygenase-1 (COX-1), therefore impairing 
activated platelets’ ability to produce endoperoxides PGG2 and PGH2 and eventually throm-
boxane A2 (TXA2). TXA2 is a potent prothrombotic agent that stimulates platelet activation 
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and increases their aggregation by mediating the expression of the glycoprotein complex 
GPIIb/IIIa in the cell membrane of platelets. An intrinsic limitation of aspirin, bound to its 
mechanism of action, is that it invariably inhibits endoperoxide PGH2 synthesis in endothelial 
cells as well, therefore preventing the production of prostacyclin (PGI2) in the endothelium, 
a potent anti-aggregating and vasodilator agent. Its value in primary prevention has been 
questioned in recent meta-analysis, considering the increase of major bleeding events59, 
while there have been concerns regarding its eff ectiveness in women60. 
Thienopyridines / P2Y12 antagonists: Ticlopidine was the fi rst agent of a new class of an-
tiplatelet drugs, the thienopyridines, that exert their action through inhibition of adenosine 
diphosphate (ADP) binding to P2Y12 receptors on the platelet surface. Despite its proven 
effi  cacy, particularly in ACS patients undergoing percutaneous coronary intervention (PCI) 
with stent implantation61, 62, ticlopidine was also characterized by signifi cant side eff ects the 
most common being gastrointestinal (diarrhea 12.4%) and the most severe hematological 
toxicity (neutropenia 2.4%, rare cases of aplastic anemia and thrombotic thrombocytopenic 
purpura). Therefore it was replaced in clinical practice by clopidogrel, a thienopyridine with 
less toxicity but mostly the same pharmacodynamic properties63-65. Clopidogrel’s main dis-
advantage is that it’s actually a pro-drug that undergoes a two-step metabolism to an active 
compound by cytochrome (CYP) P450 isoenzymes in the liver, making its bio-availability 
more sensitive to other drugs’ co-administration. 
Platelet Glycoprotien (GP) IIb/IIIa receptor anatgonists: Abciximab, eptifi batide and tiro-
fi ban are potent parenteral antiplatelet agents, exhibiting their action through inhibition of 
platelet surface membrane glycoprotein (GP) IIb/IIIa receptors. Following platelet activation, 
the GP IIb/IIIa receptor undergoes a conformational change rendering it competent to bind 
protein ligands including fi brinogen, fi bronectin, von Willenbrand factor and vitronectin 
thereby facilitating and stabilizing platelet adhesion and thrombus formation. Abciximab 
is a Fab fragment of a chimeric human-murine monoclonal antibody irreversibly inhibiting 
GP IIb/IIIa receptor, while tirofi ban and eptifi batide are high affi  nity non-antibody receptor 
inhibitors demonstrating a reversible mode of action with platelet activity restored within 4 
to 5 hours following discontinuation of intravenous infusion. GP IIb/IIIa receptor antagonists 
have all proved particularly benefi cial in reducing major cardiovascular peri-procedural 
events for both elective and urgent PCIs66-69. The benefi t seems to be higher for diabetics 
and high risk patients70, while for tirofi ban and eptifi batide there is evidence for a possible 
benefi cial eff ect in ACS patients even if a PCI is not scheduled68, 71. The major drawback of 
GPIIb/IIIa inhibitors has to do with the observed increased risk of bleeding, due mainly to 
their potent platelet anti-aggregatory properties although a small risk of thrombocytopenia 
has also been reported (1.5 to 2.8%). The potent inhibition of platelet aggregation represents 
a signifi cant problem in cases where an urgent coronary artery bypass graft (CABG) operation 
is warranted or major hemorrhagic complications from the puncture site are observed. This 
has led to a lot of discussion regarding the appropriate selection of cases suitable for GPIIb/
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IIIa inhibitors administration, timing of their administration (in respect to patients’ catheter-
ization) and duration of treatment.  
Anticoagulant therapy
Unfractionated heparin (UFH) exerts its action by forming a complex with antithrombin 
(AT, formerly known as ATIII) therefore becoming a potent inhibitor of thrombin, factor Xa 
and to a lesser extent factors XIIa, XIa, and IXa. Despite its extensive use, heparin’s limitations 
are well recognized. A major limitation, deriving from its mechanism of action, has to do with 
its dependency on antithrombin to exert its function and its inability to inhibit clot-bound 
thrombin. Moreover, it is characterized by a marked interpatient variability in its therapeutic 
response and the need for frequent partial thromboplastin time (PTT) monitoring. Thera-
peutic window is relatively small and the risk of bleeding increases substantially in patients 
with low body weight, female gender and advanced age. Moreover, heparin induced throm-
bocytopenia (HIT) is a well-recognized and potentially fatal complication of UFH therapy, 
occurring to 2.6% of patients exposed to heparin for more than 4 days while there have 
been concerns for reactivation of ischemia in ACS patients treated conservatively following 
heparin discontinuation, most likely due to a rebound thrombin generation72.
Many of these issues have been addressed with the use of low molecular weight heparins 
(LMWH) the main representatives being enoxaparin, nadroparin, dalteparin and tinzaparin. 
Compared to UFH they have a better bioavailability when given by subcutaneous injection 
and a longer duration of anticoagulant eff ect permitting administration once or twice daily. 
Despite their potent Xa inactivation, they have a smaller eff ect on thrombin and they do 
not prolong PTT. This characteristic, along with their weight-adjusted dosing scheme, makes 
regular monitoring unnecessary (for non-pregnant patients) and they have proven safe for 
administration even in the outpatient setting73. Finally, they are much less likely to induce HIT 
compared to UFH74. Main limitations of LMWH have to do with the increased bleeding risk, 
particularly in patients above the age of 75, cumbersome dose calculation in patients with 
renal insuffi  ciency and lack of an effi  cient antidote to reverse its action in case of emergency.
Fondaparinux is a synthetic pentasaccharide closely related but not belonging to the 
class of LMWH. It binds to AT with a higher affi  nity compared to UFH or LMWH, therefore 
eff ectively inhibiting Xa, it lacks however any kind of action against thrombin. The use of 
fondaparinux as an antithrombotic agent in the setting of unstable angina/non-ST elevation 
myocardial infarction (UA/NSTEMI) and ST elevation myocardial infarction (STEMI) was tested 
in the Organization for the Assessment of Strategies for Ischemic Syndromes (OASIS-5 and 
6) trials where it proved as least as eff ective to enoxaparin and UFH respectively in terms of 
primary end point reduction, while signifi cantly reducing bleeding rates75, 76.
Vitamin K antagonists are not any more routinely prescribed for secondary prevention of 
STEMI/NSTEMI survivor patients, since dual antiplatelet therapy proved more convenient, 
safer and at least as effi  cacious77, 78. The narrow therapeutic window, the increased bleeding 
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risk, the need for frequent international normalized ratio (INR) control, the potential tera-
togenic eff ects when prescribed during pregnancy, set signifi cant limitations in vitamin K 
antagonists’ use.
4. CURRENT RESEARCH GOALS
Based on a better understanding of the molecular and cellular mechanisms underlying 
atherosclerosis, thrombosis and lipid disorders, and given the shortcomings and restrictions 
of the current therapy, the current research goals and new drug developments in CAD are 
focused on: 1) Lipid therapy; including HDL-raising medications, and novel treatments of dys-
lipidemia among diabetics, 2) Anti-infl ammatory treatment of atherosclerosis and vulnerable 
plaque stabilization, 3) New anti-anginal medications; including novel heart rate-reducing 
and vasodilating agents, and 4) New antiplatelet and anticoagulant treatment.
Medical research is simultaneously pointing into two directions, namely evolution of current 
therapeutic strategies by developing newer agents that will prove either more eff ective or with 
less side-eff ects and research for novel therapeutic targets that have not been explored yet.
5. SCIENTIFIC RATIONALE
5. 1 Novel HDL-C raising therapies
There are diff erent proposed mechanisms for the HDL-C protective role; reverse cholesterol 
transport, the process of transporting excess cholesterol from the arterial wall’s foam macro-
phages to the liver, bile, and feces is one of HDL’s anti-atherogenic properties79, 80. Furthermore, 
HDL’s anti-oxidative activity further protects against atherosclerosis81, 82. In the endothelium, 
nitric oxide protects against infl ammation, HDL promotes vasoprotection by enhancing nitric 
oxide synthase and thereby increasing the production of nitric oxide83, 84. In addition to protec-
tion against platelet activation through endothelial protection, HDL inhibits the coagulation 
cascade through serine protease protein C, which inactivates factors Va and VIIa83. 
Circulating HDL particles are very heterogeneous with a very complex metabolic profi le. 
There are three subclasses of HDL which vary in quantitative and qualitative content of 
lipids; discoid HDL particles (lipid-free HDL or apolipoprotein A-1) which mediates reverse 
cholesterol transport; further esterifi cation of these HDL particles generates the other two 
subclasses; HDL2 and HDL3 which are spherical HDL particles. These mature HDL particles 
may induce further cholesterol effl  ux. Smaller HDL3 particles may more effi  ciently promote 
cholesterol effl  ux79, 85. Thus it appears that the subtype of HDL seems to matter. The next few 
years should provide answers to whether we should target raising specifi c HDL subclasses 
rather than HDL-C itself.
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Structural and functional changes accompany HDL in the setting of acute or chronic infl am-
mation, CHD or type 2 diabetes mellitus. These changes are induced by leukocyte myelo-
peroxidase which may alter the function of the normally atheroprotective anti-infl ammatory 
HDL molecules into the so-called dysfunctional HDL with pro-infl ammatory properties. This 
results in reduced effi  cacy of reverse cholesterol transport, and the ability of HDL to counter-
act the inhibitory eff ect of oxidized LDL on vascular relaxation86, 87.     
5.1.1 CETP inhibitors
Cholesteryl ester transfer protein (CETP) is a plasma protein that catalyzes the exchange of 
cholesteryl esters and triglycerides (TG) between the atheroprotective HDL and the athero-
genic apolipoprotein (apo) B– containing lipoproteins, especially very low density lipopro-
tein (VLDL)88. Reduction in CETP activity resulting from genetic mutations or pharmacologic 
inhibition has been associated with reductions in cholesterol within the apo B-containing 
particles and cholesterol enrichment of HDL89, 90.
5.1.2 Extended-release (ER) Niacin and ER Niacin/Laropiprant combination
Niacin was the fi rst lipid-lowering drug developed91. Despite clear lipid-lowering eff ects and 
some proof of clinical benefi t in early prevention studies92, 93, niacin is not used very often in 
clinical practice. There are multiple reasons, the most important being the high rate of side 
eff ects and the stronger LDL-C reduction and the better documented eff ects of statins94, 95. 
Currently, with the rising interest in HDL-raising therapies, niacin has been under intense 
re-evaluation. 
The main side eff ect of niacin is fl ushing, which is a result of cutaneous vasodilatation medi-
ated via prostaglandin D2 (PGD2)96, although the rate of fl ushing was decreased by using 
the extended-release formulations, it still represents a hurdle for its clinical use. Since the 
fl ush induced by niacin is primarily mediated through the interaction of prostaglandin D2 
with a specifi c receptor (prostaglandin-D2-receptor-1) a selective antagonist of this receptor 
was developed (MK-0524, laropiprant)97, 98, thus it seems rational to combine ER niacin with 
laropiprant especially that the addition of laropiprant doesn’t change the eff ect of niacin on 
lipoproteins99.
5.1.3 Dual Peroxisome proliferator-activated receptor (PPAR)-α/γ agonists
Peroxisome proliferator-activated receptors (PPARs) are ligand-dependent transcription 
factors that control gene expression. Dual PPARα/γ agonists have the potential to combine 
the benefi cial PPARα agonist properties of fi brates (decreasing plasma levels of triglycerides 
and very low-density lipoprotein particles and increasing levels of high-density lipoprotein 
cholesterol) with the benefi cial PPARγ agonist eff ects of thiazolidinediones (reduction of free 
fatty acid fl ux,  insulin resistance, and blood glucose levels)100.
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5.1.4 Reconstituted HDL infusion
Short-term infusions of reconstituted HDL have been a target of reverse cholesterol transport 
therapy. CSL-111 is reconstituted HDL consisting of apolipoprotein A-1 from human plasma 
combined with soyabean phosphatidylcholine and chemically and biologically resembles 
native HDL101.
5.1.5 Apolipoprotien A-1(Apo A-1) Milano infusion
ApoA-I Milano is a variant of apolipoprotein A-I identifi ed in individuals in rural Italy who 
exhibit very low levels of HDL (10-30 mg/dl), yet despite of that had a reduced atherosclerotic 
disease burden and longer lives102, 103. Infusion of recombinant Apo A-I Milano–phospholipid 
complexes (ETC-216) produces rapid regression of atherosclerosis in animal models, which 
can occur in as little as 48 hs104, 105. Moreover, it was recently found in animal studies that 
ApoA-1 Milano administration not only induced plaque size regression but was also as-
sociated with a signifi cant reduction in markers of plaque vulnerability, suggesting further 
plaque stabilization106.
5.2 Atherosclerosis anti-infl ammatory and antioxidant therapy
5.2.1 Selective phospholipase A2 inhibitors
There are two groups of phospholipase A2; secretory phospholipase A2 (sPLA2), and 
lipoprotein-associated phospholipase A2 (Lp-PLA2). The sPLA2 represent a family of enzymes 
that hydrolyze fatty acids, in a calcium-dependent process, producing lipoprotein particles 
that are proatherogenic107. Lp-PLA2 represents a calcium-independent phospholipase that 
is predominantly synthesized by macrophages108, 109. Lp-PLA2-modifi ed and sPLA2-modifi ed 
lipoproteins and the resulting oxidized bioactive by-products activate redox-sensitive 
infl ammatory pathways110, impair endothelial-dependent vasorelaxation111 and serve as 
chemo-attractants for monocytes110, 112. The products of Lp-PLA2 activity have been identi-
fi ed in human atherosclerotic vessel wall113. Lp-PLA2 and sPLA2 have gained more interest as 
emerging biomarkers of CV risk that are pharmacologically modifi able. 
5.2.2 Heme oxygenase-1 inhibitors (Probucol analogues)
Probucol is a lipid-lowering prototype agent which exhibits vascular protective eff ect through 
anti-infl ammatory and antioxidant activities. Probucol has demonstrable anti-infl ammatory 
actions in animal models of atherosclerosis114. It reduces adhesion of mononuclear cell to the 
endothelium in vivo115 and inhibits the expression of vascular cell adhesion molecule-1116. 
This result in reduced macrophage infi ltration, associated with a decrease in matrix metal-
loproteinases and other enzymes that may participate in plaque rupture and proatherogenic 
activities which likely translates into improved plaque stability116. 
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However, Probucol is no longer available in many countries due to concerns of effi  cacy117 and 
safety118, 119. In search of other compounds with similar anti-infl ammatory and antioxidant 
properties but without the potentially deleterious eff ect of probucol, succinobucol, previ-
ously known as AGI-1067, was developed120.
5.3 New Anti-anginal treatments
5.3.1 Ivabradine
Ivabradine (IVA) is a novel, specifi c, heart rate (HR)-lowering agent that acts in sinoatrial node 
(SAN) cells by selectively inhibiting the pacemaker If current in a dose-dependent manner by 
slowing the diastolic depolarization slope of SAN cells, and reducing HR at rest and during 
exercise with minimal eff ect on myocardial contractility, blood pressure, and intracardiac 
conduction121. It has been shown to be non-inferior to B-Blockers122 or calcium antagonists123 
in HR reduction. Whether Ivabradine has a role beyond mere heart rate reduction is still a 
matter of focused scientifi c research.
5.3.2 Rho-Kinase (ROCK) Inhibitors
Rho-kinase (ROCK) inhibits myosin phosphatase activity by phosphorylating the myosin-
binding subunit of the enzyme, promoting actin-myosin-mediated contractile force gen-
eration, thus resulting in the augmented vascular smooth muscle contraction in a calcium-
independent manner124, 125.
The activation of ROCK is involved in the regulation of vascular tone, endothelial dysfunction, 
infl ammation and remodeling .The inhibition of ROCK has a benefi cial eff ect in a variety of 
cardiovascular disorders. Evidence from animal models and from clinical use of ROCK in-
hibitors, such asY-27632, fasudil supports the hypothesis that ROCK is a potential therapeutic 
target126.
5.3.3 Ranolazine
Ranolazine, a piperazine derivative, acts through the inhibition of the late sodium current 
(INa current) in cardiac myocytes. During myocardial ischemia, there is a build-up of intracel-
lular sodium, which leads to an increase in intracellular calcium via the sodium-calcium 
exchanger127. By regulating this imbalance in ion shifts, ranolazine may improve myocardial 
relaxation and reduce left ventricular diastolic stiff ness, which in turn can enhance myocar-
dial contractility and perfusion. Ranolazine has minimal eff ects on the resting and exercise 
heart rate and blood pressure in patients with angina, and has shown antiarrythmic activity 
in experimental models128.
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5.4 RAS inhibition- Direct renin inhibitors
Renin catalyzes the rate-limiting step in RAS activation, i.e. the formation of angiotensin I 
from angiotensinogen and shows remarkable substrate specifi city for angiotensinogen. 
These characteristics make it an attractive target for a therapeutic RAS blockade. Renin inhibi-
tion diff ers mechanistically from the established strategies of RAS blockade with angiotensin 
converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs). The increase 
of plasma rennin concentration caused by renin inhibition is much more pronounced 
compared to ACE inhibitors and ARBs129. This may be of clinical relevance because recent 
evidence suggests that renin, besides its enzymatic function, might exert direct, angiotensin 
II-independent, cellular eff ects via the (pro)renin receptor (PRR). Stimulation of this receptor 
may increase profi brotic pathways and activate gene programs implicated in vascular end 
organ damage and atherogenesis130, 131.
5.5 Novel antiplatelet agents
1.5.1 Cox-1 Inhibitors
As mentioned before, a major limitation of aspirin is that irreversibly inhibits COX-1 of both 
platelets and endothelium therefore reducing the production of benefi cial prostacyclin as 
well. Aiming the same pathophysiological mechanism, i.e. inhibition of TXA2 pathway, three 
diff erent alternatives would seem feasible: selective inhibition of platelet only COX-1, throm-
boxane-synthase direct inhibition (therefore reducing the end-product) and thromboxane-
receptors blockade since it has been shown that accumulating peroxides can per se activate 
them, the same way as TXA2132.
5.5.2 Novel ADP/P2Y12 receptor anatgonists
Introduction of platelet ADP receptor inhibitors represented a breakthrough in the modern 
treatment of ACS, especially in the fi eld of interventional cardiology. Newer agents resolv-
ing the bioavailability issues of clopidogrel are expected to minimize treatment failures and 
improve outcomes whereas it seems reasonable that agents with reversible inhibition of the 
ADP receptor will result in less bleeding complications.
5.5.3 Protease Activator Receptor 1 (PAR-1) inhibitors
Thrombin is arguably the most potent activator of platelets, exerting its action through the 
protease activator receptor 1 (PAR-1). In vitro studies suggest that minimal concentrations of 
thrombin are suffi  cient to activate this platelet receptor leading to platelet shape modifi ca-
tion and aggregation, making development of PAR-1 inhibitors a challenging therapeutic 
option. 
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5.5.4 Selective 5-Hydroxytryptamine,5-HT2A receptor antagonists
Serotonin (5-Hydroxytryptamine, 5-HT) is known to participate in the regulation of cardio-
vascular system and is therefore linked to cardiovascular events. Serotonin release following 
a vascular injury induces platelet aggregation, vasoconstriction, increase of vascular perme-
ability and cell proliferation following a vascular injury. These functions are mediated by 
the 5-HT2A receptor and development of selective inhibitors could be used for the eff ective 
treatment of ischemic heart disease. 
5.6 Novel antithrombotics
The previously mentioned limitations of current antithrombotic agents have led medical 
research to the development of new compounds. The major classes of these newer antico-
agulants are the factor Xa inhibitors and the direct thrombin inhibitors with some of these 
agents being orally administered.
5.6.1 Direct thrombin inhibitors
Thrombin is the fi nal enzyme in the clotting cascade, representing a reasonable target of 
most of the current clinical anticoagulants. The rationale for the clinical use of direct throm-
bin inhibitors is their ability to inactivate fi brin-bound thrombin, in contrast to both UFH and 
LMWH – AT complexes. They are also unaff ected from other limitations of current therapeutic 
strategies like acquired or inherited AT defi ciency, they demonstrate a better bioavailability 
profi le, and avoid the problem of HIT.  
5.6.2 Factor Xa inhibitors
Factor Xa inhibitors demonstrate a high affi  nity to Xa, without the need of AT, achieving 
eff ective inhibition of the thrombotic cascade. As in the case of thrombin inhibitors, these 
agents seem to have a rapid onset and off set of action making the concomitant use of UFH/
LMWH obsolete while at the same time being safer in terms of bleeding complications. They 
are designed to have a relatively stable pharmacodynamics profi le, without need for routine 
monitoring, making them theoretically superior to vitamin K antagonists for long-term use.
5.6.3 Other agents
Other agents have also been tested, taking advantage of our extensive knowledge regard-
ing the clotting cascade. Factors V, VII, VIII, IX, and XII have all been considered as potential 
targets of treatment, therefore interfering in the diff erent steps of the cascade. Thrombin 
is unique among the serine proteases of this cascade that possesses both pro-coagulant 
and anti-coagulant properties. It induces coagulation by activating platelets through their 
PAR-1 receptors, activating factors V, VIII, XI and XIII and inhibiting fi brinolysis through the 
thrombin-activated fi brinolysis inhibitor; on the other hand, when bound to thrombomodu-
lin on the vascular endothelial cell surface it becomes an anticoagulant enzyme by activating 
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protein C. Since currently developed thrombin inhibitors interfere with both types of throm-
bin activity, engineering an inhibitor that would selectively inhibit thrombin’s pro-coagulant 
properties, leaving its anti-coagulant functions intact would seem reasonable. In the same 
context, administration of recombinant activated protein C, therefore promoting natural 
anti-coagulation mechanisms, could be expected to produce favorable results.
6. COMPETITIVE ENVIRONMENT (TABLE)
6.1 Novel HDL-C raising therapies
6.1.1 CETP inhibitors
Several effi  cacious CETP inhibitors have been identifi ed; these include torcetrapib (Pfi zer, 
New York, NY, USA), dalcetrapib (previously referred to as RO4607381/JTT-705, Roche/Japan 
Tobacco, Basel, Switzerland), and anacetrapib (MK-0859, Merck & Co., Whitehouse Station, 
NJ, USA). 
Torcetrapib, a CETP inhibitor, has been shown to produce substantial increases in HDL-C and 
modest reductions in LDL-C133-138. However, in a study conducted on hyperlipidemic mice, it 
was found that torcetrapib did not reduce atherosclerosis beyond atorvastatin and induced 
more proinfl ammatory lesions than atorvastatin139. Moreover, treatment with torcetrapib was 
associated with an increase in blood pressure, an eff ect that has not been reported with other 
CETP inhibitors in development140, 141. This blood-raising eff ect of torcetrapib may be merely 
compound-specifi c and unrelated to the mechanism of CETP inhibition, and is thought to 
be related to an increase in plasma aldosterone and corticosterone levels142. A clinical out-
comes study of torcetrapib in high-risk patients, ILLUMINATE (Investigation of Lipid Level 
Management to Understand its Impact in Atherosclerotic Events), was stopped early owing 
to an excess in cardiovascular events and death in patients treated with the combination 
of torcetrapib and atorvastatin versus atorvastatin alone133. Subsequently, 3 studies have 
reported that torcetrapib did not reduce the atherosclerotic burden assessed in the coronary 
arteries (by intravascular ultrasonography) and in the carotid arteries (by ultrasonography of 
intima-media thickness)134, 136, 138. 
Dalcetrapib has demonstrated a favorable safety profi le in a phase II study, and no changes in 
vital signs including blood pressure have been observed143-145. Several phase III clinical trials 
are ongoing with the objective of evaluating the clinical effi  cacy and safety of dalcetrapib. 
One of these, dal- VESSEL, is focused on modulation of vascular function by CETP inhibition 
and will shed further light on the mechanisms implicated in the improved endothelial func-
tion which was recently observed in hypercholesterolaemic subjects with low baseline HDL-C 
subsequent to dalcetrapib treatment146. Another trial, the impact of dalcetrapib on atheroscle-
rotic plaque development (dal-PLAQUE), has been initiated in some 100 patients with CHD 
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using positron emission tomography/computerized tomography and magnetic resonance 
imaging147. Finally, in order to evaluate the eff ects of dalcetrapib on mortality and morbid-
ity, >15 600 high-risk CHD patients considered to have stable disease after a recent acute 
coronary syndrome event have been recruited into the ongoing dal-OUTCOMES trial148, 149.
Anacetrapib is currently the most potent CETP inhibitor under evaluation, with associated 
increases in HDL-C levels up to 129% and decreases in LDL-C levels of up to 38%141. Two phase 
I RCTs for anacetrapib have demonstrated the effi  cacy and safety of the new drug without 
blood pressure eff ects or serious side eff ects141, and a phase III RCT recruiting a total of 1623 
patients with CAD or CAD equivalents is still ongoing in order to obtain suffi  cient safety and 
effi  cacy data150, 151.
Table: Newly developing drugs in CAD treatment:








Dalcetrapib Hoff mann-La 
Roche






Anacetrapib Merck CETP inhibitor CAD Phase III-
expected 




ER Niacin Abbott Water-soluble 
vitamin-B complex








































Aleglitazar Hoff mann-La 
Roche
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Table: Continued




















Apo-A1 based HDL 
mimetic
CAD Phase II- 
expected 



















Succinobucol AtheroGenics Heme oxygenase-1 
inhibitor















Ranolazine A. Menarini 
Pharma/ Gilead 
Sciences
Late sodium current 
(INa) blocker


















Trifl usal Uriach 
Laboratories
COX-1 inhibitor CAD, CVD Phase IV Antiplatelet agent




CAD, PCI Phase III and IV Antiplatelet agent
Ticagrelor Astra Zeneca P2Y12 receptor 
inhibitor
CAD, PCI Phase III Antiplatelet agent
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Table: Continued
















CAD, PCI Phase II Antiplatelet agent
Vorapaxar Merck PAR-1 receptor 
inhibitor
CAD, PCI, CVD Phase II and III Antiplatelet agent
Atopaxar Eisai Inc. PAR-1 receptor 
inhibitor
CAD Phase II Antiplatelet agent
Terutroban Servier TXA2 receptor 
inhibitor
CAD, CVD Phase III Antiplatelet agent
Picotamide LGM Pharma TXA2 receptor and 
TXA2 synthase 
inhibitor





CAD, PAD, CVD, 
PCI
Phase III and IV Antiplatelet agent
DZ-697b Daiichi Sankyo Ristocetin-mediated 
platelet activation 
inhibitor
CAD, CVD Phase I Antiplatelet agent














Argatroban GlaxoSmithKline Direct thrombin 
inhibitor
HIT, CVD Phase IV Anticoagulant




HIT, CAD, PCI Phase IV Anticoagulant
Ximelagatran AstraZeneca Direct thrombin 
inhibitor









VTE, AF Phase III and IV Anticoagulant





Idrabiotaparinux Sanofi -Aventis Factor Xa inhibitor VTE, AF Phase III Anticoagulant




Sanofi -Aventis Factor Xa inhibitor VTE Phase III Anticoagulant
Rivaroxaban Johnson & 
Johnson / Bayer
Factor Xa inhibitor VTE, PE, AF, CAD Phase II and III Anticoagulant
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Table: Continued





Squibb / Pfi zer
Factor Xa inhibitor VTE, PE, AF, CAD Phase III Anticoagulant
Edoxaban Daiichi Sankyo Factor Xa inhibitor VTE, PE, AF Phase III Anticoagulant
SR123781A Sanofi -Aventis Factor Xa inhibitor, 
thrombin inhibitor
VTE, CAD Phase II and III Anticoagulant
LY517717 Eli Lilly Factor Xa inhibitor VTE Phase II Anticoagulant
Betrixaban Portola 
Pharmaceuticals
Factor Xa inhibitor VTE, AF Phase II Anticoagulant
YM150 Astellas Pharma Factor Xa inhibitor VTE, AF, CAD Phase II and III Anticoagulant
PCI: percutaneous coronary intervention, CAD: coronary artery disease, CVD: cerebrovascular disease, PAD: 
peripheral artery disease, HIT: heparin induced thrombocytopenia, VTE: venous thromboembolism, AF: 
atrial fi brillation, PE: Pulmonary embolism.
6.1.2 Extended-release (ER) Niacin and ER Niacin/Laropiprant combination
Two recently published Phase III RCT93, 152, have shown the effi  cacy of ER Niacin as regards to 
lipid lowering and retarding atherosclerosis progression. It has been recently documented 
that endothelial-vasoprotective eff ects of HDL-C are impaired in patients with type 2 dia-
betes mellitus compared to healthy subjects, and that ER Niacin not only increases HDL-C 
plasma levels but markedly improves endothelial-protective functions, which is potentially 
more important153.
In studies evaluating the combination of niacin with laropiprant on fl ushing it was shown 
that the rate of fl ushing was signifi cantly decreased compared to patients on niacin without 
laropiprant99, 154, 155. Currently, the AIM-HIGH study (Atherothrombosis Intervention in Meta-
bolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes) 
is an ongoing RCT which randomly allocates patients (45 years and older) with vascular 
disease and atherogenic dyslipidemia to therapy with simvastatin alone or simvastatin and 
ER niacin, and are being evaluated over a 5-year period to better defi ne the additive eff ect 
of HDL-raising therapies156. Another trial, the HPS2-THRIVE (Treatment of HDL to Reduce the 
Incidence of Vascular Events)157, is recruiting 25,000 patients with a history of CHD, stroke, or 
peripheral arterial disease and randomizing them to placebo or the new ER niacin/laropip-
rant combination. 
6.1.3 Dual Peroxisome proliferator-activated receptor (PPAR)-α/γ agonists
Ragaglitazar increased HDL-C by 31%, decreased triglycerides by 62%, and decreased hemo-
globin A1c by 1.3%, but the adverse events of edema, anemia, and leukopenia have drawn 
concern158, 159. Muraglitazar increased HDL-C by as much as 16% in type 2 diabetic patients, 
but, as with ragaglitazar, weight gain and edema were more common with muraglitazar 
therapy160, 161. An analysis of muraglitazar’s phase 2 and 3 data revealed an increase in risk of 
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death, cardiovascular events, and congestive heart failure associated with muraglitazar162. 
Tesaglitazar, a third agent in this drug class, can increase HDL-C by 13%163-165. Because of the 
observed side-eff ects, all these aforementioned compounds were stopped. Recently, a phase 
2 trial of aleglitazar was shown to increase HDL-C by 20% and also decrease hemoglobin A1c 
in a dose-dependent manner, with a small increase in edema but not congestive heart failure 
or myocardial infarction166. As a result, a phase 3 study (Alecardio study) of aleglitazar in type 
2 diabetic patients with a recent acute coronary syndrome is now ongoing167.
6.1.4 Reconstituted HDL(rHDL) infusion
In a small study of healthy subjects, these intravenous infusions promoted reverse cho-
lesterol transport168. Based on that a randomized placebo-controlled trial was conducted, 
ERASE101, which showed that short-term infusions of reconstituted HDL (CSL 111) in patients 
with recent onset acute coronary syndromes showed no signifi cant reduction in coronary 
atheroma volume, nonetheless, it induced a possibly favorable change in the quality of coro-
nary atheroma. There was a high incidence of liver function test abnormalities with the high 
doses of HDL infusions, these were however self-limiting without any clinical consequence 
or intervention. Recently published results from a fi rst-in-man randomized controlled study 
evaluating the safety and feasibility of autologous delipidated HDL plasma infusions (Plasma 
selective delipidation converts αHDL to preβ-like HDL, the most eff ective form of HDL for 
lipid removal from arterial plaques) in patients with ACS showed promising results regarding 
regression in the atheroma volume. Two ongoing phase I/II trials are testing the safety and 
effi  cacy of single intravenous infusions of rHDL in healthy volunteers169, 170.
6.1.5 Apolipoprotien A-1(Apo A-1) Milano infusion
This therapy was piloted in humans when ETC-216, recombinant apolipoprotein A-I Milano 
complexed with phospholipid, was randomly infused in 57 patients within 2 weeks of an 
acute coronary syndrome (ACS) over 5 weekly treatments171. There was signifi cant reduction 
in intravascular ultrasound (IVUS)-measured coronary atheroma burden with ETC-216, with 
1 patient reported to have a signifi cant rise in transaminases171. In a trial of 47 patients after 
an acute coronary syndrome, recombinant apolipoprotein A-I Milano infusion was associated 
with reverse coronary remodeling and reduced atheroma burden172. A future study will assess 
the eff ects of CER-001, an ApoA-I-based HDL mimetic, on indices of atherosclerotic plaque 
progression and regression as assessed by IVUS measurements in patients with ACS173.
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6.2 Atherosclerosis anti-infl ammatory and antioxidant therapy
6.2.1 Selective phospholipase A2 (PLA2) inhibitors
6.2.1.1 Selective secretory phospholipase A2 (sPLA2) inhibitors
Varespladib sodium (A-001; Anthera Pharmaceuticals, San Mateo,CA or previously Eli-
Lilly LY 315920), and varespladib methyl (A-002; Anthera Pharmaceuticals, San Mateo,CA 
or previously Eli-Lilly LY 333013) are both selective sPLA2 inhibitors. Varespladib sodium is 
intravenous formulation and varespladib methyl is the oral formulation of the selective sPLA2 
inhibitors.
A phase II, randomised, double-blind, placebo-controlled, dose-response study (Phospholi-
pase Levels and Serological Markers of Atherosclerosis [PLASMA])174 conducted in 393 CAD 
patients showed that varespladib methyl reduced the enzymatic activity of sPLA2, LDL-C 
and oxidized LDL levels in a dose-dependent manner, and had anti-infl ammatory eff ects as 
evidenced by a reduction in infl ammatory markers, which suggest that A-002 might be an 
eff ective anti-atherosclerotic agent. In the 500 mg A-002 treatment group, there was one se-
rious adverse event (exacerbation of underlying chronic obstructive pulmonary disease), but 
the proportion of patients reporting treatment-emergent adverse events did not diff er from 
placebo. The main side-eff ects of the drug included headache, nausea, and diarrhea. PLASMA 
II is an ongoing RCT that examines the eff ects of once daily dosing of varespladib methyl 
(250mg, 500mg) on sPLA2 mass, lipids and lipoproteins in 135 patients with stable CAD174, 175. 
Other ongoing studies, FRANCIS-ACS and VISTA-16 trials, will assess the safety and effi  cacy 
of A 002 in subjects with ACS176, 177. Furthermore, The sPLA 2 Inhibition to Decrease Enzyme 
Release after PCI (SPIDER-PCI) trial will investigate the eff ects of treatment with varespladib 
methyl on peri-percutaneous coronary intervention (PCI) myocardial infarction incidence in 
patients undergoing elective PCI178. 
6.2.1.2 Selective lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitors
Several selective and highly potent azetidinone inhibitors have been developed as pharma-
cological tools. Darapladib (SB 480848, GlaxoSmithKline, Philadelphia, PA) represents the 
azetidinone selected for human clinical trials.
In a phase II multicenter, randomized, double-blind, parallel-groups study involving 959 
stable CAD or CAD equivalent patients receiving atorvastatin, it was found that darapladib 
produced sustained inhibition of plasma Lp-PLA2 activity, and reduction of cardiovascular 
infl ammatory biomarkers with no serious adverse events, only malodor of urine and faeces 
was reported in the darapladib treated group179. In another study, Integrated Biomarker 
and Imaging Study-2 (IBIS-2)180, Lp-PLA2 inhibition with darapladib prevented necrotic 
core expansion, a key determinant of plaque vulnerability. Further ongoing phase III trials 
are addressing the potential role of darapladib in atherosclerotic plaque stabilization181, 182 
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and improved endothelial function183. These fi ndings suggest that Lp-PLA2 inhibition may 
represent a novel therapeutic approach, whether this was associated with favorable eff ects 
on CV events needs to be further emphasized in future studies.
6.2.2 Heme oxygenase-1 inhibitors (Probucol analogues)
Succinobucol (AGI-1067, AtheroGenics Inc., Alpharetta, GA, USA) is a metabolically stable, 
orally available derivative of probucol. It has greater intracellular antioxidant effi  cacy in 
vitro than probucol without its QT prolonging eff ect184. Succinobucol has anti-infl ammatory 
properties185, 186, and has been found to reduce some circulating biomarkers of infl amma-
tion namely myeloperoxidase, but not C-reactive protein (CRP)187. Both succinobucol and 
probucol lower the risk of restenosis after percutaneous coronary intervention184. Addition-
ally, succinobucol seemed to reduce progression of atherosclerosis in non-treated coronary 
reference segments184, although this was not confi rmed in a recently published study187.
In a phase III, randomized, double-blind, placebo-controlled study among 6144 patients with 
recent acute coronary syndromes, the Aggressive Reduction of Infl ammation Stops Events 
(ARISE) trial188, succinobucol had no eff ect on the composite primary endpoint (of time to fi rst 
occurrence of cardiovascular death, resuscitated cardiac arrest, MI, stroke, unstable angina, or 
coronary revascularization), however,  the composite secondary endpoint of cardiovascular 
death, cardiac arrest, MI or stroke occurred in fewer patients in the succinobucol group, and 
there was 63% relative reduction in the tertiary endpoint of the occurrence of new-onset 
diabetes. These results were seen despite the unfavorable changes in lipids (increasing LDL-C 
and decreasing HDL-C), blood pressure, and CRP, suggesting that the antioxidant and anti-
infl ammatory eff ects of succinobucol might have favorably aff ected the clinical outcomes. 
These hypothesis-generating observations should draw further attention to future trials with 
succinobucol targeting high risk CAD patients.
In the ARISE trial, it is worth mentioning that there were more cases of hepatic derangement 
in the succinobucol arm, and one patient had liver failure which resolved after discontinua-
tion of the drug. There was an increase in the occurrence of new onset atrial fi brillation in the 
succinobucol arm. Whether this observation is related to the small increase in blood pressure 
noted with succinobucol needs further studies.
6.3 New Anti-anginal treatments
6.3.1 Ivabradine
Ivabradine (Procoralan, Les Laboratories Servier, France; also available under the following 
names: Coralan, Corlentor, and Coraxan) has been established as an eff ective treatment 
to prevent myocardial ischemia in patients with chronic stable angina122, 189, 190, and recent 
subgroup analysis raised the hypothesis that ivabradine may be helpful to reduce major 
cardiovascular events26, 191. This constituted the rationale for an ongoing study, Study assess-
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InG the morbidity–mortality beNefi ts of the If inhibitor ivabradine in patients with coronarY 
artery disease (SIGNIfY), which will assess the eff ects of ivabradine in terms of CV morbidity 
and mortality192. It has been found as well, that ivabradine therapy on top of commonly used 
dosage of B-Blocker therapy had an additional effi  cacy with no untoward eff ect on safety or 
tolerability193. 
In the recently published results of the SHIFT randomized placebo-controlled study (Iv-
abradine and outcomes in chronic heart failure)194, it was found that in patients allocated 
to ivabradine , the relative risk of the primary end-point (cardiovascular death or hospital 
admission for worsening heart failure) dropped by 18% compared to placebo, supporting the 
importance of heart rate reduction with ivabradine for improvement of clinical outcomes in 
heart failure patients.  
Pre-clinical animal studies have shown that ivabradine eff ect might extend beyond heart rate 
reduction. It was associated with decreased vascular oxidative stress, improved endothelial 
fuction and reduced atherosclerotic plaque formation195. This has stimulated further research 
with a planned phase IV RCT, to assess the eff ect of ivabradine therapy on reducing infl am-
matory markers in patients with acute coronary syndromes195, 196.
6.3.2 Rho-Kinase (ROCK) Inhibitors
Recently, it was shown that inhibition of ROCK’s activity by fasudil (Schering AG, Berlin, 
Germany) exerts anti-ischemic benefi ts. Fasudil inhibits coronary vasospasm in patients with 
unstable angina pectoris197, and signifi cantly increases the ischemic threshold of angina 
patients during exercise with a trend toward increased exercise duration198. The vasodilatory 
eff ect of fasudil is more potent than that of nitroglycerin199 and has been shown to further 
dilate segments of vasospastic coronary artery that have already been pre-treated with 
nitroglycerin200. These fi ndings support the potential of fasudil as a novel therapeutic agent 
for coronary vasospasm and ischemia.
Furthermore, Fasudil has been found to improve endothelial function in patients with CAD, 
through restoration of NO bioavailability in humans with atherosclerosis.201. This has fueled 
further research to determine whether fasudil would be useful in treating atherosclerosis and 
hypercholesterolemia202 
6.3.3 Ranolazine
Ranolazine (Ranexa, A. Menarini Pharma UK, High Wycombe, UK) has been shown in several 
large trials to be an effi  cacious adjunctive agent in reducing symptoms of CAD203-206. It has 
been shown to increase exercise duration, reduce frequency of angina and reduce need for 
increased antianginal therapy. Ranolazine was generally well tolerated with the most com-
monly occurring side eff ects being dizziness, nausea, asthenia, and constipation207, and its 
safety has been emphasized on long term follow-up208. Interestingly, the Metabolic Effi  ciency 
With Ranolazine for Less Ischemia in Non−ST-Elevation Acute Coronary Syndromes (MERLIN)-
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TIMI 36 trial has indicated potential antiarrhythmic eff ects of ranolazine in a large population 
of NSTEMI-ACS patients, through reducing the percentage of clinically signifi cant ventricular 
arrhytmias205. Currently, a phase IV RCT is ongoing to evaluate the eff ect of ranolazine 1000 
mg administered twice daily compared to placebo on exercise-induced reversible myocardial 
perfusion defect size (PDS), assessed by gated single photon emission computed tomog-
raphy (SPECT) myocardial perfusion imaging (MPI) in subjects with documented exercise 
induced myocardial ischemia at baseline209. 
6.4 RAS inhibition-Direct rennin inhibitors
Aliskiren is a direct renin inhibitor, with potent antihypertensive eff ects. Recently, a group 
of phase 2 and 3 clinical trials have been launched to assess the infl uence of aliskiren on 
plaque progression in established atherosclerosis using high resolution 3-D MRI210 or using 
intravascular ultrasound211, and to examine the infl uence of aliskiren in improving ventricular 
hemodynamics in subjects stabilized after ACS212. Also another study is planned; hypothesiz-
ing that long-term Aliskiren treatment will improve endothelial function and the production 
and function of endothelial progenitor cells (EPCs) in patients with early atherosclerosis213. 
We are still awaiting the results of the ASPIRE trial evaluating  the effi  cacy and safety of 
aliskiren on the prevention of left ventricular remodeling in high risk post-acute myocardial 
infarction patients when added to optimized standard therapy214.
6.5 New Antiplatelet agents
6.5.1 COX-1 inhibitors
Trifl usal is an antiplatelet agent structurally related to aspirin, although it does not belong 
to salicylates. Its mechanism of action involves inhibition of TXA2 production through se-
lective COX-1 inhibition, while at the same time preserving vascular prostacyclin synthesis. 
Moreover, trifl usal is also a phosphodiesterase inhibitor resulting in cyclic AMP increase and 
therefore leading to reversible inhibition of platelet aggregation, vasodilation, and inhibition 
of vascular smooth muscle cell proliferation. Evidence from small clinical studies suggest 
that it is as eff ective as aspirin in prevention of vascular events (myocardial infarctions and 
strokes) while associated with lower risk of bleeding complications215.
6.5.2 Novel ADP/P2Y12 receptor anatgonists
6.5.2.1 Prasugrel
Prasugrel (CS-747, LY640315) is an orally administered thienopyridine prodrug that, as in the 
case of clopidogrel, is activated in the liver through CYP. The active metabolite irreversibly 
binds platelet ADP receptor, to a similar extent as the active metabolite of clopidogrel. How-
ever, in the case of plasugrel, in vivo availability of the active metabolite is signifi cantly higher 
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compared to clopidogrel. As a result, the recommended loading dose of 60 mg followed by 
a 10 mg daily maintenance regimen induces a more rapid, potent and consistent inhibition 
of platelet function compared to the currently used doses of clopidogrel (300 to 600 mg 
loading, followed by 75 mg daily for maintenance)216. Prasugrel has already been established 
as a valuable therapeutic option in clinical practice following the results of the Trial to Assess 
Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel – 
Thrombolysis in Myocardial Infarction (TRITON-TIMI 38), a phase III 13608-patient random-
ized trial, including moderate to high risk ACS patients undergoing PCI. In this study where 
prasugrel (60 mg loading and 10 mg maintenance) in addition to aspirin was immediately 
compared to clopidogrel (300 mg loading and 75 mg maintentance) plus aspirin, prasugrel 
was associated with a signifi cant reduction of the primary end point (cardiovascular death, 
nonfatal MI, or nonfatal stroke) over a 15-month follow up period, in the expense of an 
increase in major bleeding (including fatal bleeding)217. The benefi cial results of prasugrel 
were associated with a signifi cant reduction of defi nite or probable stent thrombosis (1.1 
vs 2.4%) while as predicting determinants of major bleeding were identifi ed the history of 
stroke or transient ischemic attack, age of more than 75 years and body weight of less than 60 
kg. In a pre-specifi ed TRITON-TIMI 38 study of 3524 STEMI patients undergoing primary PCI, 
prasugrel also proved more eff ective than clopidogrel in preventing ischemic events, without 
a signifi cant excess of bleeding complications218. Largely based on the TRITON-TIMI 38 trial, 
prasugrel has now been approved both in Europe and by FDA for the prevention of ischemic 
events in ACS patients undergoing PCI.  
6.5.2.2 Ticagrelor
Ticagrelor (AZD6140) belongs to a new class of antiplatelet agents, the cyclopentyltriazo-
lopyrimidines. Although its mechanism of action is also exerted through P2Y12 platelet 
receptor inhibition, in contrast to clopidogrel and prasugrel, this inhibition is reversible. It’s 
an active metabolite (no metabolism of a pro-drug is required) with a rapid onset of action 
and greater degree of platelet inhibition compared to clopidogrel. The effi  cacy and safety of 
ticagrelor were evaluated in the Platelet Inhibition and Patient Outcomes (PLATO) trial where 
18624 ACS patients (38% of them with STEMI) were randomly assigned to either ticagrelor 
(180 mg loading dose followed by 90 mg twice daily) or clopidogrel  (300 to 600 mg load-
ing dose followed by 75 mg daily) for one year. All patients were also receiving aspirin. At 
the end of the follow up period, patients on ticagrelor presented signifi cantly lower rates 
of the composite primary end point (cardiovascular death, myocardial infarction or stroke) 
compared to clopidogrel (9.8 vs 11.7%) without any signifi cant diff erence in the rates of 
major bleeding among the two groups219. Despite the encouraging results, ticagrelor is not 
clinically available yet, while some have serious concerns regarding the eff ects of a possible 
poor compliance to medication; given the reversible nature and the not yet fully explained 
side-eff ect of dyspnea. Pending in offi  cial registration, ticagrelor is already, like prasugrel, 
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announced in the new ESC guidelines for myocardial revascularization as class I indication for 
the treatment of NSTE-ACS and STEMI220.  
6.5.2.3 Cangrelor
Cangrelor is a direct acting reversible platelet P2Y12 inhibitor. Unlike the previously described 
agents, cangrelor is administered intravenously with its eff ect rapidly reversed following end 
of the infusion. Similar to prasugrel and ticagrelor, cangrelor is characterized by a rapid onset 
of action and more eff ective platelet inhibition compared to clopidogrel, with a favorable 
safety profi le concluded from the initial phase II trials. Cangrelor underwent two phase III 
clinical trials, the “Clinical Trial to Demonstrate the Effi  cacy of Cangrelor (PCI)”221, 222 and the 
“Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition 
(Platform)”223 that were discontinued due to insuffi  cient evidence of cangrelor’s clinical ef-
fectiveness. Cangrelor is still being studied as a bridge for patients on clopidogrel who are 
planned for CABG operation (BRIDGE: Maintenance of Platelet inihiBition With cangRelor 
After dIscontinuation of ThienopyriDines in Patients Undergoing surgery)224.
6.5.2.4 Elinogrel
Elinogrel (PRT060128) is a novel, direct-acting, reversible P2Y12 antagonist that can be 
administered both orally and intravenously resulting in a simplifi ed and eff ective treatment 
regimen and covering the full spectrum of care from acute onset to chronic care. A recent 
pilot trial (Early Rapid ReversAl of Platelet ThromboSis with Intravenous Elinogrel before PCI 
to Optimize REperfusion in Acute Myocardial Infarction, ERASE-MI) provided preliminary data 
about the feasibility and tolerability of escalating doses of intravenous elinogrel as an ad-
junctive therapy for primary PCI for STEMI225. Another double blind, randomized, phase II trial 
completed earlier this year (a Novel Antiplatelet Therapy in Patients Undergoing Non-urgent 
Percutaneous Coronary Interventions, INNOVATE-PCI), evaluated the safety, tolerability and 
effi  cacy of elinogrel in patients undergoing non-urgent PCI226.
6.5.3 PAR-1 receptor inhibitors
Vorapaxar (SCH 530348) is an orally administered agent that reversibly inhibits platelet prote-
ase activated receptor-1, through which thrombin induces its eff ect on platelet aggregation, 
and thus, thrombus formation. A number of phase II clinical trials have provided promising 
results and two phase III clinical trials are ongoing; Eff ects of Vorapaxar  in Preventing Heart 
Attack and Stroke in Patients With Acute Coronary Syndrome (TRA•CER)227 and Eff ects of Vora-
paxar  in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 
50)228) examining the safety and effi  cacy of vorapaxar in preventing the composite end-point 
of cardiovascular death, MI, stroke or urgent coronary revascularization in patients with an 
ACS (UA/NSTEMI) or atherosclerosis. Results of these studies are still pending. 
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Another agent of this class, Atopaxar (E5555) with potential antithrombotic and anti-
infl ammatory properties has recently completed two phase II trials (Japanese - Lesson from 
Antagonizing the Cellular Eff ect of Thrombin or J-LANCELOT, and Lesson from Antagonizing 
the Cellular Eff ect of Thrombin in Acute Coronary Syndromes or LANCELOT ACS)229, 230 in 
a Japanese population with either ACS or high risk CAD. Results from these studies have 
been announced in the ESC 2010 and TCT 2010 congresses with atopaxar demonstrating a 
satisfactory safety profi le in terms of bleeding complications and a potential to reduce major 
adverse cardiovascular events. There were some concerns regarding the liver function and 
prolongation of the QTc interval which may be due to the increased atopaxar doses used231. 
Further studies with phase III clinical trials and reduced dosing schemes are expected.
6.5.4 Thromboxane synthase and thromboxane receptor inhibitors
Terutroban (S 18886) is a selective antagonist of thromboxane receptor, inhibiting throm-
boxane induced platelet aggregation and vasoconstriction. Preliminary studies in humans 
have shown that terutroban induced regression and stabilization of atherothrombotic 
plaques in magnetic resonance studies232 and that it successfully inhibited platelet aggre-
gation in peripheral artery disease patients (an eff ect comparable to aspirin). A phase III 
clinical study (Prevention of cerebrovascular and cardiovascular events of ischemic origin 
with terutroban in patients with a history of ischemic stroke or transient ischemic attack, 
PERFORM) has recently been completed and the results are expected233. Recruiting 18000 
patients, this study investigated the effi  cacy of terutroban in secondary prevention of further 
cerebrovascular and cardiovascular events following a stroke or a TIA, compared to aspirin.  
Picotamide acts as an equally eff ective TXA2 synthase and TXA2 receptor inhibitor. It inhibits 
aggregation of human platelets while it also preserves prostacyclin production by re-orient-
ing endoperoxides’ metabolism, accumulated as a result of the TXA2 synthase blockade234. 
Picotamide inhibits TXA2 formation both intra and extra-vascular while, apart from platelets, 
it has an eff ect on other cells (monocytes etc) and seems to interact in vivo with the vascular 
endothelium235. The eff ects of picotamide in clinical practice have been tested in the double 
blind, randomized ADEP (Atherosclerotic Disease Evolution by Picotamide) and DAVID (Drug 
Evaluation in Atherosclerotic Vascular Disease in Diabetics) trials that both involved patients 
with peripheral artery disease (PAD)236, 237. In the DAVID study, 1200 patients with PAD and 
diabetes were randomized to receive either picotamide (600 mg twice daily) or aspirin (320 
mg once daily), with all-cause mortality as a primary end point. Patients on picotamide did 
signifi cantly better with a total mortality of 3% vs 5.5% for the aspirin group237. Moreover this 
didn’t come on the expense of more bleedings, with the agent being well tolerated. The DA-
VID study was a landmark study, demonstrating the increased effi  cacy of an agent (compared 
to aspirin) in the highly problematic group of diabetic patients. However its potential role in 
the treatment of patients with CAD needs further investigation.
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6.5.5 Other agents
We previously discussed the potential role of trifl usal in the treatment of CAD. The role of 
other phosphodiesterase inhibitors is also under investigation; cilostazol has been approved 
for the treatment of intermittent claudication. It has also been found to reduce smooth 
muscle proliferation and intimal hyperplasia after endothelial injury, properties that led to 
trials evaluating its effi  cacy for the prevention of restenosis after PCI238, 239. In the largest of 
these trials, cilostazol on top of regular aspirin and clopidogrel treatment signifi cantly re-
duced angiographic in-stent restenosis, although this did not refl ect to a diff erence in the 
rate of target vessel revascularization238. Moreover, these studies were performed before the 
era of drug eluting stents that largely resolved the issue of in-stent restenosis. Further studies 
are needed to determine a possible role of cilostazol (or other phosphodiesterase inhibitors) 
in current treatment strategies. 
Better understanding of platelet biology and function has indicated other potential treat-
ment targets; DZ-697b is a new orally active antiplatelet agent that inhibits collagen and 
ristocetin-mediated platelet activation. It does not require metabolisation to generate its 
active compound and has a safer profi le than clopidogrel in pre-clinical studies. In a recently 
published study, oral DZ-697b showed potent, dose-dependent, antithrombotic eff ects 
comparable to clopidogrel, without prolonging bleeding times240. Its clinical effi  cacy remains 
yet to be studied.
6.5.6 Reduced dose of GP IIb/IIIa receptor antagonists
Although GPIIb/IIIa inhibitors are routinely used in clinical practice, increased concern of 
bleeding complications and their potential eff ect on outcomes, has led to re-evaluation of 
our strategies and set the pace for studies investigating the safety and effi  cacy of bolus-only 
GPIIb/IIIa receptor antagonists schemes241. In a study reporting single-center experience with 
1001 patients, bolus-only dosing schemes of abciximab, tirofi ban and eptifi batide resulted in 
low rates of in-hospital death (0.1%), myocardial infarction (4.3%), and repeat revasculariza-
tion (0%) that are comparable to the outcomes observed when mainstream dosing schemes 
are followed, while achieving lower rates of major or minor bleeding (2.3%)242. However, since 
this was an observational and not a randomized trial, the results must be cautiously evalu-
ated.
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6.6 New Antithrombotic agents
6.6.1 Direct thrombin inhibitors
6.6.1.1 Parenteral direct thrombin inhibitors
Hirudin, lepirudin (a recombinant hirudin), argatroban and bivalirudin are all parenterally 
administered direct thrombin inhibitors. The rationale for their clinical use as well as their 
benefi ts over UFH and LMWH has been analyzed before.
Hirudin and (its recombinant analogue) lepirudin are mainly used for the treatment of HIT. 
Lepirudin has also been evaluated for the treatment of acute coronary syndromes (both 
unstable angina and non-ST elevation myocardial infarction) but results were disappointing; 
a benefi t was indeed observed in terms of death, re-infarction and revascularization reduc-
tion, but this was on the expense of increased moderate or major bleeding, attributed to its 
narrow therapeutic window243, 244. Similarly, in the case of STEMI patients, randomized trials 
failed to support a substantial benefi t from the use of either hirudin or lepirudin, although in 
this case an increased risk of bleeding was not observed243, 245.
Argatroban has also been FDA approved for the treatment of HIT. It has a short in vivo half-
life and dose adjustments are not required in the presence of renal failure. As in the case of 
hirudin/lepirudin, a randomized trial failed to prove a benefi t from using it in the setting of 
acute myocardial infarction patients246. 
Bivalirudin has also a short plasma half-life (of about 25 minutes) and undergoes predomi-
nantly non-organ elimination (proteolysis), inclining for a rather safe profi le in terms of bleed-
ing complications. It is the fi rst agent of this class that has been approved as an eff ective 
anticoagulant in the setting of interventional cardiology. In the Acute Catheterization and 
Urgent Intervention Triage Strategy (ACUITY) study (involving 14000 patients with moderate 
or high risk ACS undergoing PCI) bivalirudin (as the only anticoagulant) proved as eff ective 
as the combination of UFH or enoxaparin with GPIIb/IIIa in terms of ischemic complications 
at 30 days, while signifi cantly reducing the bleeding complications, with the greater benefi t 
observed in those aged more than 75 years247. The effi  cacy of bivalirudin in the setting of 
STEMI was further studied in the Harmonizing Outcomes With Revascularization and Stents 
in Acute Myocardial Infarction (HORIZONS AMI) trial, where bivalirudin plus provisional use 
of GPIIb/IIIa was tested against standard therapy, in a series of 3600 patients. Both at the 
30-day and 12-month time points, bivalirudin proved safer in terms of the combined end 
point of major bleeding or major cardiovascular event248; however a slightly higher risk of 
acute stent thrombosis (i.e within the fi rst 24 hours) was observed in the bivalirudin group, 
underlying the need for early P2Y12 inhibitors initiation and possibly for a prolonged bivali-
rudin infusion, in selected patients249. Based on the results of HORIZONS AMI and ACUITY, 
bivalirudin has been included in the guidelines of treatment of ACS patients. Bivalirudin 
(with provisional use of GPIIb/IIIa inhibitors) can also be used as a substitute of UFH-GPIIb/IIIa 
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combination for stable angina and low risk ACS patients, as demonstrated in the Randomized 
Evaluation in Percutaneous Coronary Intervention Linking Angiomax to Reduced Clinical 
Events (REPLACE-2) study250. 
6.6.1.2 Oral direct thrombin inhibitors
Ximelagatran was the fi rst oral direct thrombin inhibitor to get into phase III clinical trials. 
However, despite the promising results of the Stroke Prevention by ORal Thrombin Inhibitor 
in atrial Fibrillation (SPORTIF) trials in terms of thromboembolism prevention, it was with-
drawn due to the observed incidence of hepatotoxicity251, 252.
Dabigatran etexilate is a prodrug of the active compound dabigatran that has been tested 
for the prevention and treatment of both venous and arterial thromboembolic disease253, 
254. In the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial pub-
lished recently, 18113 patients with atrial fi brillation and at least one risk factor for stroke 
(mean CHADS2 score 2.1) were randomly assigned to receive either dabigatran (two dosing 
schemes were tested, 110 or 150 mg twice daily) or warfarin (target INR 2.0-3.0). Dabigatran 
in the lower dosing scheme proved as eff ective as dose adjusted warfarin (in terms of isch-
emic stroke and systemic embolism prevention) while safer in terms of hemorrhagic stroke 
and major bleeding incidence. On the other hand, the higher dosing scheme of dabigatran 
proved more eff ective in terms of thromboembolic events’ prevention, being at the same 
time as safe as warfarin in major bleeding incidence253. Dabigatran represents an attractive 
alternative to contemporary warfarin treatment, since (in addition to the advantages of both 
dosing schemes mentioned) it does not require monitoring of the INR, it’s less susceptible to 
dietary and drug interactions and it’s not limited by warfarin’s narrow therapeutic window. 
On the other hand, besides the increased cost of therapy, adoption of the new agent can-
not yet be recommended due to the lack of long term safety data. Other issues that can be 
mentioned are the inconvenient dosing scheme (twice daily), the lack of data for patients 
with renal insuffi  ciency and the lack of an eff ective antidote.  
6.6.2 Factor Xa inhibitors
In addition to the thrombin inhibitors previously mentioned, a new class of direct factor Xa 
inhibitors is under clinical development. This new class of agents (xabans) that has both oral 
and parenteral representatives is generally characterized by a rapid onset of action and a 
rather stable pharmacodynamics profi le without a need for routine monitoring, making them 
an attractive option as a substitute of traditional anti-coagulants.
6.6.2.1 Parentral factor Xa inhbitors
Idraparinux sodium (SR34006) is a synthetic pentasaccharide administered subcutaneously 
with a similar chemical structure and same method of action as fondaparinux but with a 
much longer elimination half-life, making feasible a once-a-week dosing scheme. The drug 
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never reached the market due to concerns of excessive bleeding following the use of this 
agent, documented in the AMADEUS trial which tested its effi  cacy in preventing thromboem-
bolic events, against adjusted dose vitamin K antagonists, in patients with atrial fi brillation255. 
Instead Idrabiotaparinux (SSR126517), a biotinylated version of idraparinux, was developed. 
Despite the similar mode and duration of action, Idrabiotaparinux can be safely inactivated, if 
this becomes necessary, by i.v. infusion of avidin that neutralizes its anti-Xa activity256. Results 
from phase III trials, assessing idrabiotaparinux’s effi  cacy in preventing thromboembolism in 
the setting of deep vein thrombosis and atrial fi brillation, are expected257, 258. 
Otamixaban (XRP0673) is a short-acting, intravenously administered, selective inhibitor 
of factor Xa. It has already been tested in two phase II trials in the setting of routine PCI 
interventions and NSTEMI ACS ((Prevention of Ischemia with Anti-Xa inhibition in acute 
coronary syndromes 1 - Thrombolysis in Myocardial Infarction 42, SEPIA-ACS1 TIMI 42 and 
Otamixaban in Comparison to Heparin in Subjects Undergoing Non-Urgent Percutaneous 
Coronary Intervention, SEPIA-PCI) with promising results259, 260. A Phase III trial, comparing it 
to standard therapy in high risk ACS patients undergoing early invasive strategy, is currently 
recruiting patients261.
Ultra low molecular weight heparin (AVE5026) is a hemi-synthetic molecule with an average 
molecular weight of 2000 to 3000 Da (almost half compared to other LMWH). It has nearly 
pure anti-Xa activity and is currently being assessed in phase III trials as an alternative to 
standard therapy for prevention of DVT thromboembolism262-264.
6.6.2.2 Oral factor Xa inhibitors
Rivaroxaban (BAY 59-7939) is an orally administered direct factor Xa inhibitor with a bioavail-
ability of 80 percent and peak plasma concentrations occurring 2.5 to 4 hours following 
administration. As in the case of previous agents mentioned in this category, it does not 
require routine monitoring. It has proved favorable to enoxaparin in the prevention of ve-
nous thromboembolism in patients undergoing orthopedic surgery, without increasing the 
bleeding complications265. A phase II clinical trial in ACS patients demonstrated a benefi cial 
eff ect in terms of ischemic events reduction along with a dose-dependent increased bleeding 
risk266. Phase III clinical trials are currently testing its effi  cacy in the setting of ACS267, recurrent 
thromboembolism prevention268 and prevention of stroke in the setting of non-valvular atrial 
fi brillation269.
Apixaban (BMS-562247-01) has also been tested for the prevention of thromboembolism, 
mainly in the setting of orthopedic surgery. In a recently published study, apixaban did not 
meet the pre-specifi ed non-inferiority criteria compared to enoxaparin but its use was associ-
ated with lower rates of clinically relevant bleeding270. However, in another phase III clinical 
trial also involving knee-replacement surgery patients, apixaban proved more eff ective than 
enoxaparin without increasing bleeding risk271. Further studies, assessing its effi  cacy in the 
setting of atrial fi brillation272 and ACS patients273 are on their way.
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Edoxaban (DU-176b) has completed a number of phase II clinical trials testing its effi  cacy 
in non-valvular atrial fi brillation274 and phase II and III trials in thromboembolism preven-
tion following orthopedic surgery275, 276. A large phase III trial (Eff ective aNticoaGulation with 
factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 
48, Engage AF-TIMI 48) comparing edoxaban to warfarin in terms of stroke prevention in 
patients with non-valvular atrial fi brillation is currently recruiting patients277, with results 
expected in 2012.
SR123781A is a synthetic hexadecasaccharide with a mixed profi le of AT-dependent anti-Xa 
and anti-thrombin activities. In a dose-ranging study for the prevention of thromboembolism 
following orthopedic surgery (NCT00338897), it demonstrated a reasonable risk to benefi t 
ratio compared to enoxaparin278.
LY517717 and Betrixaban (PRT-054021) are two more agents of this category that have been 
tested in phase II trials against enoxaparin in orthopedic patients279, 280. Both were well toler-
ated and gave promising results, with further phase III trials expected in the near future. 
YM150 is another direct factor Xa inhibitor that is currently being tested in a phase II study in 
subjects with acute coronary syndromes281 after proving safe and eff ective for prevention of 
venous thromboembolism after hip replacement. 
7. POTENTIAL DEVELOPMENT ISSUES
7.1 Cell-based therapy
Cell-based revascularization strategies have the potential to become a major therapeutic 
advance for severe CAD. Intra-myocardial bone marrow stem cell injection is currently being 
investigated as a new therapeutic option for patients with chronic ischemia who are ineli-
gible for revascularization. Bone marrow mononuclear CD34+ stem cells, harvested from the 
iliac crest or by leukapheresis after granulocyte colony–stimulating factor, are injected into 
the ischemic myocardium. In small randomized placebo- controlled studies282, 283, myocardial 
injection was found to be safe and to be associated with a modest but statistically signifi cant 
improvement in myocardial perfusion, left ventricular ejection fraction (LVEF), exercise ca-
pacity, and Canadian cardiology society (CCS) class. This technique is still in the experimental 
stages, and further studies are required to assess long-term results and effi  cacy for reducing 
mortality and morbidity.
7.2 New therapeutic targets of cholesterol metabolism
With the increasing burden of CAD, there will be a continuing demand for on-going research 
into cholesterol metabolism and the development of drugs to modify it favorably:
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7.2.1 Squalene Synthase inhibitors
Squalene synthase inhibitors decrease circulating LDL cholesterol by the induction of he-
patic LDL receptors in a similar manner to statins without the risk of myotoxicity284. Two new 
potent squalene synthase inhibitors (EP2306 and EP2302) have been described in vitro285, 
the squalene synthase inhibitor EP2302 inhibited cholesterol synthesis in a dose-dependent 
manner with a similar potency to that of simvastatin. Further in vivo studies are required for 
further evaluation.
7.2.2 Microsomal triglyceride transfer protein (MTP) inhibitors and Apo-B mRNA antisense 
oligonucleotides
An alternative approach to lowering LDL-C is to limit hepatic assembly of very low density 
lipoprotein (VLDL), the precursor of LDL. One strategy is to develop inhibitors of MTP (which 
is essential for the assembly of VLDL). Whilst this may eff ectively lower LDL cholesterol, it 
also causes hepatic triglyceride accumulation286. Another approach is to use Apo B mRNA 
antisense oligonucelotides (Apo B is the principal protein of VLDL and LDL)287. These hold the 
promise of preventing VLDL formation without causing hepatic steatosis288, and might hold 
promise for treatment of patients not reaching target LDL cholesterol levels on stable statin 
therapy289
7.3 Anticoagulants in development
Apart from improving the pharmacodynamics and pharmacokinetics of currently available 
agents, new anticoagulants aiming other factors of the coagulation cascade are also devel-
oped and tested. In a relatively recent study, recombinant nematode anticoagulant protein 
c2 (rNAPc2), a potent inhibitor of the tissue factor/factor VIIa complex, gave promising results 
without increasing major or minor bleeding290. In the same perspective, selective inhibitors of 
factors IXa and XIIa have also been considered as potential therapeutic agents291, 292.
An alternative method seems to be manipulating the clotting cascade pathway by either 
interfering with key-cofactors (like factors Va and VIIIa) or modulating the pro-coagulant/
anticoagulant balance of thrombin activities. In this context recombinant activated protein 
C, that inactivates factors Va and VIIIa, has been shown to ameliorate the coagulopathy as-
sociated with severe sepsis and reduce mortality293. Whether this agent would prove eff ective 
as an anticoagulant in the treatment of CAD is not yet known. Furthermore, recombinant 
soluble thrombomodulin (ART-123), an agent that binds thrombin and inactivates its pro-
coagulant eff ects while leaving its anti-coagulant properties intact, has been tested in septic 
patients with disseminated intravascular coagulation294 while another phase II trial suggests 
it’s effi  cacious for venous thromboembolism prophylaxis following total hip replacement 
surgery295.
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8. EXPERT OPINION
• There is established evidence that high levels of HDL-C in nature are associated with a 
lower risk of CAD. Unlike LDL-C, the mechanisms controlling HDL-C are more complex. 
Lifestyle interventions are safe but only modestly increase HDL-C. The best treatments 
available currently seem the niacin derivatives, although the newer CETP inhibitors, 
reconstituted HDL infusion and apolipoprotein A-1 Milano infusion hold much promise. 
The next 5 years should provide information on whether improving vascular protective 
function of HDL is more important than HDL-C levels and also whether we should target 
raising specifi c HDL subclasses rather than HDL-C itself.
• Treatment of dyslipidemia in diabetic patients remains a very challenging issue in CAD 
prevention, there is an increased interest in treatments that has a dual favorable eff ect on 
both glycemic control and lipid control, most important in this issue is the up-growing 
role of glitazars, especially aleglitazar, which is foreseen to be the upcoming treatment for 
lipid regulation in diabetic patients. 
• Nowadays, with a better understanding of the immunological and infl ammatory mecha-
nisms underlying atherosclerosis, treatments that stabilize vulnerable plaques and halts 
atherosclerosis progression are gaining wide interest and will show promising results 
within the next few years. Lp-PLA2 is an emerging biomarker of CV risk that is phar-
macologically modifi able through specifi c Lp-PLA2 inhibitors, as darapladib. Moreover, 
Aliskiren, a direct renin inhibitor is gaining wide interest in terms of plaque stabilization 
and regression in established atherosclerosis.
• Combination therapy can provide marked lipoprotein changes in patients at risk for 
atherosclerotic events. Three large clinical trials, involving more than 45,000 patients in 
aggregate, are currently testing the eff ect on major clinical endpoints of adding niacin 
or ezetimibe to statin treatment in patients at high risk156, 157, 296. Results of these trials are 
expected in 2012–2013. Nevertheless, a recent systematic review of 102 studies found no 
benefi t of combination therapy over high-dose statin monotherapy in terms of mortality, 
MI, stroke, and revascularization procedures in patients requiring intensive lipid-lowering 
therapy297. An eff ective strategy in patients requiring intensive lipid-lowering therapy is 
critically needed and still controversial, and is a fi eld for further research.
• Novel anti-anginal treatments, as ivabradine, fasudil and ranolazine have gained wide 
interest because of the absence of eff ect on blood pressure, regional myocardial blood 
fl ow or myocardial contractility, a benefi t that they have over conventional anti-anginal 
therapies. They have proved to have an additive benefi t in terms of anginal pain relief 
and exercise tolerance. Whether these treatments have a further role beyond anti-anginal 
eff ect, as vasoprotective and endothelial function infl uence, is still a fi eld of intensive 
research and the ongoing studies will answer this question.
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• Antiplatelet agents and anti-thrombotics represent a major advancement in the current 
treatment of ACS and CAD. Despite the progress achieved, the fraction of non-responders 
among the population treated, the narrow therapeutic window of many of the agents 
used and the increased bleeding complications often observed limit their usefulness and 
sets the pace for the research and introduction of novel therapeutic options.
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ABSTRACT
The techniques and materials used during percutaneous coronary intervention have 
advanced considerably over the past 3 decades, yet restenosis remains one of the major 
drawbacks of this procedure. Many innovative technologies, including drug-eluting 
stents, with or without specifi c polymers, and fully biodegradable stents have been and 
continue to be developed in the search for a safe and eff ective antirestenosis therapy. 
Remarkable advances in stent design and nanoparticle delivery systems (‘nanovehicles’) 
have already fueled revolutionary changes in the prevention and treatment of in-stent 
restenosis. In this Review we provide an overview of the latest innovations for optimizing 
outcomes of coronary stenting, and up-to-date information about prevention and treat-
ment of in-stent restenosis.
KEY POINTS
• Although drug-eluting stents decrease the incidence of restenosis, they do not yet 
fully prevent this problem; furthermore, long-term safety issues indicate that new 
technologies are still warranted
• New-generation polymer coatings, including biocompatible permanent polymers 
and biodegradable polymers, and stents without a polymer, represent innovative 
technologies that aim to preserve vascular biology in the long-term
• Biodegradable stents prevent the long-term problems associated with foreign mate-
rial in the coronary arteries; the fi rst human studies employing these stents show 
promising results
• Nanoparticle-mediated drug delivery systems are expected to revolutionize the devel-
opment of innovative therapeutic devices, allowing local or targeted delivery of the 
drug with an excellent biocompatibility profi le
• Drug-eluting balloons provide homogenous drug distribution in the vascular wall and 
represent a favorable option for the treatment of restenosis
• Gene-eluting stents are expected to play an important role in the prevention of in-
stent restenosis, particularly in patients with a high genetic-risk profi le
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INTRODUCTION
Since its introduction in the late 1970s,1 percutaneous coronary intervention (PCI) has be-
come the most important and widely used treatment for patients with obstructive coronary 
disease. Although the technique and the materials used during the procedure have advanced 
tremendously, restenosis—the renarrowing of the treated obstruction—remains one of the 
major complications of PCI.2 Intravascular stents were developed as an adjunct to primary 
angioplasty for the management of early complications, including arterial dissection, and for 
the treatment for early elastic recoil. Despite the benefi cial eff ects of stenting, however, rates 
of restenosis remained persistently high, giving rise to a new problem—in-stent restenosis 
(ISR). The introduction of drug-eluting stents (DESs) was seen as a solution to this problem 
and, initially, DESs reduced the incidence of ISR considerably.3 However, these promising 
results led to increased use of DESs in a diverse range of complex coronary lesions, and for 
off -label indications, leading to a resurge in the rates of ISR.4,5
In light of the increasing number of PCI procedures being performed, the diffi  culty of treat-
ing ISR, and the increasing cost of adjuvant medication and devices, defi ning subsets of 
patients at increased risk for restenosis would be useful. These patients could benefi t from 
additional treatment modalities. Until now, identifi cation of subgroups has been only par-
tially successful, as was discussed in detail in Part 1 of this Review.6 The ongoing eff orts to 
better understand the underlying pathophysiological mechanisms of restenosis and vascular 
biology continuously fuel research on the prevention and treatment of ISR. Here, in Part 2 of 
the Review, we will assess the most important innovations for optimizing the outcomes of 
coronary stenting, and data on the prevention and treatment of restenosis in general, and ISR 
in particular, published in the 5-year period up to August 2011.
PREVENTION OF RESTENOSIS
In general, PCI with DESs is currently the best approach for the prevention of restenosis.7 
However, safety concerns about stent malapposition, late stent thrombosis, and delayed 
restenosis have arisen.8,9 The main cause of these problems has, in addition to patient-related 
and lesion-related factors, been attributed to the stent polymer.10 Additionally, the eluted 
antiproliferative agent and the stent platform (metal alloys and strut thickness) have been 
implicated in ISR. These concerns have fueled research in stent development, utilizing new 
antiproliferative agents, polymer technology, and metal stent platforms (Table 1).
Antiproliferative agents
Sirolimus (rapamycin)-eluting stents (SESs; Cypher®, Cordis Corporation, Bridgewater, NJ, 
USA) and paclitaxel-eluting stents (PESs; Taxus®, Boston Scientifi c, Maple Grove, MN, USA), 
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which were approved by the FDA in 2003 and 2004, respectively, were the fi rst two DESs that 
were approved for use in humans. Although they both eff ectively reduce rates of restenosis 
compared with bare-metal stents (BMSs), their local adverse eff ects on the vasculature are 
fairly divergent. High concentrations of locally released paclitaxel have been shown to have 
detrimental eff ects on the vascular wall in a mouse model,11 suggesting a narrower thera-
peutic range of this potent drug. On the other hand, sirolimus has a less-harmful eff ect than 
paclitaxel on the vascular wall.11 Data from comparisons of fi rst-generation DESs show that 
PESs are associated with a higher risk of ISR and stent thrombosis than SESs.7,12 Two stents 
eluting sirolimus analogs—everolimus (Xience V®, Abbott Cardiovascular Systems, Inc., Santa 
Clara, CA, USA) and zotarolimus (Endeavor®, Medtronic Vascular, Inc., Santa Rosa, CA, USA)—
have also been approved by the FDA.
Many studies have been dedicated to comparing the various available DESs. In 2011, the 
2year follow-up results of two large-scale, randomized, controlled trials showed a sustained 




Sirolimus derivatives (biolimus A918,19,22 and 
novolimus23)
Clinical*
Polymer Biolinx® (Medtronic Vascular, Inc., Santa Rosa, CA, 
USA)25,26
Clinical*; preliminary‡
Polymer PolyzeneF27–29 Clinical*; preliminary‡
Polymer Biodegradable (polylactic acid, polylactic-
co-glycolic acid,30–32 SynBiosys® [InnoCore 
Technologies, Groningen, the Netherlands], 
Eureka® SOLO [Surmodics, Inc., Eden Prairie, MN, 
USA])37
Clinical*
Stent design Polymer-free stent (Biofreedom®, Biosensors 
International Group, Hamilton, Bermuda)41,42
Clinical*; preliminary‡
Coating Endothelial progenitor cell capturing stent 
(Genous®,48–50,56 Combo Stent®38,53 [OrbusNeich 
Medical, Inc., Fort Lauderdale, FL, USA])
Clinical*
Coating Titanium-nitride-oxide-coated stents (Titan2™ 
stent [Hexacath, Rueil-Malmaison, France])55–61
Clinical*
Stent platform Bioabsorbable stent (magnesium stent [Biotronik, 
Berlin, Germany])71–76
Clinical*
Drug delivery Nanomedicine79,80 Preclinical§
Stent platform/
metal alloys
Platinum–chromium alloy stents (Promus 
Element® and Taxus Element® (Boston Scientifi c, 
Maple Grove, MN, USA)66–69
Clinical*
Drug delivery Magnetic targeting stents81 Preclinical§
Miscellaneous Gene-based therapy82–90 Preclinical§
Miscellaneous Systemic treatment91,93,95–97,99–101,104,105 Clinical*
*Clinical: development is currently being tested in a clinical setting. ‡Preliminary: fi rst clinical results in small 
studies await replication in larger trials. §Preclinical: development is currently being tested in animal models
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benefi t of everolimus-eluting stents (EESs) over PESs in terms of safety and effi  cacy.13,14 On 
the other hand, zotarolimus-eluting stents (ZESs) were found to have a higher angiographic 
restenosis rate compared with PESs, although clinically driven repeat revascularization rates 
were similar for both stent types.15 In patients receiving routine clinical care, SESs have 
proven to be superior to ZESs.16 The 2year outcomes of the RESOLUTE All Comers trial17 
showed sustained similar safety and effi  cacy between ZESs and EESs. Unfortunately, few data 
are available on the direct EES versus SES comparison. Therefore, sirolimus and its analogs 
seem to be marginally superior to paclitaxel, whereas diff erences between the various limus-
eluting stents remain to be elucidated.
In search for greater antirestenotic effi  cacy and improved long-term safety, new compounds 
specifi cally designed for use with DESs are being developed and studied. Biolimus  A9 is a 
novel rapamycin derivative that, like sirolimus, inhibits smooth muscle cell proliferation 
via binding to the FK506-binding protein 1A and subsequent inhibition of the mammalian 
target of rapamycin (mTOR) and is specifi cally developed for local delivery to coronary arter-
ies (Figure 1).18 Besides its anti-infl ammatory and antiproliferative potential and improved 
pharmacokinetic profi le, the increased lipophilicity of biolimus A9 improves uptake by the 
coronary vessel wall, resulting in a more localized eff ect and lower systemic drug exposure19 
than sirolimus eluted from the Cypher® stent.20,21 Compared with fi rst-generation DESs, 
biolimus A9-eluting stents (BESs) have been shown to be associated with better recovery of 








































Figure 1: Chemical structure of biolimus A9. This compound consists of a 31-membered triene macrolide 
lactone that preserves the core sirolimus ring structure with a 2ethoxyethyl group addition to the hydroxyl 
group at position C (40) of the sirolimus molecule. One rationale for the inclusion of the ethoxyethyl group 
was to increase lipophilicity and, thus, to improve uptake by the coronary vessel wall. Permission obtained 
from John Wiley and Sons © Ostojic, M. et al. Catheter. Cardiovasc. Interv. 72, 901–908 (2008).
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Novolimus is a metabolite of sirolimus and represents another new antiproliferative mTOR 
inhibitor specifi cally developed for the stent. The newly developed DESyne® (Elixir Medical, 
Sunnyvale, CA, USA) novolimus-eluting stent has been tested in a clinical study, showing 
superiority over ZESs regarding angiographic in-stent late loss.23
Polymer technology
New-generation polymer coatings have been produced with the specifi c aim of mimicking 
the endothelial lining in order to prevent late thrombotic complications. Basic research has 
shown that some polymeric materials could potentially upregulate genes related to infl am-
mation, proliferation, thrombosis, and vasoconstriction24—processes that are considered to 
be pivotal in the development of restenosis.6
One example of current progress is the Biolinx® (Medtronic Vascular, Inc.) polymer, currently 
used in the Endeavor Resolute® ZES. This blend of three diff erent polymers—the hydropho-
bic C10 polymer to control drug release, the biocompatible and hydrophilic C19 polymer, and 
polyvinyl pyrrolidone—allows an early burst followed by controlled drug release25 so that at 
least 85% of the zotarolimus is released within 60 days and the remainder within 180 days, 
avoiding long-term release of the drug. Such release patterns are designed to match the 
delayed healing times seen in complex lesions. The Resolute® ZES was shown to signifi cantly 
lower target lesion revascularization (TLR) compared with an earlier Endeavor® ZES, which 
utilized a phosphorylcholine coating.26
Another polymer, polyzeneF is highly biocompatible and has anti-infl ammatory, bacteria-
resistant, and prohealing qualities. The coating ensures that the stent has a very low surface 
thrombogenicity, potentially reducing the risk of stent thrombosis. Evaluation of cobalt 
chromium stents nanocoated with polyzeneF in an animal model yielded favorable results.27 
Preliminary studies evaluating the Catania™ (CeloNova Biosciences, Newnan, GA, USA) stent 
in humans demonstrated a good safety profi le and high-level effi  cacy.28,29 Eff orts to improve 
polymer stent coatings are ongoing.
Biodegradable polymers
Given the issues of polymer-induced infl ammation, thrombosis, and restenosis, the devel-
opment of biodegradable polymers has become a focus for research. The most-studied 
biodegradable polymers are polylactic acid and polylactic-co-glycolic acid, which degrade 
over time and could, therefore, eliminate the problems associated with lack of polymer bio-
compatibility and polymer-induced infl ammation. To date, several biodegradable polymer 
stents eluting biolimus A9, sirolimus, or paclitaxel have been clinically evaluated, which have 
so far proven to be eff ective and safe in the short term (≤30 days) and midterm (≤1 year).30–32 
In 2010, the 3year follow-up data from the LEADERS trial33 was presented, showing the 
sustained benefi t of BESs with a biodegradable polymer over SESs with a durable polymer. 
Great expectations exist within the cardiology community that biodegradable-polymer DESs 
Tarek Ahmed bw.indd   150 15-11-11   18:05
Restenosis after PCI. Prevention and therapy 151
could become the stents of choice in years to come; the results of the ongoing ISAR-TEST6 
trial,34 testing the safety and effi  cacy of the Nobori® (Terumo Corporation, Tokyo, Japan) 
biodegradable polymer BES and the Xience V® permanent polymer ZES will, therefore, be 
eagerly awaited.
New polymer technology presents some challenges, such as establishing the optimal degra-
dation time, biocompatibility, composition, and formulation of the polymer. Several factors 
infl uence the velocity of degradation; therefore, the balance between drug-release kinetics 
and the rate of polymer degradation, as well as the eff ects of the degradation products all 
aff ect the effi  cacy of biodegradable polymer stent systems in the coronary vasculature.35 
Furthermore, studies in porcine coronary arteries have shown that even biodegradable 
polymers can cause infl ammatory reactions, which could be attributable to the combination 
of the parent polymer compound and the biodegradation products.36 Two new biodegrad-
able polymers (SynBiosys® [InnoCore Technologies, Groningen, the Netherlands] and Eureka® 
SOLO [SurModics, Inc., Eden Prairie, MN, USA) have been tested in animal studies and yielded 
fewer acidic byproducts, and had a better degradation rate and biocompatibility profi le than 
polylactic acid and polylactic-co-glycolic acid making them well-tolerated in vivo.37 In a pig 
model, stainless-steel R Stents® (OrbusNeich Medical, Inc., Fort Lauderdale, FL, USA) with Syn-
Biosys® coating and high-dose sirolimus (5 μg/mm) was associated with the lowest amount 
of neointima thickness after 28 days when compared with Xience V® and Cypher® stents.38
Polymer-free stents
In an attempt to overcome the problems encountered with polymers or their degradation 
products, ‘polymer-free’ DESs have been developed and have proven to be safe in clinical 
studies.39,40 In an animal study, polymer-free biolimus A9 coated stents (Biofreedom®, Bio-
sensors International Group, Hamilton, Bermuda) demonstrated more sustained intima in-
hibition, improved healing, and reduced infl ammation compared with the polymer-coated 
sirolimus eluting Cypher® stent at 180-day follow-up.41 The ongoing fi rst-in-man study of the 
Biofreedom® stent showed promising results compared with the Taxus® PES.42
Polymer-free, dual DESs have been tested over the past few years. No apparent benefi t 
was observed by adding estradiol to a polymer-free SES in the ISAR-PEACE trial.43 However, 
results from the ISAR-TEST2 study44 revealed that a novel, polymer-free sirolimus-eluting and 
probucol-eluting dual DES was noninferior to the Cypher® SES and the Endeavor® ZES. The 
antirestenotic effi  cacy of both the dual DES and the ZES remained durable during the 2year 
follow-up period.44 The larger ISAR-TEST5 study,45 which was powered for clinical events, 
showed similarly durable results for the dual DES.
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Novel prohealing stent coatings
Endothelial progenitor cell-capturing stent
An increased rate of endothelialization is thought to lead to reductions in restenosis and stent 
thrombosis.46 This hypothesis underlies the development of the endothelial progenitor cell 
(EPC)-capturing stent. The bioengineered Genous® (OrbusNeich Medical, Inc.) EPC-capturing 
stent has a stainless-steel platform that is coated with an abluminal polysaccharide matrix 
and covalently coupled monoclonal murine antihuman CD34 antibodies. These antibodies 
bind bone-marrow-derived EPCs from the peripheral blood. These EPCs are hypothesized to 
diff erentiate into a functional endothelial layer after immobilization and populate the surface 
of the stent.47 The safety and effi  cacy of the Genous® stent have been shown in preliminary 
human studies,48,49 and further evaluation and comparison with other stents is currently 
ongoing.50
Despite its benefi t in enhancing re-endothelialization, and thereby possibly preventing stent 
thrombosis, EPC capturing is not expected to potently inhibit neointimal proliferation. On 
the contrary, CD34 antibodies have even been shown to capture other progenitor cells, for 
example, smooth muscle cell progenitor cells, which could exaggerate restenosis.51 There-
fore, a major challenge in the development of an EPC-capturing DES is to maintain sustained 
inhibition of smooth muscle cell proliferation while promoting formation of a functional 
endothelial layer. This concept was tested in an animal study showing that immobilization of 
anti-CD34 antibody on SESs enhances endothelialization.52 The REMEDEE study38,53 investiga-
tors are currently testing the Combo Stent® (OrbusNeich Medical, Inc.), which incorporates 
low-dose abluminal sirolimus together with EPC-capturing technology and a biodegradable 
polymer. The combination of an EPC-capturing stent with a drug-eluting balloon is also an 
attractive alternative, as has been shown by the results of the PERFECT STENT study.54
Titanium-nitride-oxide-coated stent
The Titan2™ stent (Hexacath, Rueil-Malmaison, France) is a stainless-steel stent coated in 
titanium-nitride oxide that has been shown to inhibit platelet aggregation, minimize fi brin 
deposition, reduce infl ammation, and promote healing.55 This stent signifi cantly reduced late 
lumen loss and TLR compared with a BMS at 6months follow-up,56 with preserved benefi ts 
up to 5years.57 Additionally, the Titan2™ stent demonstrated favorable results compared with 
the Taxus® PES in a randomized controlled trial of 425 patients with STsegment elevation 
myocardial infarction,58 as well as in routine clinical practice.59 Despite the absence of an 
antiproliferative drug, use of the Titan2™ stent resulted in less TLR than the Taxus® stent, 
although this reduction was not statistically signifi cant.58 The Titan2™ stent was noninferior 
to the Xience V® EES in the primary results of the large randomized controlled BASE-ACS 
trial60 conducted in patients with acute coronary syndrome. However, the Titan2™ stent failed 
to prove noninferiority to the Endeavor® ZES in terms of angiographic in-stent late lumen 
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loss at 6 months in the TIDE study,61 although clinical outcomes at 1 year were comparable 
for both stent types.
Future prohealing stent designs
A step further to optimize the prohealing stent design is to create a bioactive stent that also 
elutes a drug (a bioeluting stent). Animal studies of a newly designed titanium-nitride-oxide 
stent eluting L-arginine, a precursor of nitric oxide with positive eff ects on endothelium func-
tion,62 or a sulfated polysaccharide extracted from seaweed have shown up to 50% reduction 
in late lumen loss compared with the standard titanium-nitride-oxide stent.63 A future clini-
cal trial (the VINCI fi rst-in-man study) is planned to test the effi  cacy and safety of this new 
generation of stents.63
Another approach to creating a prohealing stent would be to reduce the binding of platelets 
to an implanted stent, thereby reducing the infl ammatory response and allowing surround-
ing endothelial cells to properly re-endothelialize the stent.64 A stent created from a bioactive 
ligand, such as an integrin-binding motif, has been successfully used in noncardiac applica-
tions in vivo to promote device integration.65 The ideal ligand should only interact with integ-
rins uniquely present on endothelial cells and not on platelets, infl ammatory cells, or smooth 
muscle cells.64 Continued in vitro and in vivo studies with such biomaterials could lead to the 
creation of next-generation prohealing stent surfaces that promote the endothelialization 
of the stent while simultaneously inhibiting the adhesion and thrombus formation, and not 
stimulating smooth muscle cell proliferation.
Stent platforms
Metal alloys
A platinum–chromium alloy developed in the early 2000s has been combined with everoli-
mus on the Promus Element® (Boston Scientifi c) and with paclitaxel on the Taxus Element® 
(Boston Scientifi c) stents, which were granted ‘CE’ European safety marks in November 
2009 and May 2010, respectively. Unlike stainless steel and cobalt–chromium alloys, plati-
num–chromium has the advantage of increased radial strength enabling the stent to have 
thinner struts, which have been proven to reduce clinical and angiographic restenosis.66,67 In 
PLATINUM,68 the Promus Element® stent was shown to have comparative effi  cacy and safety 
when compared with Xience V®. Similarly, the effi  cacy and safety of the Taxus Element® stent 
is comparable with that of the Taxus Express2® (Boston Scientifi c) stent.69 In a fi rst-in-man 
study published in 2010, the Taxus® Petal™ (Boston Scientifi c) platinum–chromium bifurca-
tion stent was successfully implanted in 25 of 28 patients (89.3%), with satisfactory clinical 
and angiographic outcomes at 1 year.70 
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Bioabsorbable platforms
The problems encountered with DES have encouraged research into innovative, temporary 
vascular scaff olds or bioabsorbable stent platforms, which gradually degrade until healing 
and re-endothelialization have occurred. Eventually, no foreign material is left exposed to the 
blood, thus mitigating the problem of late stent malapposition and stent thrombosis. These 
stents have the potential to preserve endothelial function, reactive vasomotion of the artery, 
and permit late lumen enlargement (expansive remodeling).71 Initially, a high restenosis rate 
of 45% was observed in the PROGRESS-AMS trial72 in which a non-drug-eluting bioabsorbable 
magnesium stent (Biotronik, Berlin, Germany) was evaluated. Yet more favorable results with 
stents with a poly-L-lactic acid backbone eluting everolimus (Abbott Vascular, Santa Clara, CA, 
USA) were reported in the ABSORB trial71,73 with sustained clinical benefi t at 3years follow-up. 
The fi rst generation (revision 1.0) of bioabsorbable vascular scaff olds showed slight signs of 
shrinkage at 6 months contributing to late luminal loss.74 However, the second generation 
(revision 1.1) showed substantial improvements with effi  cacy comparable to that of current 






Figure 2: The bioabsorbable stent. a | The fi rst-generation (revision 1.0) and b | the second-generation (revi-
sion 1.1) of a bioabsorbable, everolimus-eluting stent. A clear change in the device design between the two 
generations is evident, with the out-of-phase zigzag pattern connected directly or by straight bridges in 
revision 1.0 being replaced by the in-phase hoops linked by straight bridges in revision 1.1. c | In addition, 
the maximum circular (red circles) unsupported cross-sectional areas (green contours) are larger in revi-
sion 1.0 than in d | revision 1.1. Parts a | and b | reprinted from Journal of the American College of Cardiology, 
56 (Suppl. 10), Garg, S. & Serruys, P. W., Coronary stents: looking forward. S43–S78, © 2010, with permission 
from Elsevier. For parts c | and d |, permission obtained from Wolters Kluwer Health © Serruys, P. W. et al. 
Circulation 122, 2301–2312 (2010).
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Nanomedicine
In addition to its promising application in cancer chemotherapy, great interest has been 
generated in the application of nanotechnology in optimization of local drug delivery. 
Nanoparticles are liposomes consisting of lipids and polymers that can be loaded with a drug 
and used to nanotexture stents, in molding processes to make stents, and for drug delivery 
from stents.77 Nanoparticle-mediated drug delivery systems are expected to revolutionize 
the development of innovative therapeutic devices, allowing local or targeted delivery of 
the drug with an excellent biocompatibility profi le. This strategy controls the concentration 
and duration of drug release, thereby potentially reducing systemic toxicity.78 Of the drugs 
investigated for restenosis prevention and treatment, only paclitaxel and sirolimus have 
been successfully administered through nanoparticle-based delivery systems and only in 
preclinical studies.79,80 Paclitaxel eluted from a cobalt–chromium stent coated with porous 
carbon–carbon nanoparticles showed promising results with respect to endothelialization 
and neointimal hyperplasia.79 Sirolimus incorporated into nanoparticle delivery systems 
(poly-D,L-lactide) showed improved release kinetics.80 Furthermore, these sirolimus-loaded 
nanovehicles selectively inhibited cell viability and proliferation of cultured human coronary 
artery smooth muscle cells, while human coronary artery endothelial cells were inhibited to a 
less extent, thus leaving endothelial cells viable to an extent that allows re-endothelialization 
of a stented vessel and still prevents smooth muscle cell proliferation.80
In another approach, Chorny et al. have investigated the novel concept of ‘magnetic targeting 
stents’ by combining uniform fi eld-induced magnetization and a biocompatible magnetic 
nanoparticle formulation in a rat model of carotid stenting.81 Magnetic targeting allows a 
drug to be delivered on demand to an in vivo site with various dosing regimens. These inves-
tigators demonstrated that the magnetic nanoparticles loaded with paclitaxel adequately 
inhibited neointima formation after uniform-fi eld-controlled targeting when compared with 
nonmagnetically-treated animals.81 Nanomedicine is, therefore, an innovative and promising 
perspective in stent design, but has yet to be demonstrated as safe and eff ective in clinical 
practice.
Gene-based therapy
Gene-based therapy has emerged over the past few years as a promising tool for the pre-
vention of ISR. Numerous transgenes have shown to be eff ective in reducing ISR in animal 
models (Ta ble 2) and various modes of local gene delivery have been developed. An eff ective 
method of gene delivery is by means of ‘gene-eluting stents’, which elute plasmid DNA or ad-
enoviral vectors.82,83 Pyrrole–imidazole polyamide is a powerful gene-regulating compound 
(‘gene silencer’) that inhibits the interaction between proteins, such as transcription factors, 
and DNA.84 An in vivo animal study conducted by Yao et al. showed that synthetic pyrrole–im-
idazole polyamide can suppress neointimal hyperplasia by downregulation of transforming 
growth factor β1 and connective tissue growth factor,85 as well as monocyte chemotactic 
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protein 1, matrix metalloproteinase 9, and intercellular adhesion molecule 1,86 making it a 
promising next-generation agent.
Nuclear ‘orphan’ receptors comprise a group of ligand-activated receptors for which specifi c 
ligands have not yet been identifi ed, but which are known to directly bind and interact with 
the promoter of target genes.87 Nuclear receptor related proteins 1 and 77 have been identi-
fi ed as having a role in ISR development; overexpression of these proteins inhibits intimal 
proliferation and ISR in animal models.88,89 A small-molecule drug that enhances the activity 
of these receptors, namely 6mercaptopurine, represents an attractive novel target for local 
intervention in restenosis.89
Finally, reducing the proliferative capacity of vascular smooth muscle cells could be of benefi t 
in reducing neointimal hyperplasia following PCI. The biology of microRNAs and their ability 
to modify smooth muscle biology has been reviewed by O’Sullivan and colleagues.90 Two 
microRNAs, mir143 and mir145, were shown to have a key role in the regulation of vascular 
smooth muscle cells in vivo and might, therefore, have therapeutic potential.




Mode of delivery Findings
Brito et al.82 eNOS (NOS3) Plasmid-mediated gene delivery from 
lipopolyplex-embedded stents




Plasmid-mediated gene transfer via cationic 
gelatin-coated stents
Accelerated RE, reduced 
ISR, and inhibition of 
subacute IST
Fishbein et al.136 iNOS (NOS2) Adenoviral-mediated gene delivery from stents Reduced ISR
Sharifi  et al.137 eNOS (NOS3) Adenoviral-mediated gene delivery from stents Accelerated RE and 
inhibition of ISR
Johnson et al.138 TIMP3 Adenoviral-mediated gene delivery from stents Reduced ISR
Egashira et al.139 Anti-MCP1
(anti-CCL2)
Plasmid-mediated gene delivery from stents Reduced ISR
Walter et al.140 VEGF2 
(VEGFC)
Gene-eluting stent of naked plasmid DNA Increased RE and 
reduced ISR
Brasen et al.141 EC-SOD 
(SOD3)
Catheter-mediated intramural delivery of 
adenovirus 
Accelerated RE and 
reduced ISR
Abbreviations: Anti-MCP 1, antimonocyte chemoattractant protein 1; CCL2, chemokine (CC motif ) ligand 2; 
ENTPD, ectonucleoside triphosphate diphosphohydrolase; ECSOD, extracellular superoxide dismutase; 
eNOS: endothelial nitric oxide synthase; iNOS, inducible nitric oxide synthase; ISR, in-stent restenosis; IST, 
in-stent thrombosis; NOS2, nitric oxide synthase 2, inducible; NOS3, nitric oxide synthase 3 (endothelial 
cell); pE-NTPdase, placental ectonucleoside triphosphate diphosphohydrolase; RE, re-endothelialization; 
SOD3, superoxide dismutase 3, extracellular; TIMP3, tissue inhibitor of matrix metalloproteinase 3; VEGF2, 
vascular endothelial growth factor 2; VEGFC, vascular endothelial growth factor C.
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Systemic treatment
Since local drug delivery does not eradicate ISR completely, systemic treatment has also been 
explored, despite the obvious risk of adverse eff ects. We will briefl y discuss the evidence for 
the antirestenotic eff ects of several antiproliferative and anti-infl ammatory drugs.
The major role of the infl ammatory system in restenosis formed the rationale for using pred-
nisone for the prevention of this condition. The IMPRESS trial91 showed favorable results with 
oral prednisone in patients undergoing coronary BMS implantation both in angiographic and 
clinical outcomes. In addition, a subanalysis from the ongoing CEREA-DES trial,92 reported by 
Pesarini et al. in 2010,93 showed that high doses of oral prednisone reduced late lumen loss, 
probably via a reduction in the release of tumor necrosis factor.
Preclinical studies have demonstrated that systemically administered sirolimus (rapamycin) 
reduces neointimal proliferation after vascular injury.94 Several clinical trials confi rmed the 
benefi t of oral sirolimus in reducing ISR after BMS implantation,95,96 making it a possible ef-
fective and cost-saving alternative to DES implantation. However, the long-term results of 
the OSIRIS trial,97 reported by Kufner and co-workers in 2009, showed an attenuated benefi t 
of oral sirolimus after 4 years and, moreover, raised concerns regarding a related increase in 
newly diagnosed malignancies.
Cilostazol, a phosphodiesterase III inhibitor, has antiproliferative eff ects98 and has been shown 
to reduce intimal hyperplasia and restenosis after both BMS and DES implantation.99,100 In a 
meta-analysis published in 2011, Kamal et al. concluded that addition of cilostazol to standard 
dual antiplatelet therapy reduces angiographic restenosis without signifi cantly aff ecting 
rates of major adverse cardiac events or bleeding.101 However, cilostazol was associated with 
an increase in the incidence of minor adverse eff ects, such as headaches, gastrointestinal 
complaints, and palpitations.102
Pioglitazone, a thiazolidinedione peroxisome proliferator-activated receptor gamma agonist, 
is used for the treatment of diabetes. An additional antiatherogenic eff ect of the drug in 
vascular cells limiting lesion development in animal models of atherosclerosis has been de-
scribed.103 Several clinical studies have demonstrated a reduced incidence of ISR after stent 
deployment with thiazolidinedione (pioglitazone or rosiglitazone) administration.104,105
Although rates of ISR have been shown to be reduced with the systemic use of various drugs, 
the concentration of drug accumulated at the site of interest is limited by toxicity. Systemic 
treatment will, therefore, probably never be superior to local drug delivery with DESs. This 
strategy could, however, be useful as an adjunct to BMS implantation.
RESTENOSIS: PRESENTATION AND OUTCOMES
If measures to prevent the development of restenosis fail, the clinical presentation of this 
condition is not always benign and can have a spectrum of acuity.106 Multiple mechanisms 
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underlie myocardial infarction associated with ISR. An occlusive restenosis can be diffi  cult to 
diff erentiate from a thrombotic event and a highly stenotic ISR lesion can promote local non-
occlusive thrombosis and lead to a clinical presentation of non-ST-segment elevation myo-
cardial infarction or troponin-positive unstable coronary syndrome.107 Whether a diff erence 
exists between the use of DESs and BMSs in this entity of ‘thrombosis on top of restenosis’ 
remains to be elucidated. A pathology study by Nakazawa et al. confi rmed the occurrence of 
neoatherosclerosis in the neointimal growth after implantation of both BMSs and DESs, but 
unstable features of neoatherosclerosis were encountered more frequently and earlier with 
DESs.108 Whether this fi nding translates into a diff erence in outcomes between stent types is 
still questionable.109
One factor that does infl uence outcomes associated with ISR is the angiographic pattern of 
restenosis (Figure 3), which can be broadly classifi ed into focal (<10 mm) and nonfocal (>10 
mm) lesions. Mehran et al. showed that the pattern of ISR independently predicts the long-
term need for revascularization, with an increase in the rate of TLR with increasing ISR class.110 
a
b
Type IA: articulation or gap Type IB: margin
Type IC: focal body
Type II: intrastent Type III: proliferative
Type IV: total occlusion
Type ID: multifocal
Figure 3: Patterns of in-stent restenosis. Schematic image of four patterns of in-stent restenosis (ISR). a | 
Pattern I (focal ISR) contains four types (A–D). Restenotic lesions are ≤10 mm and are located at the articula-
tion or gap between stents (Type IA), at either the distal or proximal margin of the stent (Type IB), within 
the body of a stent (Type IC), or a combination of these distributions (Type ID). b | Patterns II–IV (diff use 
ISR) are defi ned according to the anatomical position of ISR in relation to the previously implanted stent. 
Type II lesions are >10 mm and do not extend beyond the margins of the stent; Type III lesions are >10 mm 
and extend beyond the stent margins; Type IV lesions represent total occlusion and have a Thrombolysis in 
Myocardial Infarction fl ow grade of 0. Permission obtained from Wolters Kluwer Health © Mehran, R. et al. 
Circulation 100, 1872–1878 (1999).
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The morphologic patterns of DES restenosis are diff erent from those of BMS, favoring a more 
focal and easily treated pattern with expected improved clinical outcomes.111 In DES-treated 
patients, the rates of TLR were signifi cantly higher in diff use ISR compared with focal ISR.112
TREATMENT OF RESTENOSIS
The optimal treatment for ISR remains debatable. The options include vascular brachy-
therapy; conventional balloon, cutting balloon, or drug-eluting balloon angioplasty; BMS or 
DES implantation; and CABG surgery. This diversity of available treatments and the variability 
in the underlying etiology of restenosis make selection of the most appropriate modality 
diffi  cult. In other words, the treatment of ISR should be tailored and individualized according 
to the clinical situation and in view of the underlying etiological factors. Several of the treat-
ment options for restenosis are discussed in detail below.
Vascular brachytherapy
Intracoronary brachytherapy was once recommended as an eff ective treatment for ISR on 
the basis of data from several randomized, controlled trials published in the early 2000s.113,114 
Antiproliferative δ (iridium192) or β (phosphorus32) irradiation is delivered locally to the 
target lesions via dedicated catheters. Currently, however, brachytherapy with either β or δ 
radiation is of very limited use. The diffi  culty in performing this procedure, particularly han-
dling the radioactive substances, and the increasingly widespread use of DESs has gradually 
displaced brachytherapy from the armamentarium of the interventionist. Nevertheless, the 
5year follow-up data from the SISR study, presented at the 2011 ACC i2 summit, suggest that 
brachytherapy could be an equivalent treatment option to SES implantation for the treat-
ment of ISR.115
Cutting-balloon angioplasty
The cutting balloon consists of a balloon catheter with three to four blades or ‘atherotomes’ 
designed to create discrete longitudinal incisions in the atherosclerotic lesion during bal-
loon infl ation. Such controlled dilatation theoretically reduces the force needed to dilate an 
obstructive lesion compared with standard balloon angioplasty and avoid slipping-induced 
vessel trauma during PCI, potentially decreasing the risk of ISR development.116 Although 
this expected benefi t was not demonstrated when the device fi rst came into use in the early 
1990s,117 the later REDUCE III study did show that an IVUS-guided cutting balloon procedure 
followed by BMS implantation yielded restenosis rates similar to those achieved with DESs, 
thereby, providing an eff ective alternative.118 However, use of the cutting balloon remains 
uncommon for the treatment of ISR, especially when used without stent placement. In 2010, 
Park et al. raised concerns that cutting-balloon angioplasty might be associated with a higher 
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risk of myocardial infarction than conventional balloon angioplasty;119 this technique is, 
therefore, unlikely to become an important ISR treatment modality.
Drug-eluting balloon angioplasty
Non-stent-based local delivery of an antiproliferative drug, particularly using drug-eluting 
balloons, theoretically represents a very attractive treatment for ISR that avoids the limita-
tions associated with DES platforms. Drug-eluting balloons improve drug delivery by allow-
ing homogenous drug transfer to the entire vessel wall rather than only to the areas covered 
by stent struts, as with DESs. All currently available drug-eluting balloons use paclitaxel 
in various coating formulations with a typical dose of 3 μg/mm2 of balloon surface. Drug-
eluting balloon angioplasty has been shown to be more eff ective than conventional balloon 
angioplasty,120 and as eff ective as PES implantation121 for the treatment of ISR. However, drug-
eluting balloons of course cannot prevent the almost immediate elastic recoil phenomenon.
Currently, research in this area is focused on comparisons of the various available drug-
eluting balloons. For example, in a preclinical study in an advanced porcine model of coro-
nary restenosis, Joner et al. found that the Pantera® Lux (Biotronik, Berlin, Germany; 3.0 μg/
mm2 paclitaxel), the SeQuent® Please (B. Braun Melsungen AG, Berlin, Germany; 3.0 μg/mm2 
paclitaxel), and the Elutax™ (drug-eluting balloons (Aachen Resonance, Aachen, Germany; 
2.0 μg/mm2 paclitaxel) all resulted in delayed healing when compared with conventional bal-
loon angioplasty.122 However, the investigators also demonstrated signifi cant heterogeneity 
in neointimal suppression between the balloons, with superiority of Pantera® Lux.115 This 
diff erence was attributed to the ‘excipient’ used as an eff ective carrier for paclitaxel in the 
Pantera® Lux and SeQuent® Please balloons. The 6month results of the PEPPER trial,123 which 
were presented at the ACC i2 summit in April 2011, showed excellent results for the Pantera® 
Lux balloon for the treatment of ISR both in BMSs and DESs. The detailed subgroup analysis, 
and 12-month follow-up data, are expected to be announced in late 2011.
In the 2010 guidelines for myocardial revascularization published by the European Society 
of Cardiology, drug-eluting balloons were considered a class IIa indication for the treatment 
of ISR.124 Nevertheless, further large studies need to be implemented before these devices 
can be fully integrated into clinical practice. Patients are currently be recruited for an ongo-
ing trial125 to investigate the effi  cacy of a drug-eluting balloons for the treatment of ISR in 
patients with DESs.
Drug-eluting stents
DESs are known to have fairly low rates of ISR.4,5 The proportion of restenotic lesions treated 
with DES in the studies providing this data is, however, low. Since restenotic lesions have a 
tendency towards recurrent restenosis, as discussed in Part 1 of this Review,6 the outcomes 
associated with stent (DES) implantation in these lesions is likely to be diff erent to those for 
DES placement in de novo lesions. In addition, ISR after BMS implantation diff ers from ISR 
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associated with DES use and, therefore, a distinction between these two types of restenosis 
should also be made in terms of treatment.
Favorable outcomes of DES treatment for BMS-related ISR have been reported in several 
studies, even after long-term follow up.118–121 Treatment with DES placement was found to 
be more eff ective and safer than conventional balloon angioplasty,126 vascular brachythera-
py,127,128 or BMS implantation within the original stent.129 DESs should, therefore, be the treat-
ment of choice for the treatment of BMS-related ISR. By contrast, the same cannot be said 
for DES-related ISR, which continues to be a therapeutic challenge. To date, the treatment of 
this condition has been investigated in only one randomized controlled trial, which showed 
comparable effi  cacy for SES reimplantation or a switch to PES implantation in patients with 
SES-related ISR.130 Other small nonrandomized trials have produced inconsistent results, 
limiting the possibility of drawing any defi nitive conclusions about the optimal treatment of 
DES-related ISR.107
An individual’s resistance to a particular eluted drug can be a factor in restenosis develop-
ment.131,132 This hypothesis provides the rationale for switching to a diff erent DES for the 
treatment of DES-related ISR. However, to date, no clinical study has demonstrated clear 
clinical benefi t of implanting an alternative diff erent DES.130,133 Whether resistance to siroli-
mus also implies resistance to other limus derivatives remains questionable, as no reports 
have been published on the use of zotarolimus, everolimus, or biolimus A9-eluting stents for 
the treatment of SES-related ISR. Another uncertainty is whether the angiographic pattern 
of DES-related ISR provides a clue to the involvement of drug resistance. Drug resistance is 
expected to cause a diff use pattern of ISR, so perhaps a future study focused on patients with 
diff use patterns of ISR would clarify the potential benefi ts of changing the agent eluted by 
the stent. In the ongoing prospective, randomized Italian GISE-CROSS trial,134 treatment with 
a stent that elutes the same drug as the original restenosed stent (no CROSS group) is being 
compared with a crossover to an alternative DES in patients with ISR after either PES or SES 
implantation. The results of this study are eagerly awaited. Patients treated with DES for ISR 
are at high risk for recurrent ischemic events and should be maintained on dual antiplatelet 
therapy unless a complication emerges.107 Therefore, individuals who have a contraindication 
for, or show noncompliance with, dual antiplatelet therapy should be considered for CABG 
surgery.
CABG surgery
CABG surgery is usually considered as the ‘last resort’ treatment for ISR in the clinic. However, 
this strategy is an appropriate fi rst-line therapy for certain complex cases, such as multivessel 
ISR, diff use ISR, multiple subsequent DES restenosis treated by repeat DES implantation, a 
strong genetic predisposition to ISR that precludes further interventional options, or in cases 
where dual antiplatelet therapy is not appropriate, as discussed above. To our knowledge, no 
studies of CABG surgery for the treatment of in-stent restenosis have been conducted.
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CONCLUSIONS
Restenosis is a complex disease with a diversity of underlying mechanisms that are still not 
fully understood. Many innovative technologies, including DESs (with or without specifi c 
polymers) and fully biodegradable stents, have been and continue to be developed in the 
diligent search for an ideal antirestenosis therapy that is both eff ective and safe in the 
long term. Developments in the fi eld of gene therapy might also impact future restenosis 
therapies. Advances in stent design and nanoparticle delivery systems (‘nanovehicles’) in the 
past 5 years have already fueled revolutionary changes in the concept of ISR prevention and 
treatment. In addition, several clinical algorithms for ISR treatment have been proposed on 
the basis of angiographic pattern of restenosis.107,134,135 Treatment of ISR should be tailored 
to the individual, taking into consideration the available evidence and the best strategy for 
the patient, as well as the best method of treating the lesion. We believe that investing in the 
prevention of ISR is worth much more than investing in its treatment.
REVIEW CRITERIA
The articles on which this Review is based were identifi ed by searching MEDLINE using the 
following keywords and Medical Subject Headings (MeSH) terms: “coronary restenosis”, 
“drug-eluting stent”, “biodegradable stent”, “gene therapy of restenosis”, and “nanomedicine”. 
We checked for papers published up to August 2011. Only papers in the English language 
were included. Although we realize that not all available evidence could be incorporated, the 
most relevant and infl uential articles were selected for inclusion in this Review.
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INTRODUCTION
Since the introduction of drug eluting stents (DES), the incidence of coronary stent restenosis 
has been signifi cantly reduced. However, the safety of DES became a major issue after several 
studies associated DES with an increased risk of the rare but often devastating development 
of late and very late stent thrombosis 1-3. Several risk factors have emerged as being impor-
tant in the development of stent thrombosis, including stent malapposition. Although it is 
still under debate what the exact role of stent malapposition in this respect is, it appears 
undeniable that stent malapposition is involved in the development of this severe complica-
tion after stent implantation in at least a part of the cases 4-10. 
In this chapter several aspects of stent malapposition will be discussed.
DEFINITION AND CLASSIFICATION
Stent malapposition (SM), also known as incomplete stent apposition, is defi ned by a separa-
tion of at least one stent strut from the intimal surface of the arterial wall with evidence of 
blood behind the strut, without involvement of side branches 11.  Stent malapposition may 
increase the thrombotic risk due to the presence of intraluminal stent struts 12. Although 
appropriate apposition of the stent to the vessel wall is an important aspect for all stents, 
it seems to be critical in the case of DESs to ensure antiproliferative drug delivery as well as 
circumferential vascular support.
Depending on the time point of detection, the following classifi cation can be made; acute if 
present immediately after the index procedure and late if detected at follow-up.  
Furthermore, resolved if present after stent implantation but not at follow up, persistent if 
present both directly after stent implantation and at follow up and as acquired when the 
stent is well apposed after the index procedure but SM is detected at follow up. Diff erentiat-
ing between the diff erent forms of SM therefore requires intravascular imaging both at stent 
implantation and at follow up. Schematically this is shown below as depicted by Hur et al., 
Cardiovasc Revasc Med 2009 13.(Figure 1)
It is important to realize that the distinction between acute and late SM also implies diff erent 
pathogenetic mechanisms for these two entities. Furthermore, each form will require a diff er-
ent therapeutic approach, which will be addressed later in the chapter.
PATHOPHYSIOLOGY
The current thought is that acute SM is mostly technique dependent and may result from 
inadequately sized stent selection or inadequate stent expansion, whereas late acquired SM 
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may result from vessel wall changes in the stented segments that occur during the follow-up 
period.
Focusing on late SM, several mechanisms have been postulated;1 positive vascular remodel-
ing of the vessel wall;2 decrease in plaque volume;3 chronic stent recoil and4 a hypersensitivity 
reaction to one of the stent constituents.
Positive remodeling is the increase in vascular dimension measured by intravascular imaging 
using intravascular ultrasound (IVUS) or optical coherence tomography (OCT) by analyzing 
the change in cross sectional area of the external elastic membrane (EEM) in comparison with 
the change in plaque volume over time. Several studies reported a greater increase of the 
EEM compared to the change in plaque volume. Since the size of the stent cannot increase 
over time, except for the now rarely used self expanding stents, this process will eventually 
lead to stent malapposition 13-19. A recent study of Kang et al. used IVUS immediately after 
intervention and at the 6-month and 2-year of follow-up to evaluate serial vascular changes 
after DES implantation 19. Their main conclusion was that the development of malapposi-
tion was not limited to the fi rst 6 months after implantation as a result of ongoing vascular 
remodeling even after this period. Therefore, the reported incidence of acquired late SM in 
previous studies (between 0% and 25% 20) maybe underestimated due to relative short-term 
follow-up periods 19.
Figure 1. Various types of stent malapposition by Hur et al., Cardiovasc Revasc Med 2009. 13
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Besides an increase of the vascular dimensions, another possible mechanism to stent malap-
position is a decrease of the plaque volume. This can be caused by dissolution of a thrombus, 
present at the stent implantation, mainly seen in patients with acute myocardial infarction 4, 
13, 14, 21, 22. Furthermore, regression of the plaque under stringent statin treatment can result in 
creating space between the stent and the vessel wall; however this seems to be only the case 
in a minority of lesions 12, 21, 23. 
The pattern of late acquired SM is usually focal and is more often found at the borders of the 
stents (up to 90%, as reported by Mintz et al.)17. Additionally, acquired SM is more likely to 
occur in the relatively disease-free side of the vessel wall, probably because the normal vessel 
gets more injured during DES implantation and the delayed healing due to the drugs loaded 
on these stents 13, 24 . It is therefore more likely that positive remodeling is the most important 
mechanism for the development of late SM and that the contribution of plaque change is 
more limited 13. Although chronic stent recoil could theoretically be one of the causes of SM, 
it has not been detected using IVUS in patients with SM, making it therefore unlikely to be a 
factor in the development of SM 17, 25. 
Another factor of possible infl uence is the infl ammatory response to these stents. In contrast 
to bare-metal stents (BMS), DES provokes infl ammatory responses in animal models, either 
by a local hypersensitivity reaction to the non-biodegradable polymers of the stent or to the 
drug released by the stent. Since in a pig model the hypersensitivity reaction only peaks after 
complete release of the drug, it appears more likely that the polymer is the cause 22. Also in 
human thrombectomy specimens, histopathological signs of infl ammation were found, thus 
supporting the theory that a hypersensitivity reaction underlies the development of SM and 
stent thrombosis 5.  Furthermore, a growing number of reports documented the formation 
of coronary artery aneurysm (CAA) after DES implantation. Although the exact mechanism 
is still unknown, the available evidence suggest that it may be a hypersensitivity-mediated 
reaction to the delivery polymer 26. Studies of related polymers have demonstrated local and 
systemic hypersensitivity reactions to intravascular polymers 5, 27-29. Also, animal studies of 
DES show that 25% of pigs receiving DES develop eosinophilic infi ltrates 29. Bare-metal stents 
have not been demonstrated to elicit such hypersensitivity reactions in human autopsy 
series of over 400 stents 29.
RISK FACTORS
Predictors of acute SM include aneurysmal appearance of the target lesion, larger vessels, le-
sion calcifi cation, higher patient age, longer lesions and lower balloon pressure 21, 30. This is in 
line with the above statement that acute SM is most likely technique dependent, since these 
predictors are contributing to the complexity of the target lesion or to the technique itself.
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Also for late SM, several factors related to the diff erent proposed mechanisms of SM have 
been shown to be independent predictors.
The highest incidence of 25% of late SM in DES stented patients has been reported in the 
MISSION! Intervention study, including patients with acute myocardial infarction 21. Several 
studies have shown AMI as an independent predictor of SM 14, 16. The explanation for this can 
be found in the second proposed mechanism of SM, since the presence of a thrombus, par-
ticularly large thrombus load, which is frequently encountered in AMI may predispose to the 
occurrence of SM later after the dissolution of the thrombus at the site of stent implantation. 
Diabetes mellitus has been associated with a lower rate of stent malapposition. The diabetic 
subpopulation is known to have an increased neointimal growth leading to more restenosis 
in BMS. Poor glycemic control has been associated with diminished effi  cacy of sirolimus on 
smooth muscle cell proliferation, which may explain the lower rate of late SM in these patients 
21, 30-32. Opposing these reports however, another study found a signifi cant greater proportion 
of diabetic patients in DES cohort with late SM compared to the BMS cohort 14. They reasoned 
that the proinfl ammatory role of diabetes may be responsible for a local enhanced infl amma-
tory reaction after DES implantation eventually increasing the risk of late SM.
Another predictor of SM is directional coronary atherectomy (DCA) before stenting. The 
higher incidence of late SM in DCA before stenting might be explained by the fact that 
aggressive debulking with DCA is associated with deep vessel injury and promotes more 
positive remodeling 15.
Despite angiographic optimization with high pressures and adequately sized balloons, 
malapposed stent struts are frequently found in complex coronary lesions and more often 
following the implantation of Cypher Select stents which have a thicker stent strut and closed 
cell design 33. Other factors associated with the lesion complexity, such as longer stent length, 
C-type lesions and overlapping stents, larger vessel reference diameter, have also been as-
sociated with an increased risk of SM 14, 16, 21. Also, chronic total occlusion (CTO), defi ned by 
the absence of antegrade fl ow or only minimal fl ow of contrast distal to the occlusion during 
coronary angiography before stent implantation, has been reported as an independent 
predictor of late SM after DES implantation 16.
Patient age has been associated with the risk of SM, although not consistently. In a recent 
report of Steinberg et al., subjects with acute SM are older than those without acute SM, 
whereas (younger) age was the only independent predictor of late acquired SM. Their expla-
nation for this last fi nding is that most of the other reported risk factors for SM were excluded 
from their study 30.
As will be discussed in the next section, also the stent type is associated with the risk of late 
stent malapposition. All risk factors are summarized in Table 1.
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Table 1. Risk factors for stent malapposition
Clinical factors Procedure related factors
Acute myocardial infarction (L) Drug eluting stent (L)
Absence of diabetes mellitus (L) Lower maximum balloon pressure (A, L)
Chronic total occlusion (L) Larger vessel reference diameter (A, L)
Patient age (A,L) Longer stent length (A, L)
Overlapping stents (A, L)
C-type lesion (A,L)
Directional coronary artherectomy (L)
(A) Risk factor for acute stent malapposition, (L) Risk factor for late stent malapposition
BMS VERSUS DES
Acute SM is frequently observed both after DES and BMS implantation 21, 30. Considering the 
mechanism of acute SM, a similar incidence in both DES and BMS is in the line of expectation. 
Late SM is rare after BMS and seems to be related to stent under-expansion in most patients 
21. Although not all, several studies have reported that late SM is much more common after 
DES implantation 6, 14, 21, 24, 30, 34. A recent meta-analysis of Hassan et al, aimed on clarifying this, 
included 2453 patient after BMS implantation and 2195 patients receiving DES from a total 
of 17 studies 20.  The incidence of late acquired SM after DES varied between 0% and 25%, 
whereas after BMS implantation the highest reported incidence of SM was 6% at 6 months. 
They concluded that the risk of late acquired SM was 4.4-fold higher in patients after DES 
implantation compared to those with BMS. A comparison of paclitaxel- with –limus-eluting 
stents did not yield signifi cant fi ndings. The higher risk of SM after DES is likely due to the 
eff ects of the drugs on the vessel wall, resulting in positive remodeling 20, 21 In BMS the lumen 
changes at the site of SM are more related to plaque burden 21.
Furthermore, Hassan et al. also conducted a meta-analysis on the risk of (very) late stent 
thrombosis in patients with late SM. They concluded that the risk of stent thrombosis is 6.5 
times higher (95% confi dence interval 1.34-34.91) in patients with late SM compared with 
those without late SM 20. 
So late SM appears to be more frequent after DES implantation and is associated with an 
increased risk of late stent thrombosis. After adequately lowering the incidence of restenosis, 
the primary complication of balloon dilatation and BMS implantation, we may have created a 
potentially more devastating obstacle with late SM and subsequent stent thrombosis in DES.
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DIAGNOSTICS
Although intravascular ultrasound (IVUS) has been usually regarded as the gold standard for 
in vivo assessment of stent strut apposition to the vessel wall, more accurate evaluation of 
stent strut apposition cannot be successfully performed in some lesions with minimal stent 
malapposition due to the limited resolution capacity in IVUS (100-150um) 35. Furthermore, 
this limited axial resolution of IVUS makes it virtually impossible to discriminate between 
atherosclerotic plaque and thrombus 21. It also has problems with stent-related artifacts 12, 
possibly resulting in underestimation of the evaluation of re-endothelialization. SM is as-
sociated with a decreased re-endothelialization  after DES implantation 22, which is in turn 
associated with an increased risk of stent thrombosis 7. 
Optical coherence tomography (OCT) is a relatively new imaging modality. In contrast with 
IVUS, OCT visualizes intra-coronary features using near-infrared light instead of ultrasound, 
leading to a far better axial resolution, able to resolve detail up to 10 μm 12. Multiple stud-
ies investigating stent malapposition using OCT and comparing it with IVUS fi ndings have 
already been published. There is evidence that minimal stent malapposition which is not 
detectable by IVUS may disappear or decrease in follow-up OCT evaluation 35 and SM without 
complete re-endothelialization is associated with presence of OCT-detected thrombus 12. 
More detailed information provided by OCT imaging also led to the conclusion that rate of 
stent strut coverage and malapposition were signifi cantly diff erent among diff erent DES types 
and among the type of clinical presentation. More SM was found in sirolimus-eluting stents 
and paclitaxel-eluting stents compared to zotarolimus-eluting stents and the rate of SM was 
higher in patients presenting with acute coronary syndrome compared to those with stable 
angina pectoris 36, 37. Despite the clear advantages of OCT over IVUS, some disadvantages 
should also be mentioned. The cost of the device is higher than that of IVUS and the device 
is not available in every center. A major limitation of OCT is the requirement of a blood-free 
imaging fi eld because red blood cells scatter light. This can be achieved with a continuous sa-
line fl ush administration or with a temporary balloon occlusion catheter, leading to transient 
ischaemia which is not desirable and or tolerated in all cases. Another disadvantage of OCT 
is poor penetration into non-transparent tissues thus allowing evaluation of only superfi cial 
structures including coronary plaques with thin-caps 38.
TREATMENT
The most important and potential devastating complication of SM is stent thrombosis. The 
mechanism by which SM may contribute to stent thrombosis remains unclear. SM may serve 
as a local nidus for thrombus formation, allowing fi brin and platelet deposition. Delayed 
re-endothelialization, impaired vasomotion and also involvement of chronic infl ammation 
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and delayed healing, leading to tissue necrosis around the stent, all contribute to creating a 
thrombogenic environment 20, 23.
When performing intravascular imaging directly post stent implantation, immediate action 
can be taken after diagnosing acute stent malapposition by re-dilatation of the target le-
sion, further expanding the stent. Considering dissolution of a jailed thrombus as a possible 
mechanism of SM, it may be important to eff ectively remove thrombotic material prior to 
stent implantation. Unfortunately, it has been shown that immediate post-intervention IVUS 
showing no malapposition does not guarantee an uneventful course after DES implantation 8.
After diagnosing stent malapposition during follow-up, defi ning a proper treatment strategy 
is diffi  cult, especially when the patient is asymptomatic. The main goal should be off  course 
to prevent stent thrombosis.  One option could be pharmacological with long-term double 
anti-thrombotic treatment 11. However, this will also lead to a continuous increased bleeding 
risk and it is evident that SM may also persist for years without leading to complications, 
creating a risk of exposing patients to unnecessary side eff ects of the treatment without 
having the benefi t of it. Another option could be dilatation and implantation of a second, 
larger, stent 39.
FUTURE PERSPECTIVES
It goes without saying that all the, until now, unanswered questions about the mechanism of 
stent malapposition, its association with stent thrombosis and the best treatment of SM are 
to be clarifi ed in future larger studies.
One of the current developments in this fi eld is the development of a bioabsorbable stent. The 
theoretical advantages of such a stent is that it might have less potential for late stent throm-
bosis because there will eventually be no foreign material exposed to the bloodstream.  
Also problems with later surgical revascularization, eliminating vasomotor reactions and 
interference with imaging techniques could be prevented 40. However, this remains to be 
proven and also partial/unequal stent dissolution may perhaps cause problems.
Lately, there have been some ongoing clinical trials addressing the use of self-expandable 
nitinol stents in the treatment of AMI patients with long-term follow-up IVUS and OCT 41-43. 
The hypothesis generated in these trials was that the self-expandable stents would better 
accommodate to early changes in the vessel wall (thrombus dissolution and vasodilatation) 
with better apposition due to its self-expandable properties. Initial results have shown that 
these stents provided 20% increase in lumen area with perfect apposition on 3 days follow 
up OCT. However, long-term (safety) results are still lacking.
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CONCLUSION
Stent malapposition appears to be a relative common fi nding after stent implantation, espe-
cially diagnosed using OCT which has a superior resolution compared to IVUS. The incidence 
of late SM is higher after DES implantation, mainly caused by positive vascular remodeling. 
Although SM is associated with stent thrombosis, this is a relatively rare complication. Since 
the incidence of SM is vastly greater than that of stent thrombosis, SM is not necessarily sine 
qua non, but more likely only one factor in a complex system. Nevertheless, stent thrombosis 
is a devastating complication and must be prevented where possible. Therefore, further 
research unraveling the exact mechanisms of stent malapposition and stent thrombosis and 
possible treatments will continue in future clinical trials.
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SUMMARY AND CLOSING REMARKS
This thesis aimed to evaluate the importance of combined pharmacological and mechanical 
adjunctive therapies for optimization of outcomes of primary percutaneous coronary inter-
vention (PPCI) in the setting of ST-elevation myocardial infarction (STEMI), and to assess the 
predictors of large thrombus burden among STEMI patients and to what extent that would 
infl uence the outcomes and the pre-hospital triage of these patients. Furthermore, a special 
focus was granted on the clinical performance of biodegradable-polymer drug eluting stents 
(DES) comparing the incidence of defi nite stent thrombosis (DST) and target lesion revascu-
larization (TLR); a) between biodegradable-polymer biolimus, sirolimus and paclitaxel DES, 
and b) between biodegradable-polymer DES and permanent polymer DES. We also discussed 
the recently emerging drugs for coronary artery disease, with special focus on antiplatelets, 
antithrombotics and antidyslipidemics. Finally, we provided an overview of post-stenting 
problems of in-stent restenosis and late stent malapposition. 
SUMMARY
The introduction and outline of this thesis (chapter 1) begin with a description of current in-
sights in aspiration thrombectomy and abciximab as adjunctive therapies in PPCI to decrease 
thrombus burden. We then tackle the subject of biodegradable-polymer DES as a new gen-
eration of stents. Finally, we provide a brief overview of in-stent restenosis and thrombosis 
defi nitions and classifi cation, as well as stent malapposition and the recent innovations that 
may prevent its occurrence.
In Chapter 2, we evaluate the adjunctive role of aspiration thrombectomy in PPCI for STEMI 
patients receiving early, in-ambulance, abciximab within a fi xed protocol (Leiden MISSION! 
Project).   158 patients with STEMI were enrolled, in whom abciximab was started early 
before arrival at the hospital (in-ambulance); 79 patients had PPCI without thrombus aspira-
tion (Conventional PCI group), and 79 had PPCI with thrombus aspiration (thrombectomy-
facilitated PCI group). The 2 groups were comparable for baseline clinical and angiographic 
characteristics. The rate of complete ST-segment resolution at 90 minutes was signifi cantly 
higher in the thrombectomy-facilitated group (p=0.002), and multivariable logistic regression 
analysis identifi ed only thrombectomy as an independent predictor of ST-segment resolution 
(odds ratio= 9.4, 95% CI = 2.6-33.5, p=0.001). Among patients with higher thrombus grades, 
distal embolization was higher in the conventional PCI group. No diff erence was observed 
between both groups in enzymatic infarct size assessed by peak CK (p=0.7), and peak Tn-T 
levels (p=0.4). Also the LVEF at 3-months was similar (p=0.9). At 12 month clinical follow-up, 
thrombus aspiration was however associated with reduced all-cause mortality (log-rank p= 
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0.03). Thus it appears that a selective strategy of thrombus aspiration still may have an addi-
tive benefi t, even with early abciximab administration.
The hypothesis of the study presented in Chapter 3 was that early prediction of thrombus 
grade is possible which may infl uence the pre-hospital triage of STEMI patients. One-hun-
dred and fi fty-three consecutive patients presenting with STEMI and undergoing PPCI were 
included. Thrombus was evaluated on angiography and scored according to the TIMI study 
group score. Next, patients were categorized into two groups having either high thrombus 
grade (HTG; score 4-5) or low thrombus grade (LTG; score 1-3). We evaluated predictors of 
angiographic thrombus grade among a number of clinical, angiographic and laboratory data. 
We also assessed infarct size and scintigraphic left ventricular ejection fraction (LVEF) at 3 
months in both patient groups. Ninety-four patients (58±11 y, 75% males) presented with 
HTG, whereas 59 patients (58±12 y, 78% males) presented with LTG. Pre-infarction angina 
was more frequently encountered in the LTG group than in the HTG group (25% vs. 10%, 
p=0.009). Pre-procedural TIMI fl ow was signifi cantly lower in the HTG group (p<0.001), and 
thrombosuction was more frequently applied in the HTG group (p<0.001). Absence of pre-
infarction angina (OR=0.29, 95% CI=0.11-0.75, p=0.01) and proximal culprit lesion (OR=2.10, 
95% CI=1.02-4.36, p=0.04) were the only independent predictors of HTG. HTG proved an 
independent predictor of higher peak levels of CK (p<0.001) and troponin-T (p<0.001), as well 
as lower LVEF (p=0.05) along with male gender and absence of prior statin therapy. Thus, pre-
infarction angina is associated with lower thrombus grade, whereas proximal culprit lesions 
are associated with higher thrombus grade. Higher thrombus grade is associated with larger 
infarct size and slightly worse LV function. This may have clinical implications in planning 
strategies, particularly regarding pharmacotherapy, that aim to decrease thrombus burden 
prior to stent implantation.
In Chapter 4 we present a meta-analysis and systematic review on biodegradable-polymer 
DES. We sought to; 1) evaluate the risk of target lesion revascularization (TLR) and defi nite 
stent thrombosis (DST) among diff erent groups of second generation biodegradable-polymer 
(BioPol) DES, and 2) to compare them with permanent polymer (PermPol) DES. We searched 
PubMed and relevant sources from January 2005 until October 2010. Inclusion criteria were 
(a) Implantation of a drug eluting stent with biodegradable polymer; (b) available follow-
up data for at least one of the clinical end-points (TLR/DST) at short term (30 days) and/or 
mid-term (up to one year). A total of 22 studies, including randomized and observational 
studies, with 8264 patients met the selection criteria; 9 studies with 2042 patients in whom 
biodegradable-polymer sirolimus eluting stents (BioPol-SES) were implanted, 8 studies with 
1731 patients in whom biodegradable-polymer paclitaxel eluting stents (BioPol-PES) were 
implanted, and 7 studies with 4491 patients in whom biodegradable-polymer biolimus A9 
eluting stents were implanted (BioPol-BES). At 30 days, there was a higher risk of TLR in the 
BioPol-BES compared to BioPol-SES (OR= 3.4, 95% CI= 1.3-9.6, p= 0.006), which was obviously 
attributed to a higher risk of DST in the former (OR= 3.9, 95% CI= 1.1-14.0, p=0.04). There 
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was no signifi cant diff erence in the other stent comparisons at short term. At 1 year there 
was an almost 3 times higher risk of TLR in the BioPol-PES (OR=2.8, 95%CI= 1.3-6.0, p= 0.01), 
and a more than twice higher risk of TLR in the BioPol-SES (OR=2.2, 95%CI= 0.2-1.0, p=0.04) 
compared to BioPol-BES, with no signifi cant diff erence between BioPol-SES and BioPol-PES. 
The risk of 1-year stent thrombosis was not statistically diff erent between the studied groups 
(overall p= 0.2), although numerically there was a 3 times higher incidence of ST in BioPol-PES 
compared to BioPol-SES (1% vs. 0.3%). In another analysis comprising randomized clinical 
trials (7 trials) comparing BioPol-DES (3778 patients) and PermPol-DES (3291 patients), the 
risks of TLR and stent thrombosis at 1 year were not signifi cantly diff erent between both 
groups, (OR=0.8, 95% CI=0.5-1.4, p= 0.5) and (OR=0.7, 95% CI= -0.2-2.4, p=0.5) respectively. 
Accordingly, performance of diff erent BioPol-DES seems to vary from each other. The short 
and mid-term success rates may not be superimposable. Furthermore, BioPol-DES may be 
not necessarily better than PermPol-DES.
Chapter 5 is a review article in which we provide an almost complete overview of the recent 
and emerging drug therapies of CAD. This includes: drugs for the treatment of atherogenic 
dyslipidemia, drugs that stabilize atherosclerotic plaques and halt their progression guided 
by novel anti-infl ammatory concepts in atherosclerosis treatment, anti-anginal treatments, 
renin angiotensin-aldosterone system inhibitors, antiplatelet and anticoagulant drugs.
Chapter 6 is a review article about in-stent restenosis (ISR). Here we provide 1) an overview of 
the recent innovations for optimizing the outcomes of coronary stenting, and 2) up-to-date 
information with regard to prevention of ISR. This includes improving stent design, novel 
stent coatings, nanoparticle-based drug delivery as well as gene therapy. We also highlight 
the current treatment options for ISR.
In Chapter 7 we presented an overview of late stent malapposition (LSM) in bare metal stent 
(BMS) and DES era. In this chapter several aspects of stent malapposition are discussed in-
cluding; defi nition and classifi cation, pathophysiology, risk factors, incidence in BMS vs. DES, 
new diagnostic tools, and fi nally current treatment options and future perspectives.
MAIN CONCLUSIONS
• Among STEMI patients treated with PPCI and receiving early (in-ambulance) abciximab, 
it appears that the adjunctive use of manual thrombectomy signifi cantly improves post-
procedural ST-segment resolution, reduces distal embolization, and may be associated 
with a lower clinical event rate. Therefore, although no benefi t was observed regarding 
the enzymatic infarct size or LV function as assessed by Gated-SPECT, it appears that a 
selective strategy of thrombus aspiration still may have  an additive benefi t, even with 
early abciximab administration.
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• Pre-infarction angina is associated with a decreased angiographic thrombus grade, 
whereas proximal culprit lesions are associated with higher thrombus grade. Higher 
thrombus grade was in turn associated with larger infarct size as well as slightly worse LV 
function. This may have clinical implications in planning strategies, particularly regarding 
pharmacotherapy, that aim to decrease thrombus burden prior to stent implantation, 
particularly in high risk patients without pre-infarction angina.
• Performance of diff erent BioPol-DES seems to vary from each other. The short and mid-
term success rates may not be superimposable and are to be carefully judged separately 
for newly emerging BioPol-DES before they can become a new standard. BioPol-DES do 
not necessarily perform better than PermPol-DES. 
• Eff orts have been made to improve the clinical eff ectiveness and safety of established 
treatment strategies for CAD and target new frontiers through developing novel treat-
ment strategies that tackle diff erent mechanisms of action. Better understanding of 
the diff erent molecular and cellular mechanisms underlying CAD has resulted in more 
innovations and achievements in CAD drug therapy, and still a lot more is anticipated in 
the coming years.
• Over the years many predictive factors of in-stent restenosis have been identifi ed. These 
factors not only are very useful in stratifi cation of the patients at risk for restenosis, they 
all contribute to our understanding of this complex disease. Many innovative technolo-
gies have been generated in the context of the diligent search for an ideal anti-restenosis 
therapy. 
• Stent malapposition appears to be a relative common fi nding after stent implantation. 
Although SM is associated with stent thrombosis, this is a relatively rare complication. 
Since the incidence of SM is vastly greater than that of stent thrombosis, SM is not neces-
sarily sine qua non, but more likely only one (important) factor in a complex system.
FUTURE PERSPECTIVES
1. Primary percutaneous coronary intervention
• Primary angioplasty is the established treatment for recanalization of coronary arteries 
during acute myocardial infarction (AMI). In addition to the pharmacological approaches, 
aspiration thrombectomy devices have been investigated to reduce the risk of emboliza-
tion. So far, it is still unknown which group of patients would benefi t most from thrombus 
aspiration, and whether a selective strategy for thrombectomy would be the best option 
based on a pre-specifi ed risk score that takes in consideration the thrombus grade, time 
to treatment among other relevant factors. Large scale multi-center randomized clinical 
trials powered for clinical end-points are still required  to answer many questions regard-
ing aspiration thrombectomy and to provide evidence-based data to be upgraded from 
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the current class IIa indication (i.e. reasonable to perform the procedure) to class I indica-
tion (i.e. procedure should be performed). 
• Pre-hospital triage of STEMI patients is gaining wide interest, however it subtends sub-
stantial logistical obstacles for many dedicated PPCI centers. In our study we present the 
experience of Leiden University Medical Center (LUMC), which implements a rigorously 
standardized protocol for management of patients with AMI (MISSION! Protocol). This 
protocol supports an integrated approach of early pharmacotherapy and mechanical 
reperfusion to attain the optimal results in patients with AMI.
• Recently, a great deal of research has focused on development of new antiplatelet agents 
that could be administered orally or intravenously and, unlike the currently applied 
thienopyridines, could provide direct-acting reversible inhibition of the platelet P2Y12 
receptor. This concept of rapidly acting and rapid reversibility of platelet inhibition could 
fuel further research regarding the pre-hospital triage of STEMI patients with suspected 
high thrombotic burden. 
• In our thesis we concluded that a bsence of pre-infarction angina predicts high thrombus 
burden. It might be of interest to develop a scoring system that utilizes clinical (like PIA), 
and rapid laboratory data (cardiac biomarkers) and integrates this with other established 
scoring systems, e.g. TIMI risk score, to identify which group of patients will benefi t most 
from early pre-hospital treatment.
2. In-stent restenosis
• Restenosis is a complex disease and all the mechanisms causing restenosis to develop 
have not been identifi ed yet. Especially genetic markers help us in unraveling the mecha-
nisms underlying the process of restenosis. They furthermore could provide evidence for 
more tailored treatment and subsequently aid in the development of novel treatment 
modalities. 
• Current developments in the fi eld of gene therapy might belong to future possibilities. 
The recent discoveries and advances in stent design and nanoparticle delivery systems 
“nano-vehicles” have already fueled revolutionary changes in the concept of (in-stent) 
restenosis prevention and treatment.
• The new biodegradable-polymer DESs may represent a step ahead on the road to 
reach an ideal stent. According to our meta-analysis, they were not clearly better than 
permanent-polymer DESs. However, Biolimus biodegradable-polymer stents provided 
very promising results, especially at long-term follow-up. Integration of improvements in; 
the anti-proliferative drug and its pharmacokinetics (biolimus/novolimus), the polymer 
(biodegradable-polymer/polymer-free), and the stent platform (biodegradable stents), 
are expected to provide a solution for the problem of in-stent thrombosis and restenosis. 
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SAMENVATTING, CONCLUSIES EN TOEKOMSTPERSPECTIEF
Het doel van dit proefschrift is om te evalueren wat de relevantie is van gecombineerde 
farmacologische en aanvullende mechanische therapieën ter verbetering van de uitkomst 
van primaire percutane interventies (PPCI) voor de behandeling van het ST-segment elevatie 
myocardinfarct (STEMI). Ook worden de voorspellende factoren van de hoeveelheid stolsel 
(thrombus graad) bij STEMI patiënten in kaart gebracht en is beschreven hoe de relatie is met 
de uitkomst en het eff ect op de pre-hospitale behandeling van deze patiënten. Daarnaast 
wordt speciale aandacht geschonken aan de klinische resultaten van biodegradable-polymer 
drug-eluting stents (DES = medicijnafgevende stents) met betrekking tot het risico op stent 
thrombose en hernieuwde revascularisatie procedures van het behandelde vaatsegment. 
Daarbij wordt er een vergelijking gemaakt tussen a) biodegradable-polymer biolimus-, si-
rolimus- en paclitaxel-eluting stents en tussen b) biodegradable-polymer eluting en perma-
nente polymer eluting stents. Vervolgens worden enkele nieuw verschenen geneesmiddelen 
voor de behandeling van coronairlijden besproken, met speciale aandacht voor middelen 
die de bloedplaatjes remmen, antistollingsmiddelen en middelen voor de behandeling van 
dyslipidemieën. Tenslotte geven we een overzicht van problemen die na het plaatsen van 
een stent kunnen optreden, in het bijzonder in-stent restenose en stent malappositie.
SAMENVATTING
De introductie van dit proefschrift (Hoofstuk 1) begint met een beschrijving van de huidige 
inzichten in de toepassing van stolselverwijdering door middel van aspiratie en abciximab 
als aanvullende behandelingen rondom de PPCI om de hoeveelheid stolsel te verminderen. 
Daarna worden de nieuwe biodegradable-polymer DES beschreven. Tenslotte wordt er een 
overzicht gegeven van in-stent restenose en thrombose defi nities en classifi caties, en van 
stent malappositie en de recente innovaties die het optreden hiervan kunnen voorkomen.
In Hoofdstuk 2 wordt de aanvullende rol van mechanische thrombus verwijdering door mid-
del van aspiratie gedurende de PPCI voor STEMI patiënten onderzocht die in de ambulance 
abciximab hebben gekregen volgens het Leidse MISSION! protocol. Daarbij werden 158 
patiënten onderzocht die voor aankomst in het ziekenhuis al abcixmab hadden gekregen: 
79 patiënten ondergingen PPCI met thrombusaspiratie en 79 zonder thrombusaspiratie. De 
groepen waren vergelijkbaar qua pre-procedurele klinische en angiografi sche karakteristie-
ken. Het voorkomen van compleet ST-segment herstel na 90 minuten was hoger in de groep 
behandeld met thrombusaspiratie (p=0.002), en multivariate logistische regressieanalyse 
identifi ceerde alleen thrombusaspiratie als een onafhankelijke voorspeller van ST-segment 
herstel (odds ratio= 9.4, 95% CI = 2.6-33.5, p=0.001). Er werd geen verschil gezien tussen 
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de groepen in enzymatische infarctgrootte zoals bepaald met de piek-CK (p=0.7) en piek 
troponine-T (p=0.4) waarden. Ook de LV ejectiefractie na 3 maanden was vergelijkbaar tus-
sen de groepen (p=0.9). Na 12 maanden klinische follow-up, liet de thrombusaspiratie groep 
een lagere sterfte zien (log-rank p=0.03). Op basis van deze studie lijkt een selectieve bena-
dering van thrombusaspiratie een aanvullende waarde te hebben, ook wanneer abciximab 
is toegediend.
De hypothese van de studie zoals beschreven in Hoofdstuk 3 was dat vroege voorspelling 
van de hoeveelheid stolsel mogelijk is, en dat dit eff ect zou kunnen hebben op de pre-
hospitale triage van STEMI patiënten. 153 opeenvolgende patiënten die zich presenteerden 
met een STEMI werden geïncludeerd. De aanwezigheid van thrombus werd vastgesteld door 
middel van angiografi e en gecategoriseerd volgens de TIMI Study Group score. Vervolgens 
werden patiënten ingedeeld in twee groepen: hoge thrombus graad (HTG: score 4-5) of lage 
thrombus graad (LTG: score 1-3). Naar voorspellers voor angiografi sche thrombus graad werd 
gezocht onder klinische, angiografi sche en laboratorium parameters. De infarctgrootte en 
scintigrafi sche LV ejectiefractie na 3 maanden werd in beide groepen bepaald. 94 patiënten 
(58±11 jaar, 75% man) presenteerden zich met HTG en 59 patiënten (58±12 jaar, 79% man) 
met LTG. Pre-infarct angina pectoris werd vaker gezien in de LTG groep (25% vs. 10%, p=0.009). 
De pre-procedurele TIMI fl ow was lager in de HTG groep (p<0.001). Thrombusaspiratie werd 
vaker verricht in de HTG groep (p<0.001). De afwezigheid van pre-infarct angina pectoris 
(OR=0.29, 95% CI=0.11-0.75, p=0.01) en proximale lokalisatie van de culprit laesie (OR=2.10, 
95% CI=1.02-4.36, p=0.04) waren de enige onafhankelijke voorspellers van HTG. HTG was een 
onafhankelijke voorspeller van hogere piek-CK (p<0.001) en -troponine-T (p<0.001) waarden 
en een lagere LV ejectiefractie (p=0.05), naast mannelijk geslacht en het niet gebruiken van 
een statine. Geconcludeerd werd dat pre-infarct angina pectoris is geassocieerd met minder 
thrombus en proximale lokalisatie van de culprit laesie geassocieerd is met meer thrombus. 
Meer thrombus is geassocieerd met grotere infarctgrootte en iets lagere LV ejectiefractie. 
Deze studie kan klinische implicaties hebben voor de behandelstrategie, vooral in de 
toepassing van farmacotherapie met als doel de hoeveelheid thrombus te verminderen 
voorafgaand aan stent implantatie.
In Hoofdstuk 4 wordt een meta-analyse en systematisch overzicht beschreven van 
biodegradable-polymer (BioPol) DES om 1) het risico van hernieuwde revascularisatie van 
het behandelde vaatsegment en het risico op stent thrombose onder verschillende groepen 
BioPol DES vast te stellen, en 2) dit te vergelijking met permanente polymer sirolimus-eluting 
stents. Op PubMed werden alle relevante artikelen tussen januari 2005 en oktober 2010 op-
gezocht. Inclusiecriteria waren (a) implantatie van een DES met biodegradable polymer, (b) 
beschikbare follow-up data van klinische eindpunten van minimaal 30 dagen en/of middel-
lange follow-up (tot 1 jaar). In totaal werden 22 gerandomiseerde en observationele studies 
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gevonden met daarin 8264 patiënten, die voldeden aan de selectiecriteria: 9 studies met 2042 
patiënten waarin biodegradable polymer sirolimus-eluting stents (BioPol-SES) werden geïm-
planteerd; 8 studies met 1731 patiënten waarin biodegradable-polymer paclitaxel-eluting 
stents (BioPol-PES) werden gebruikt; en 7 studies met 4491 patiënten waarin biodegradable-
polymer biolimus A9-eluting stents (BioPol-BES) werden geïmplanteerd. Na 30 dagen was 
er een hoger risico op revascularisatie van het behandelde vaatsegment in de BioPol-BES 
groep vergeleken met de BioPol-SES groep (OR = 3.4, 95% CI = 1.3-9.6, p=0.006), dat vooral 
veroorzaakt werd door het hogere risico op stent thrombose in de BioPol-BES groep (OR = 
3.9, 95% CI = 1.1-14.0, p=0.04). Er waren geen signifi cante verschillen tussen de andere stents 
op de korte termijn. Na een jaar was er een bijna 3x zo hoger risico op revascularisatie van het 
behandelde vaatsegment in de BioPol-PES (OR = 2.8, 95% CI = 1.3-6.0, p=0.01), en een meer 
dan 2x zo hoog risico in de BioPol-SES groep (OR = 2.2, 95% CI = 0.2-10, p=0.04), vergeleken 
met de BioPol-BES. Er was geen signifi cant verschil tussen de BioPol-SES en BioPol-PES. Het 
risico op stent thrombose na 1 jaar was niet signifi cant verschillend tussen de verschillende 
studiegroepen (p=0.2), hoewel er numeriek 3x zo vaak stent thrombose in de BioPol-PES 
groep optrad in vergelijking met de BioPol-SES groep (1% vs. 0.3%). In een andere analyse 
waarin alle gerandomiseerde studies (7 studies) met BioPol-DES (3778 patiënten) en PermPol-
DES (3291 patiënten) werden opgenomen was het risico op hernieuwde revascularisatie van 
het behandelde vaatsegment en het risico op stent thrombose niet signifi cant verschillend 
tussen de groepen (OR = 0.8, 95% CI = 0.5-1.4, p=0.5 en OR = 0.7, 95% CI -0.2-2.4, p=0.5, 
respectievelijk). De conclusie was dat de verschillende BioPol-DES van elkaar verschillen. De 
korte en middellange succespercentages zijn niet vergelijkbaar. Ook bleken BioPol-DES niet 
noodzakelijk beter dan PermPol-DES).
Hoofdstuk 5 bevat een review artikel waarin een vrijwel volledig overzicht wordt gegeven 
van recent verschenen nieuwe geneesmiddelen ter behandeling van coronairlijden. De 
besproken geneesmiddelen zijn: geneesmiddelen ter behandeling van dyslipidemie, ge-
neesmiddelen die de atherosclerotische plaque stabiliseren en hun progressie stoppen, anti-
angineuze middelen, renine-angiotensine-aldosteron-systeem remmers, anti-bloedplaatjes 
middelen en anticoagulantia.
Hoofdstuk 6 is een review artikel met betrekking tot in-stent restenose (ISR). Hierin geven 
we 1) een overzicht van recente innovaties voor het optimaliseren van de uitkomsten van 
coronaire stenting procedures, en 2) up-to-date informatie over preventie van ISR. Dit omvat 
het verbeteren van stent ontwerpen, nieuwe stent coatings, nanodeeltjes op basis van drug 
delivery en gentherapie. We belichten ook de huidige behandel opties voor de ISR.
In Hoofdstuk 7 presenteren we een overzicht over late stent malappositie (LSM) in het bare-
metal stent (BMS) en het DES tijdperk. In dit hoofdstuk worden verschillende aspecten van 
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stent malappositie besproken: de defi nitie en classifi catie, de pathofysiologie, de risicofacto-
ren, de incidentie in BMS en DES, de nieuwe diagnostische middelen om het vast te stellen en 
tenslotte de huidige mogelijkheden voor de behandeling ervan en een toekomstperspectief.
CONCLUSIES
• In STEMI patiënten die behandeld worden met PPCI en vroeg (in de ambulance) abciximab 
toegediend krijgen, lijkt manuele thrombusaspiratie de post-procedurele ST-segment 
resolutie te verbeteren en te leiden tot een betere klinische uitkomst. Daarom lijkt een 
selectieve strategie van thrombusaspiratie, ook na toediening van abciximab, waarde te 
hebben, ondanks het feit dat er enzymatisch geen verschillen waren in infarctgrootte en 
er geen verschillen in LV functie waren bij Gated-SPECT.
• Pre-infarct angina pectoris is geassocieerd met een lagere angiografi sche thrombus 
graad, in tegenstelling tot proximale locatie van de culprit lesie. Hogere thrombus graad 
is geassocieerd met grotere infarctgrootte en slechtere LV functie. Dit kan klinische im-
plicaties hebben bij de keuze van de behandelstrategie, vooral de farmacotherapie met 
als doel de thrombus graad te doen afnemen voor stent implantatie. Dit geldt vooral bij 
patiënten zonder pre-infarct angina pectoris.
• De uitkomst van de diverse BioPol-DES is verschillend. Het korte- en middellange termijn 
succes is niet uitwisselbaar en vragen om een zorgvuldige beoordeling van nieuwe 
BioPol-DES die verschijnen voordat ze een nieuwe standaard van zorg kunnen worden. 
De uitkomst van BioPol-DES is niet noodzakelijk beter dan de uikomst van PermPol-DES.
• Er is veel geïnvesteerd om tot een betere klinische eff ectiviteit en veiligheid te komen van 
nieuwe geneesmiddelen ten opzichte van de reguliere behandeling van coronairlijden. 
Een beter begrip van de verschillende moleculaire en cellulaire mechanismen die aan 
coronairlijden ten grondslag liggen, hebben geleid tot innovaties en nieuwe geneesmid-
delen voor de behandeling ervan. De komende jaren kunnen meer geneesmiddelen 
worden verwacht.
• Gedurende de laatste jaren zijn veel voorspellende factoren voor in-stent restenose ge-
identifi ceerd. Deze factoren zijn niet alleen zinvol voor de risicostratifi catie van patiënten, 
maar hebben ook geleid tot een beter begrip van de oorzaak van deze complexe aan-
doening. Vele innovatieve therapieën zijn ontwikkeld om tot een optimale anti-restenose 
therapie te komen.
• Stent malappositie is een relatief veelvoorkomende bevinding na stent implantatie. 
Hoewel stent malappositie is geassocieerd met stent thrombose, blijft het laatste een 
zeldzame complicatie. Omdat de incidentie van stent malappositie veel groter is dan die 
van stent thrombose, is stent malappositie waarschijnlijk een van de vele factoren die het 
risico op stent thrombose verhogen.
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TOEKOMSTPERSPECTIEF
1. Primaire percutane coronaire interventie
• Primaire PCI is de gevestigde behandeling om reperfusie van de coronairen te verkrijgen 
tijdens de behandeling van het acute myocardinfarct (AMI). In aanvulling op farmaco-
logische behandelingen, zijn verschillende thrombusaspiratie methoden onderzocht 
om het risico van embolisatie te verminderen. Tot dusver is het niet bekend welke groep 
patiënten de meeste baat heeft bij thrombusaspiratie en of een selectieve strategie voor 
thrombusaspiratie op basis van thrombusgraad, tijd tot behandeling of andere factoren, 
niet beter is. Gerandomiseerde studies die voldoende ‘gepowered’ zijn op klinische 
uitkomsten zijn nodig om de vele vragen over de eff ectiviteit van thrombusaspiratie 
te beantwoorden en om de huidige klasse 2 indicatie (redelijk om de procedure uit te 
voeren) te verhogen naar klasse 1 (procedure dient te worden uitgevoerd).
• Pre-hopsitale triage van STEMI patiënten wordt steeds breder toegepast. Echter, voor 
PPCI centra is dit niet mogelijk zonder belangrijke logistieke obstakels te overwinnen. 
In deze studie worden de ervaringen van het Leidse Universitair Medisch Centrum 
(LUMC) beschreven waarbij een sterk gestandaardiseerd protocol wordt gehanteerd 
voor de behandeling van STEMI patiënten (MISSION! protocol). Dit protocol omvat een 
geïntegreerde benadering van vroege farmacotherapie en mechanische reperfusie om 
een optimale uitkomst te bereiken.
• Er is veel geïnvesteerd in de ontwikkeling van nieuwe antithrombotische medicatie 
die oraal of intraveneus kan worden toegediend en, in tegenstelling tot de huidige 
thiënopyridines, resulteren in een directe werking en een reversibel eff ect hebben op 
de remming van de thrombocyt P2YP12 receptor. Het concept van snelwerkende en 
reversibele thrombocyten remming zal leiden tot verder onderzoek om de pre-hospitale 
farmacotherapeutische behandeling te optimaliseren bij patiënten met een hoge throm-
bus graad.
• In dit proefschrift concluderen we dat de afwezigheid van pre-infarct angina pectoris 
geassocieerd is met een hoge thrombus graad. Het kan nuttig zijn om een score te 
ontwikkelen waarin diverse klinische en snel beschikbare laboratoriumwaarden, even-
tueel in combinatie met andere scores (bijvoorbeeld TIMI risk score) kunnen worden 
geïntegreerd om te voorspellen welke patiënten de meeste baat hebben bij vroege pre-
hospitale behandeling.
2. In-stent restenose
• Restenose is een complexe aandoening waarvan nog niet alle pathofysiologische me-
chanismen die eraan ten grondslag liggen, worden begrepen. Vooral genetische markers 
helpen ons bij het ontrafelen van het proces van restenose. Hierdoor kunnen meer 
gerichte behandelingen worden ontwikkeld en toegepast.
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• De huidige ontwikkelingen in het veld van gen-therapie behoren wellicht tot de toe-
komstige behandelopties van restenose. Ontwikkelingen op het gebied van stent design 
en nanodeeltjes-gebaseerde toedieningsmethoden (nano-vehicles) hebben inmiddels 
geleid tot conceptuele veranderingen in de preventie en behandeling van restenose.
• De nieuwe biodegradable polymer DES zouden weleens een belangrijke stap voorwaarts 
kunnen zijn op weg naar de ideale stent. Zoals de meta-analyse laat zien zijn ze niet 
duidelijk beter dan de permanente polymer DES. Echter, met de biolimus-biodegradable 
stents zijn veelbelovende resultaten geboekt, vooral bij de lange-termijn follow-up. De 
integratie van nieuwe inzichten in de anti-proliferatieve drugs en de farmacokinetica 
ervan (biolimus/novolimus), de polymer (biodegradale-polymer/polymer-free) en het 
stent platform (biodegradable stents), zal naar verwachting leiden tot een oplossing van 
het probleem van in-stent thrombose en restenose.
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